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Abstract 
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Abstract 
 
Background: Prostaglandins (PGs) and hydroxyeicosatetraeinoic acids (HETEs) are 
synthesized from arachidonic acid (AA) released from the membrane phospholipids 
of cells through the activity of cytosolic phospholipase A2α (cPLA2α). In platelets AA                                                     
is metabolised through cyclooxygenase-1 (COX-1) and 12-lipoxygenase (12-LOX) 
leading to the production of a range of eicosanoids. This project determined the 
enzymes responsible for the production of the major prostanoid and HETE 
metabolites released by activated platelets and investigated the roles of these 
within the vasculature. 
Methods: The responses of whole blood and platelets collected from healthy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
volunteers or patients lacking cPLA2α were examined in the absence and presence of 
anti-platelet drugs (aspirin and/or prasugrel). The effects of selective platelet 
agonists and global stimulants of blood cells were tested to provide multiple 
functional responses against which to compare the ability of platelets and blood to 
produce eicosanoid molecules, as measured by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS).  
Results: Stimulation of blood and PRP produced large increases in the levels of TXA2, 
PGE2, PGD2, 11- and 15-HETE which were found to be produced by platelets via the 
activity of cPLA2α and COX-1 enzymes. 12-HETE was dependent upon cPLA2α but not 
COX-1. 11- and 15-HETE have not previously been reported as major platelet 
products.  A series of experiments indicated that 11-, 12- and 15-HETE had very 
weak influences on platelet aggregation/adhesion responses. Notably, 12(S)-HETE, 
which represents the enantiomer released by platelets, strongly promoted 
neutrophil chemotactic responses. Furthermore, 15(S)-HETE was identified as the 
bioactive enantiomer produced by activated platelets and was able to induce tube 
formation and cell migration in cultures of human microvascular endothelial cells 
(HMEC-1) and promote the formation of sprouts from rat aortic rings. 
Conclusions: Platelets are major producers of prostanoids and HETEs in activated 
blood. Notably, aspirin abolished the production of not only prostanoids, but also 
11-HETE and 15-HETE, identifying these as major COX-1 products. Moreover, 12(S)-
Abstract 
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HETE robustly induced neutrophil chemotaxis, while 15(S)-HETE promoted 
angiogenic responses both in vitro and ex vivo. These data identified 15(S)-HETE as a 
potential target for the development of therapies able to limit angiogenic processes 
in conditions such as tumour progression and metastasis. 
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Within the cardiovascular system platelets represent the blood component 
assigned to regulate and control haemostasis. Disruption of the vascular wall due to 
injury induces platelets to become activated and aggregate leading to thrombus 
formation and, thus, to pathological conditions which manifest clinically as acute 
cardiovascular events (e.g. heart attack). Anti-platelet therapies are currently used 
to control platelet activation and prevent the occurrence of acute cardiovascular 
events. However, chronic use of these therapies is associated with a high risk of 
gastrointestinal and intracranial bleeding, side effects that counteract the benefits 
produced by the treatment. Research is currently focused on identifying novel 
targets and elucidating platelet pathways in order to develop therapeutic 
approaches able to overcome these side effects and, thus, improve cardiovascular 
therapy. The aim of this project was to better understand the platelet LOX pathway, 
the role of which is still unclear, and investigate the interplay between COX and LOX 
pathways in the regulation of haemostasis/thrombosis. Ultimately, these studies 
may lead to the identification of novel therapeutic targets to support and 
ameliorate the therapies currently used in cardiovascular disease. 
 
1.1 Human phospholipase A2 isoforms 
 
The phospholipase A2 (PLA2) enzyme catalyses the hydrolysis at sn-2 position of the 
cell’s membrane phospholipids releasing arachidonic acid (AA), a free fatty acid 
from which active metabolites, eicosanoids, are subsequently synthesized.1,2  The 
release of AA is indeed the rate limiting step in the generation of prostanoids and 
leukotrienes.2  
 
At least 19 PLA2 isoenzymes have been identified and classified depending on their 
chemical structure, enzymatic characteristics, cellular distribution and cellular 
functions.1,3 The PLA2s have been classified in different families, the cytosolic 
calcium dependent PLA2 (cPLA), the secretory PLA2 (sPLA2) and the cytosolic calcium 
independent PLA2 (iPLA2).
3 These enzymes play a fundamental role in the 
production of lipid mediators in the presence of certain stimuli (e.g. calcium 
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ionophore) and in phospholipid remodelling.3-5 The cPLA2 family is represented by 
three different isoenzymes, cPLA2α, cPLA2β and cPLA2ϒ which are classified into 
group IVA, ICB and IVC, respectively.6-8  
 
The 85-kDa cytosolic PLA2, cPLA2α, shows a significant preference for AA over other 
fatty acids and is activated by submicromolar concentrations of Ca2+ and associated 
with inflammatory responses, platelet activation and cell proliferation.3,9-11 The 
important mechanisms by which cPLA2 activation and consequent AA release are 
regulated involve agonist-induced MAP kinase phosphorylation of the enzyme and 
Ca++-dependent translocation of cPLA2 from the soluble to the membrane fraction 
of cells where the enzyme is able to elicit its catalytic function.6,12  
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Figure 1.1 Structures of cPLA2 isoforms. a) The N-terminal region of cPLA2α and 
cPLA2β is constituted by a C2 domain responsible for Ca
2+-dependent membrane 
association. All three cPLA2 isoforms possess two catalytic domains, A and B. The 
catalytic domain A of the three isoforms has lipase consensus motifs. Only in the 
cPLA2α isoform two serine residues, Ser505 and Ser727, are present and 
phosphorylated by protein kinases in the MAPK cascade, while the C-terminal 
portion of cPLA2ϒ is isoprenylated. b) Schematic tertiary structure of cPLA2α. The 
twoCa2+ ions which leads to the exposure of hydrophobic surfaces on the top of the 
domain. The vimentin-binding site in the C2 domain is separated from the 
hydrophobic, membrane-binding region. The catalytic centre in the globular 
catalytic domain is located in the “active site hole”, into which the AA residue 
enters. PI(4,5)P2 interacts with the cationic residues (+) in both the C2 and catalytic 
domains inducing conformational change of the enzyme that brings its active site 
closer to the membrane. This allows a substrate molecule to enter the active site 
for catalytic turnover. The two critical phosphorylation sites are located in the 
interspaced region.  Figures a) and b) were adapted from those in the review of 
Makoto Murakami.3  
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The secretory PLA2s, sPLA2s, constitute the largest family of PLA2 in mammals of 
which 10 closely related isoforms have been identified, i.e. sPLA2 IB, IIA, IIC, V, X, 
IID, IIE, IIF, III and XII.3,13,14 This class of enzymes is characterised by a low molecular 
weight (14-19 KDa), histidine in the catalytic site and a Ca2+-binding loop in the 
active site.3,15 The hydrolysis requires abstraction of a proton from a water molecule 
and a nucleophilic attack on the sn-2 bond.15 SPLA2 IIA is the most wildly distributed 
subtype in humans and its production is robustly induced by pro-inflammatory 
factors.16,17 
 
 
Figure 1.2 Regulatory mechanisms for cPLA2α and sPLA2-mediated AA release. 
Upon receptor activation, phospholipase C (PLC) enzymes produce diacylglycerol 
(DAG) and inositol triphosphate (IP3), inducing an increase in intracellular Ca
2+ 
levels. In response to this Ca2+ elevation, cPLA2α translocates from the cytosol to the 
endoplasmic reticulum (ER) and perinuclear membranes, where COX isozymes are 
situated (1). The cPLA2α is activated also via the MAPK cascade, where MAPKs and 
MAPKAPKs phosphorylate Ser505 and Ser727 on the enzyme, respectively (2). This 
dual phosphorylation is required for full activation of cPLA2α. In the HSPG-shuttling 
pathway (3), the heparin-binding group II subfamily sPLA2s (IIA, IID, IIE, and V) are 
associated with the GPI-anchored HSPG glypican and are sorted into rafts. As a 
consequence these sPLA2s are internalized and release AA adjacent to COXs. The 
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PC-hydrolyzing sPLA2s (IIF, III, V and X) act on the PC-rich outer leaflet of the plasma 
membrane, the external plasma membrane pathway (4). The AA released by sPLA2s 
from the external plasma membrane is incorporated into cells, diffuses across the 
cytosol, and reaches the perinuclear COXs. The sPLA2 enzymes can also act on 
neighbouring cells to induce transcellular AA metabolism (5). Figure adapted from 
image in the review of Makoto Murakami.3 
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1.2 Eicosanoids 
Eicosanoids (eicosa: twenty) are bioactive lipids derived from carbon-20 
unsaturated fatty acids. Arachidonic acid (AA) is an essential fatty acid in humans 
and a ubiquitous component of the cell membrane from which it is hydrolysed 
through the activity of phospholipase A2 (PLA2). Once released in response to 
certain stimuli, AA becomes the precursor of a broad range of bioactive 
metabolites, known as eicosanoids, via the action of constitutive or inducible 
enzymes, non-enzymatic pathways or by transcellular metabolism18 The main 
enzymatic pathways involved in eicosanoid biosynthesis are a) PG endoperoxide H 
synthases-1 and -2 (PGHS-1 and PGHS-2) also known as COX-1 and COX-2,19 b) 5-, 
12-, 15-lypoxygenases (LOX),20 c) P450 epoxygenases.21 Eicosanoids play a crucial 
role in both physiological and pathophysiological scenarios within the 
cardiovascular system. 
 
 
 
Figure 1.3 Scheme of AA-derived eicosanoid products.  
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1.2.1 Cyclo-oxygenases and thromboxane A2/prostaglandins 
Prostaglandins and thromboxane A2 are synthesized from AA through the activity of 
COX-1 and COX-2, which catalyse both cyclooxygenase and hydroperoxidase 
reactions.22 In particular, the cyclooxygenase activity of COX includes the 
incorporation of two oxygen molecules into AA leading to the formation of an 
unstable intermediate, prostaglandin endoperoxide G2 (PGG2), which is then 
reduced to prostaglandin endoperoxide H2 (PGH2) via the hydroperoxidase (HOX) 
activity of the enzyme.22 PGH2 is subsequently converted into PGD2, PGE2 PGF2α, 
PGI2 and TXA2 via specific synthases.
23,24,25 It has been shown that the cPLA2 is 
coupled with both COX-1 and COX-2 enzymes. 
 
 
 
Figure 1.4 Structures of COX isoforms. Both COX isoforms have an EGF-like domain, 
a MBD, and a catalytic domain. The C-terminal PTEL and STEL sequences in COX-1 
and COX-2, respectively, represent an ER retention signal. Close to the C-terminus 
of the COX-2 isoform an 18 amino acid insertion is present. The residues that are 
crucial for the enzyme catalysis and for aspirin binding are indicated.  
 
Humans express two COX enzymes, COX-1 and COX-2, which are both located in the 
endoplasmic reticulum (ER).26,27 COX-1 is a constitutive enzyme which produced 
prostaglandins mainly involved in housekeeping functions, e.g. gastric protection, 
haemostasis and renal water balance.28 COX-2 is the inducible isoform activated in 
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response to inflammatory stimuli, although can be constitutively expressed in 
kidney, brain, trachea, epithelium and endothelial cells.28 
 
 
 
Figure 1.5 Biosynthesis of AA-derived prostanoids via COX activity.  
 
COX-1 is characterised by a smaller catalytic site compared to COX-2, providing an 
explanation for COX-1 being fully inhibited when the active site is acetylated by the 
COX inhibitor, aspirin, whereas COX-2 is still able to produce 15(R)-HETE.29 
Therefore, these differences in the structure lead to biological and pharmacological 
differences. Despite these structural differences both these enzymes present the 
same kinetic properties (Km).
22 These two COX isoforms after catalysing the 
cyclooxygenase and peroxidase reactions undergo suicide inactivation within 1-2 
min even in the presence of sufficient substrate.30 This phenomenon causes a fall of 
the cyclooxygenase and peroxidase activities within 2 min. 
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Thromboxane A2  
Thromboxane A2 (TXA2) is mainly a platelet-derived COX-1 product and a potent 
pro-thrombotic mediator that induces platelet aggregation, vasoconstriction and 
smooth muscle cell (SMC) proliferation. TXA2 is synthesized through the activity of 
COX-1 and thromboxane synthase (TXAS), which uses PGH2 as a precursor. Platelets 
express high levels of TXAS and, thereby, are the major source of TXA2.
31,32 This 
prostanoid is highly unstable with a half-life of only 30 s and is rapidly metabolised 
into its inactive form TXB2.
33 TXA2 elicits its effects by activating G-protein coupled 
receptors known as thromboxane/prostanoid receptors (TP receptors) of which two 
different isoforms have been identified: TPα which is highly expressed in platelets 
and TPβ mainly expressed in endothelial cells (ECs). Both these receptors have the 
same ligand binding site but differ in the C-terminal ends suggesting they are 
coupled with different G proteins.32 TP receptors are coupled with Gq and G13 
families of G proteins which trigger activation of PLC and RhoGEF, respectively.32,34 
Although TXA2 is the main agonist of TPs, also other PGs and isoprostanes can act 
through these receptors at higher concentrations.  
 
Prostacyclin 
Prostacyclin (PGI2) was discovered in 1976 as a substance inhibiting platelet 
aggregation and vasoconstriction and is generated by ECs through the activity of 
COX-1 or COX-2 and prostacyclin synthase.35,36,37 It has been suggested that in 
normal conditions the expression of COX-2 by ECs might occur as a consequence of 
physiological shear stress within the normal vasculature.38 The use of selective COX-
2 inhibitors, e.g. celecoxib and rofecoxib, has shown to be associated with a 
reduction of PGI2 levels which might suggest that COX-2, not COX-1, is involved in 
the synthesis of this product.39 Conversely, recent studies conducted on cultured 
endothelial cells not only do not support this theory but show that these cells 
mainly express the COX-1 isoform.40,41 PGI2 is a potent vasodilator and platelet 
inhibitor and, therefore, the interplay between PGI2 and TXA2 is crucial for the 
regulation of vascular haemostasis. Indeed, the balance between these opposing 
effects maintains platelets in a quiescent state in physiological conditions. PGI2 acts 
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on IP receptors (GCPR) which are expressed on platelets and SMCs leading to 
platelet inhibition and vascular relaxation, respectively. IP receptors couple with 
protein Gs and activate adenylyl cyclase leading to an increase of intracellular cAMP 
levels.42,43 Moreover, this prostanoid has a half-life of 2-3 min in the circulation and 
is subsequently metabolised to 6-keto-PGF1α which can be measured. 
 
Prostaglandin E2 
Prostaglandin E2 (PGE2) is involved in several housekeeping and pathological 
processes which include important roles in cardiovascular settings. Different 
prostaglandin E synthases (PGES) generating PGE2 from PGH2 have been identified. 
In particular, the membrane-bound isoforms, PGE synthase-1 and -2 (mPGES-1 and -
2), the cytosolic PGES (cPGES) and the µ form of the cytosolic glutathione S-
transferase (GST) family.3 The cPGES enzyme has been recognised as the only 
isoform able to use COX-1-derived, not COX-2-derived, PGH2 as a precursor for PGE2 
synthesis.3 Conversely, the mPGES is associated with COX-2 synthesis of PGE2.
3 In 
the cardiovascular system PGE2 is produced and released by several cell types, such 
as endothelial cells, vascular smooth muscle cells and platelets.44 Once released 
PGE2 acts on GPCRs, EP receptors, of which 4 different isoforms have been 
identified: EP1, EP2, EP3 and EP4. Studies have shown that PGE2 affects platelet 
aggregation by acting on both EP3 and EP4 receptors.45 In particular, low 
concentrations of PGE2 act on EP3 causing a decrease in platelets cAMP levels and, 
therefore, promoting platelet aggregation. In contrast, higher concentrations of 
PGE2 produce an increase of cAMP levels inhibiting platelet aggregation by acting 
on EP2 and EP4 receptors.44 Thus, the net effects of PGE2 on platelet function 
reflect the balance between opposing effects at EP3 and EP4 and any perturbation 
of this balance may lead to a shift from inhibition to potentiation of platelet 
function accounting for the variability of the data collected in different studies.45 
Furthermore, on vascular smooth muscle cells PGE2 induces vasoconstriction or 
vasodilatation when acting on EP1/EP3 or EP2/EP4, respectively.44 
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Prostaglandin D2 
The prostaglandin D2 synthase (PGD2), lipocalin-like PGD synthase or haemopoietic 
synthase (lPGDS or hPGDS),46 generates PGD2 which can act on two different 
isoforms of DP receptor, i.e. DP1 and DP2. Mast cells are the main source of PGD2, 
with lower amounts being generated by other cell types such as platelets, 
leukocytes and lymphocytes. It has been shown that platelet-derived PGD2 acts on 
DP1 expressed on platelets stimulating adenylyl cyclase and thus causing platelet 
inhibition.47,48  
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1.2.2 Lipoxygenases and HpETEs/HETEs  
The lipoxygenases (LOXs) are non-heme iron-containing enzymes present in both 
plants and animals.49 The LOXs metabolise AA to generate bioactive metabolites, 
hydroperoxy-eicosatetraeinoic acids (HpETEs), then reduced to the more stable 
form, hydroxy-eicosatetraeinoic acids (HETEs).50 The major products of the 
mammalian LOXs are 5-, 8-, 12- and 15-HETE.51 The human LOX genes are localised 
in a joint gene cluster mapped to chromosome 17, with the only exception of the 5-
LOX gene which is localised on chromosome 10.52  
 
The LOXs catalyse the dioxygenation of 1,4-cis, cis-pentadiene containing 
polyunsaturated fatty acids (PUFA) via hydrogen abstraction.53,54,49 The LOXs are 
classified with respect to their positional specificity of AA oxygenation55 and are, 
furthermore, differentiated in subtypes according to tissue distribution: the 
leukocyte 5-LOX which induces formation of pro-inflammatory products, i.e. 5(S)-
HETE and leukotrienes (e.g. LTB4)56; the 12-LOX which is expressed in different 
isoforms i) the platelet-type, (ii) the leukocyte-type and (iii) the epidermal-type.57 
This enzyme is abundant in platelets and synthesizes the formation of 12(S)-
HpETE/12(S)-HETE.54,58 Both the 5-LOX and the platelet-type 12-LOX are absent in 
normal epithelia, although can be often expressed in several epithelial cancers, such 
as colon cancer50; the 15-LOX of which two different subtypes are expressed in 
mammalian cells, i.e. the 15-LOX1 and 15-LOX2.55,59 The 15-LOX1, reticulocyte-type 
and leukocyte-type, is able to metabolise linoleic acid in addition to AA and is 
mainly expressed in reticulocytes, eosinophils, macrophages and airway epithelial 
cells 55. The 15-LOX2, epidermis type, is expressed in the prostate, lung and skin and 
is far less distributed than 15-LOX1. In humans the 15-LOX1 and leukocyte 12-LOX 
have a similar structure and are referred to as 12/15-LOXs since both are able to 
synthesise 12(S)-HETE and 15(S)-HETE55,59 Human 12/15-LOX exhibits predominant 
15-LOX activity and, thereby, AA-derived 15HpETE formation.60  
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Figure 1.6 Lipoxygenase pathways of AA metabolism. 1) Leukotriene A4 hydrolase; 
2) Leukotriene C4 synthase. 
 
There are significant species-species differences in the products generated through 
the different 12- and 15-LOX isoforms.52,55 Mice for example express the leukocyte-
type 12-LOX but not the 15-LOX isoform, whereas rabbits express both the 
reticulocyte 15-LOX and the leukocyte 12-LOX.61,57 These differences have to be 
taken into account when choosing an animal model and when translating data from 
these models of disease to humans. Both 12- and 15-LOX are cytosolic enzymes and 
once activated by an agonist (e.g. calcium ionophore) are able to translocate to the 
cell membrane and generate esterified eicosanoids, phosphatidyl-ethanolamine 
(PE-HETEs) or phosphatidyl-choline (PC-HETEs).55,62 The esterified 12-HETEs and 15-
HETE are abundant in human platelets and peripheral monocytes, respectively.62,63 
These esterified eicosanoids have been shown to play an important role in pro-
thrombotic and inflammatory responses.55   
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5-lipoxygenase and leukotrienes/5-HETE 
It is already established that 5-LOX is expressed in polymorphonuclear leukocytes 
(PMN) and in association with the 5-LOX-activating protein (FLAP)64 is able to 
transform AA into 5,6-epoxy-7,9-11,14-eicosatetraeinoic acid or LTA4.
65 In 
inflammatory cells such as neutrophils, macrophages and monocytes LTA4 is 
metabolised by LTA4 hydrolase (LTAH4) to form 5,12-dihydroxy-6,8,10,14-
eicosatetraenoic acid (LTB4)
66 and 5S-hydroxy-6-trans,8,11,14-cis-eicosatetraeinoic 
acid (5(S)-HETE).67 Basophils, eosinophils, mast cells and alveolar macrophages, 
instead, use LTA4 as a substrate for the synthesis of cysteinyl leukotrienes and, in 
particular, the formation of 5-hydroxy-7,9,11,14-eicosatetraeinoic acid (LTC4) 
through the activity of the LTC4 synthase (LTC4S)
68,69 which can be further 
metabolised into LTD4 and then into LTE4.
70 Leukotrienes play an important role in 
inflammation and hypersensitivity.66,67 Indeed, LTC4, LTD4 and LTE4 cause airway 
obstruction71 and LTB4 exhibits a potent leukocyte chemoattractant effect acting 
through BLT1 and BLT2 receptors.72 LTB4 has high affinity for BLT1 and is able to 
drive potent chemotactic effects on leukocytes.73,74  
 
12-lipoxygenase and 12(S)-HETE 
The platelet-derived 12-LOX is the most abundant subtype in mammalian cells. 
There is evidence that collagen and collagen-activated peptide (CRP) signalling via 
glycoprotein VI (GPVI) acutely activate the 12-LOX and promote secretion of 12-
HpETE in a dose and time dependent manner.75 Activating GPVI triggers PI3-kinase 
turnover leading to activation of phospholipase Cϒ2 (PLCϒ2) and further PKC 
activation and Ca2+ mobilization.75 PI3-kinase activation and intracellular Ca
2+ 
mobilization precede 12-LOX activation which involves 1) oxidation of the ferrous 
iron and 2) translocation of the cytosolic enzyme to the plasma or nuclear 
membrane.75 The platelet 12-LOX is slowly activated and remains active beyond the 
time required for platelets to aggregate, very differently from the COX enzyme 
which is rapidly inactivated after a short burst of activity.76 There are several 
conflicting reports regarding platelet-derived 12-LOX products, 12(S)-HpETE/12(S)-
HETE, and their ability to display pro- or anti-aggregatory effects. Studies which 
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report an anti-thrombotic effect suggest that 12-HETE inhibits endoperoxide-
induced aggregation and TXA2 formation with consequent reduction of AA-
stimulated platelet aggregation.77 In addition, in vivo studies on 12-LOX knockout 
mice showed a selective hypersensitivity of the platelets of these animals to ADP-
induced aggregation.78 In contrast, there are studies reporting that the 12-LOX 
pathway induces platelet aggregation,79,80 and dense granule secretion through 
activation of protein kinase C (PKC).81 Pro-aggregatory effects of 12-HETE/12-HpETE 
(1-2 µM) co-incubated with sub-threshold concentrations of AA have been reported 
to be associated with an increase of TXB2 levels and potentiation of platelet 
aggregation through enhancement of COX metabolism.79 Furthermore, there are 
conflicting reports on the role 12(S)-HETE plays within the vasculature. It has been 
shown that the 12-LOX product exhibits vasoactive effects, for example 
vasoconstriction by enhancing angiotensin II-induced signalling 82, or vasodilatation 
through membrane hyperpolarization.83  In vivo studies reported that the platelet-
derived 12(S)-HETE levels increase in both spontaneously hypertensive rats and 
subjects with hypertension.84,85  
 
15-lipoxygenase1 and 12(S)-HETE/15(S)-HETE 
The reticulocyte-type and leukocyte-type 15-lipoxygenase1 (15-LOX1) enzyme 
(murine ortholog 12/15-LOX) synthesizes 12-HpETE and 15-HpETE which are then 
reduced to 12-HETE and 15-HETE.54 It has been shown that both 12(S)-HETE and 
15(S)-HETE promote expression of adhesion molecules (e.g. CAM) and monocyte 
adhesion to the vasculature though PKC activation.55 These products are also 
involved in cell proliferation acting through various mitogen-activated protein 
kinase (MAPKs).86 15-LOX is also able to metabolise linoleic acid and generate 13(S)-
hydroxyoctadecadienoic acid (13(S)-HODE), a pro-inflammatory molecule which 
acts on transcriptional factors (e.g. NF-kB).87  
Foam cells originate from monocyte/macrophages or specialised smooth muscle 
cells (SMCs), and under certain circumstances have been shown to express 12/15-
LOX enzymes.88 In humans the 15-LOX1 is expressed in macrophages developed 
from peripheral blood monocytes (PBMCs) in the presence of interleukin-4 (IL-4) 
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suggesting a role of the enzyme in monocyte/macrophage transitions and/or in 
macrophage function.89 This enzyme has been identified in atherosclerotic lesions, 
although there is debate on whether it plays a pro- or anti-atherogenic role. It has 
been suggested that 15-LOX1 may act as a lipid-catabolizing enzyme at early stages 
of foam cell formation, counteracting cytosolic deposition of cholesterol esters.88 In 
contrast, during advanced stages of plaque formation, the LOX enzyme may 
contribute to the extracellular LDL oxidation promoting pro-atherogenic 
processes.90,91 The mechanistic reasons for the contrasting effects of the enzyme 
remain unclear and need further investigation. In vivo studies using 12/15-LOX 
knockout mice crossbred with pro-atherogenic mice (e.g ApoE and LDL-receptor-
deficient strains) demonstrated a pro-atherogenic effect of the enzyme.92 In 
contrast with these results, an anti-atherosclerotic effect of the enzymes was 
shown in in vivo studies employing transgenic rabbits overexpressing 15-LOX1.93 It 
has been already demonstrated that 12/15-LOX enzyme plays a role in the 
pathogenesis of both atherosclerosis and restenosis by oxidising low-density 
lipoprotein (LDL). However, this enzyme appears to be implicated also in other 
vascular pathologies that require further understanding. Indeed, both in vitro and in 
vivo studies showed that the conversion of AA to 15(S)-HETE is crucial for the 
induction of angiogenic processes opening the door for a whole area of 
investigation which sees 15(S)-HETE as an important mediator of both vascular 
pathologies and cancer.94   
 
Transcellular biosynthesis of eicosanoids 
This process relies on the cross-talk between cells for the synthesis of eicosanoids. 
In particular, a donor cell transforms AA into an intermediate that is then used by 
other cell types as a substrate to generate an active metabolite. An example of 
eicosanoid synthesis through a transcellular pathway is the formation of pro-
inflammatory LTs by ECs or platelets from neutrophil-derived LTA4.
95 Indeed, it has 
been reported that co-incubation of human umbilical endothelial cells (HUVEC) or 
platelets with neutrophils in the presence of calcium ionophore (A23187) promotes 
LTC4 production.
96,97 Trancellular biosynthesis is also involved in the formation of 
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lipoxins (LXs), which play a role in haemostasis, resolution of inflammation and 
modulation of the immune system.98,99 Among the anti-inflammatory effects, these 
metabolites inhibit PMNs and eosinophil chemotaxis,100 inhibit PMNs 
transmigration101 and modulate PMN adhesion to ECs.102 Also, in the 
microcirculation lipoxins elicit vasodilatory responses and inhibit the inflammatory 
effects of LTB4.
103 Lipoxins are the product of two distinct lipoxygenations of AA 
through either the 5-LOX and 12-LOX pathways or the 15-LOX and 5-LOX 
pathways.99 In the former scenario the leukocyte 5-LOX metabolises AA to LTA4 
which then is converted to LXs through the platelet-type 12-LOX.104,95 In the latter 
case the 15-LOX produces 15(S)-HETE from AA which is then converted to LXs 
through the PMN 5-LOX.53 Interestingly, aspirin inhibition of the COX-2 enzyme in 
ECs or epithelial cells induces the formation of aspirin-triggered lipoxins (ATLs).102 
Under pro-inflammatory conditions the COX-2 enzyme is upregulated in ECs cells 
and in the presence of aspirin, although the formation of prostanoids is inhibited, 
the enzyme is able to form 15(R)-HETE which might be used as a substrate by the 5-
LOX of PMNs for the synthesis of 15epimeric-LXA4 (or ATL).102 Other anti-
inflammatory lipid mediators (LMs), such as resolvins and protectins, have been 
identified and are generated from omega-3 and omega-6 essential polyunsaturated 
fatty acids, respectively EPA and DHA, though the activity of 5- and 15-LOX.105 
 
1.2.3 P450 epoxygenase and EETs 
AA can be further metabolised by the P450 (CYP) monooxygenases and two 
particular isoforms, CYP2C106 and CYP2J107, have been identified in human ECs. 
From this enzymatic pathway derive several region- and stereospecific cis-epoxides, 
in particular 14,15-, 11,12-, 8,9-, and 5,6-epoxyeicosatetraeinoic acids (EETs).108 
Although it is still unclear through which receptors these products act, studies have 
suggested a role in smooth muscle cells hyperpolarization and relaxation via 
activation of K+ channels.109,110 Moreover, CYP4A and 4F are two isoforms of the 
enzyme able to generate 20-HETE from AA in organs such as kidney, liver and 
lung.111,112,113 It has been proposed that 20-HETE acts through ion channels114 such 
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as the TRPV1 channels115, or through TP receptors inducing cerebral 
vasoconstriction in both humans and rats.116  
 
1.2.4 Non-enzymatic metabolism and isoprostanes 
Oxidative stress and the consequent generation of radical oxygen species (ROS) 
contribute to the development of cardiovascular disease. Free radicals indeed can 
attack the membrane phospholipids releasing AA which can be modified non-
enzymatically and generate isoprostanes (IsoPs).117 These products are a family of 
PGs isomers (e.g. F2-isoPs) and in vivo studies have shown they can act through TP 
receptors.118 Indeed, blockade of the TP receptor produced more potent anti-
inflammatory and anti-atherogenic effects than inhibition of TXA2 generation alone. 
119 Also, isoPs can be used as biomarkers of lipid peroxidation and therefore of 
oxidative stress. 
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1.3 Phospholipase A2 inhibitors 
1.3.1 Pyrrolidine inhibitors 
The AA-derived eicosanoids described above, such as PGs, HETEs, LTs and lipoxins, 
are involved in a vast array of physiological and pathophysiological processes. The 
release of AA is the rate-limiting factor in the production of these lipid mediators 
and, therefore, the development of PLA2 inhibitors to better understand the 
biosynthesis and functionality of these metabolites has been a matter of interest. 
Initially, mepacrine and p-bromophenacyl were used for this purpose, although 
their lack of specificity for the enzyme and their high IC50 values limited their 
application.120 Subsequently, these molecules were substituted by inhibitors, such 
as arachidonyl trifluoromethyl ketone (AACOCF3), which more recent studies have 
found to also be unspecific for the PLA2 enzyme.
121 In vivo studies on mice have 
demonstrated that cPLA2α is the major isoform implicated in the formation of LTs, 
PGs and PAF.122 Therefore, the identification of specific inhibitors for the cPLA2α 
isoform was thought to be crucial for the research of these lipid mediators.  
 
Pyrrolidine inhibitors, which include pyrrolidine-1 and pyrrophenone, represent a 
new class of cPLA2α inhibitors recently developed.
120,123 These inhibitors displayed 
greater potency and specificity compared to the inhibitors previously used (e.g. 
AACOCF3) when tested in vitro.120,124 The unspecific effects of pyrrophenone were 
found only at concentrations 100-fold greater than the ones required to inhibit 
synthesis of LTs in A23187-activated PMNs, suggesting that this inhibitor is a more 
reliable pharmacological tool for the investigation of eicosanoid biosynthesis and 
function in cells and tissues.120 The inhibitory effect of pyrrophenone has been 
thoroughly characterised in studies using enzyme and cell-based assays in which the 
production of PGE2 and LTC4 in THP-1 cells was inhibited at levels comparable to 
those of the  cyclooxygenase (COX) inhibitor, indomethacin, and the 5-lipoxygenase 
(5-LOX) inhibitor, AA-861 (LTC4), respectively.
123 Studies conducted in A23187-
stimulated whole blood revealed that pyrrophenone strongly blocked AA release 
with consequent decrease in eicosanoid production and without causing 
cytotoxicity.123 Ultimately, these studies suggest that pyrrophenone is suitable for in 
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vivo experiments differently from AACOCF3 which did not inhibit cPLA2α enzyme in 
assays performed in whole blood.123  
 
 
 
Figure 1.7 Structures of the cPLA2α inhibitors pyrrolidine-1 and pyrrophenone. 
 
1.4 COX inhibitors 
1.4.1 Non-steroidal anti-inflammatory drugs (NSAIDs) 
Non-steroidal anti-inflammatory drugs (NSAIDs) share the same mechanism of 
action which consists of the inhibition of the COX enzymes with consequent 
reduction of prostaglandin formation.125  NSAIDs  are commonly used for their anti-
inflammatory, analgesic and antipyretic properties and large amounts of these 
drugs are sold over the counter.126 The mechanisms by which NSAIDs inhibit the 
COX enzymes vary between the different chemical classes of these drugs according 
to their chemical structure which determines the pharmacology of the interaction 
between drug and enzyme.19 The anti-inflammatory effects of NSAIDs are a 
consequence of the inhibition of the inducible COX-2, the isoform involved in 
inflammatory responses.126 Aspirin, one of the most common COX inhibitors, has a 
higher affinity for COX-1 compared to COX-2 which accounts for its strong anti-
thrombotic effects.127 It has been well established that chronic use of NSAIDs is 
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associated with severe gastrointestinal toxicity and nephrotoxicity.128 Indeed, the 
constitutive COX-1 enzyme is involved in the synthesis of gastric mucosal 
prostaglandins (e.g. PGE2) and, thus, inhibition of their production by NSAIDs 
contributes to the development of gastroduodenal complications which may lead to 
bleeding disorders and, in the worst case, death.129 Also, inhibition of platelet COX-1 
produces an impairment of physiological wound healing processes increasing the 
risk of gastrointestinal bleeding.129 Clinical trials published since 1997 indicate that 
there is around a 20% mortality in patients who have a severe gastrointestinal bleed 
or perforation resulting from exposure to NSAIDs or aspirin .130  
 
1.4.2 Aspirin 
In the 1960s aspirin was found to exhibit anti-platelet effects and in 1970 Vane 
discovered that the mechanism of action by which NSAIDs, including aspirin, 
reduced the production of prostaglandins was inhibition of the COX enzyme.125  
Aspirin irreversibly inactivates both isoforms of the COX enzyme (COX-1 and -2) via 
acetylation of the Ser529 molecule within the active site.131,132 The catalytic site of 
the COX-1 enzyme undergoes pharmacological modifications creating a stearic 
impediment for the binding of AA to COX-1 with consequent full inhibition of the 
enzyme’s activity.19,132 Differently, acetylation of COX-2 by aspirin, although still 
preventing the formation of PGH2-derived prostanoids, allows the conversion of AA 
to 15(R)-HETE.19,133,134 This phenomenon has been suggested to be a consequence 
of the bigger size of the COX-2 catalytic site compared to COX-1 which enables AA 
to enter the active site even in the presence of aspirin acetylation.135 
 
 
Figure 1.8 Structures of the COX inhibitor, aspirin.  
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1.5 LOX inhibitors 
 
Lipoxygenases have been shown to be involved in several diseases (e.g. cancer, 
asthma, atherosclerosis) and, therefore, in order to gain a better understanding of 
their physiopathological effects, it has been of crucial importance to develop 
inhibitors against the specific LOX isoenzymes through the investigation of the 
mechanism of inhibition of these molecules.49 It had been suggested that LOX 
inhibitors have beneficial neuroprotective properties in several conditions136,137, 
although their mechanisms of action are still unclear. LOX inhibitors are commonly 
used in basic research to investigate the role of the different LOX isoenzymes in cell 
physiology/pathology, in inflammation, ischaemia/reperfusion, Alzheimer’s and 
Parkinson’s diseases.138 Data indicated that most of the LOX inhibitors have strong 
antioxidant properties by both inactivating the LOX enzymes and by directly 
scavenging free radicals.138  
 
1.5.1 Baicalein 
In the literature the use of numerous 5-LOX and 15-LOX1 specific inhibitors have 
been reported, but not platelet-derived 12-LOX. Due to the involvement of 12-LOX 
products in several pathological conditions, the identification of an inhibitor specific 
for this enzyme has the subject of research effort. Flavonoids are polyphenolic 
compounds and natural products of several fruits, vegetables and vascular plants 
which have shown to be non-toxic and potent LOX inhibitors.139-141,142 Studies have 
reported that flavonoids displayed beneficial effects due to their antioxidant143, 
anti-inflammatory144, antitumor145, antimicrobial146 and antiviral properties.147 
Baicalein (5,6,7-trihydroxy-2-phenyl-4H-1-benzopyran-4-one), a major component 
of the root of Scutellaria baicalensis (Chinese name, Huangqin), has been identified 
as a specific flavonoid LOX inhibitor.148 This drug exhibited anticancer and 
chemopreventive activities by inducing apoptosis of several human cancer cell 
lines142 and, in particular, breast, prostate, colon and pancreatic cancer cells.149,150 
Baicalein is also a strong antioxidant and a direct free radical scavenger, although 
the IC50 for its antioxidant activity is over 100 times higher than IC50 for catalytic 
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activity.49 Sekiya et al. reported that the potency of this drug is associated with its 
ability to selectively inhibit the platelet 12-LOX isoform and not other LOX 
isoenzymes.151 The mechanism of action that has been suggested for baicalein is 
chelation and consequent reduction of the active site iron of the enzyme leading to 
the oxidation of the drug to its quinone form.152 However, recent steady-state 
kinetics studies established that baicalein is not selective for the 12-LOX enzyme in 
vitro.49 Thus, further studies might be requires to establish whether baicalein is 
selective for 12-LOX in cell culture and animal models.49 Furthermore, high clinical 
doses of baicalein have been reported to be multi-therapeutic, health-promoting 
and disease-preventing.153  
 
 
 
Figure 1.9 Structure of the 12 lipoxygenase inhibitor, baicalein.  
 
1.5.2 Nordihydroguaiaretic acid (NDGA) 
Nordihydroguaiaretic acid (NDGA) is a natural compound which derives from Larrea 
tridentate and is used in traditional medicine with several biological properties in 
cardiovascular disease, neurological disorders and cancers.138,154 NDGA is a non-
selective LOX inhibitor with powerful antioxidant properties and the IC50 for its 
inhibitory effects on the LOX catalytic activity is 0.91-7 µM. Data have reported that 
low concentrations of this inhibitor showed strong radical scavenger properties.138 
Currently, this drug is undergoing phase II clinical study in men with non-metastatic 
hormone-sensitive prostatic cancer.155 Despite the numerous beneficial effects of 
NDGA, several side effects have been detected, such as cognitive disturbance, 
nausea, syncope and impaired liver function.138  
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Figure 1.10 Structure of the lipoxygenase inhibitor, NDGA.  
 
1.5.3 Other LOX inhibitors 
Zileuton is a selective iron-chelating inhibitor of the 5-LOX enzyme which exhibits 
much weaker antioxidant effects compared to other LOX inhibitors, including those 
described previously.138 Data have reported that the IC50 values for the antioxidant 
properties of this drug are significantly higher compared to those for the catalytic 
activity.156 Properties in lipid peroxidation of the drug were observed at 
concentrations of 5 µM and only at very high concentrations it prevented carbonyl 
group formation.157 Zileuton was approved by the USA FDA in 1996 for the 
prophylaxis and chronic treatment of asthma in both adults and children.158 
However, the use of this drug caused side effects which include hepatotoxicity and 
neuropsychiatric events.158,159 
 
BW870C, a selective iron-chelating redox-type inhibitor of the 5-LOX enzyme, has 
been identified as a very strong antioxidant able to significantly reduce lipid and 
protein oxidation at concentrations between 2.5 µM and 5 µM, respectively.138 This 
compound was also effective as a radical scavenger independently of the iron-
chelating mechanism.138 A therapeutic agent could not be developed as serious side 
effects were observed in rats treated with this inhibitor. 
 
AA-861 is a selective redox-active 5-LOX inhibitor and showed weak antioxidant 
effects against lipid peroxidation and no properties as a free radical scavenger.138 
The pharmacology and toxicology of this inhibitor require further investigation. In 
vitro studies have reported that treatment of human tumour cells with this 
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compound produced cytotoxic and antiproliferative effects through mechanisms 
that were not associated with 5-LOX inhibition.160  
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1.6 Platelets 
Platelets are non-nucleated blood cells present only in mammalians and circulating 
in the blood stream. The main function of platelets within the vasculature is wound 
repair upon vessel injury and they play a crucial role in both haemostasis and 
thrombosis.161   
 
1.6.1 Thrombopoiesis 
Megakaryocytes (MKs) are polyploidy hematopietic cells that reside in the bone 
marrow and develop from pluripotent haematopoietic stem cells upon the 
stimulation of the cytokine thrombopoietin (TPO).162-165 The human body produces 
about 100 billion platelets per day and each MK, under the stimulation of TPO, is 
able to produce 100-200 platelets over a 4-hour time course.164 In 1906 Wright 
established that platelets are fragments originating from pseudopodia of 
megakaryocytes58 which were subsequently described in more detail by Thiery & 
Bessis and Behnke.166,167 The ”proplatelet theory” of platelet formation was then 
proposed by Becker and Debruyn suggesting that megakaryocytes develop 
cytoplasmic pseudopodia-like processes, proplatelets, which represent the 
intermediate structures in the megakaryocyte-to-platelet transition.168 Within these 
processes proteins and granules necessary for platelet function are accumulated. 
More recent models of platelet formation suggest that proplatelets extend from 
megakaryocytes in the bone marrow through junctions in the endothelial lining of 
blood sinuses where they are then released into the circulation undergoing further 
fragmentation into individual platelets.169-171 
 
1.6.2 Mature platelets 
Mature platelets are non-nucleated products of MK fragmentation characterised by 
a discoid shape provided and supported by the cytoskeleton and have a diameter 
and thickness of 2 – 5 µM and 0.5 µM, respectively.172,173  Normal platelet count is 
around 150-350 x 109 per litre.174,175 The life-span of platelets is 7 – 10 days and 
they are ultimately sequestered by the spleen.174 The platelet cytoplasm contains 
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various organelle and, in particular, α-granules, dense granules and lysosomes. α-
granules are greater in number, 40 to 80 per platelet, and in dimension compared 
to the others. A vast range of proteins are stored in α-granules such as P-selectin, 
portions of the main platelet adherence receptors (i.e. GPIb-IX-V and integrin 
αIIbβ3), adhesive components (e.g. von Willebrand factor), fibronectin, fibrinogen, 
vitronectin, thrombospondine, coagulation factor V176,177,178 and factors involved in 
the regulation of angiogenic processes (e.g. VEGF and PDGF).179 Dense granules are 
smaller and fewer compared to α-granules and contain ATP and ADP, 5-HT, 
pyrophosphate, calcium and magnesium. Platelets also contain a surface-connected 
canalicular system characterised by invaginations of the surface membrane which 
facilitate granule release.174 
 
Although platelets are non-nucleated fragment of cells and, hence, are not in 
possession of a DNA, the legacy from MKs of low levels of mRNA, ribosomes and 
endoplasmic reticulum allow platelets to synthesize proteins. This ability is limited 
and accounts for their very short life-span (7-10 days).174 The role that platelet 
mRNA plays is currently an area of interest that requires further investigation.180 
 
Platelets express a great number of 7-transmembrane G protein-coupled receptors 
(GPCRs) and integrins on their surface. Integrins are formed by two subunits, a big 
subunit α and a smaller subunit β, and in normal conditions are present in a low 
affinity state.181 In order to be in a high affinity state integrins undergo a 
conformational change induced by intracellular signalling pathways upon platelet 
activation.181,182 This process is referred to as “outside-in signalling” and integrin 
αIIbβ3 is an example.
182 
 
1.6.3 Platelets and atherogenesis 
Atherogenesis is a progressive and inflammatory disease of the arterial vascular 
wall characterised by vascular dysfunction, deposition of oxidised LDL, neutrophil 
adhesion, monocyte and macrophage adhesion and transformation to foam cells, 
proliferation of SMCs, and accumulation of prothrombotic extracellular matrix 
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proteins.183  Activated platelets in addition to playing a major role in thrombus 
formation are also involved in the progression of atherogenesis via the release of 
inflammatory and mitogenic mediators (e.g. chemokines and growth factors).184,185 
The interaction of these mediators with the vascular wall alters the chemotactic and 
adhesive properties of ECs leading to leukocyte chemotaxis, adhesion, 
transmigration and, thereby, the development of atherosclerotic plaques.186 Also, 
reactive oxygen species (ROS) released by both ECs and activated platelets in these 
conditions contribute to the progression of this vascular disease via the oxidation of 
circulating LDL leading to the production of pro-inflammatory isoprostanes, also 
identified in atherosclerotic lesions.187  
 
1.6.4 Platelets and thrombus formation 
Physiologically platelets play a fundamental role in haemostasis, the defence 
mechanism that prevents blood loss following from disruption of the vessel by 
traumatic injury. Within the arterial laminar blood flow, where shear rate values 
range between 500 – 5,000 s-1, platelets circulate very closely to the vascular wall 
due to their small size compared to other blood cells.188 Platelets under shear are 
inhibited by active metabolites released from the vascular wall, such as PGI2 and 
NO, which maintain the cells in a quiescent state.189 At sites of atherosclerosis shear 
rates can increase significantly up to 20,000 – 40,000 s-1 just upstream of a severe 
stenosis.190 Atherosclerotic plaques are characterised by lesions rich in 
thrombogenic components, such as collagen and tissue factor, and are formed by a 
fibrous cap and a lipid-rich core.183 Therefore, these plaques are prone to rupture 
leading to the exposure of thrombogenic components to circulating platelets.191 In 
these pathological scenarios platelets adhere at the site of injury and become 
activated playing a central role in the development of arterial thrombi.190 
Moreover, it has been demonstrated that changes in the blood haemodynamics 
play crucial roles in the development of a thrombus downstream from the site of 
vascular injury also in the absence of prothrombotic mediators.192 In particular, 
vessel stenosis or thrombus formation have been shown to produce local shear 
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microgradients and the exposure of platelets to these haemodynamic changes is 
sufficient for them to become activated and form  aggregates.192 
 
1.6.4.1 Adhesion 
Vascular wall damage leads to the exposure of extracellular matrix adhesive 
proteins and in particular laminin, fibronectin, von Willebrand factor (vWF) and 
collagens. Platelets adhere to these exposed proteins, thus, initiating thrombus 
formation.193 
  
vWF 
It is well established that vWF plays a crucial role in initiating platelet adhesion and 
in supporting platelet aggregation under high shear conditions.194 VWF is both a 
plasma component and a constitutive component of the extracellular matrix of 
endothelial cells where it is associated with collagen type IV.195 Indeed, vascular 
injury leads to the immobilization of plasma vWF onto the subendothelial surface 
through the binding of extracellular proteins and through self-association with 
other vWF multimers.190 Particularly, vWF binds to collagen type I and III in deeper 
levels of the vessel wall and collagen IV in the subendothelial matrix.190 The A1 and 
A3 domains of vWF are involved in the interaction with collagen and the respective 
roles depend on the type of collagen and on the fluid dynamic conditions.196,197 In 
conditions of high shear which can be encountered in arteries and arterioles, 
platelets are captured at the site of injury via binding of the platelet GPIb-XI-V 
receptor to vWF immobilised to collagen fibrils.190,193 This particular process is 
defined tethering where the A1 domain of vWF forms a “catch bond” with the 
ligand-binding domain GPIbα of the platelet GPIb-IX-V receptor.190,198 However, this 
interaction is rapidly reversible with a fast dissociation rate and, thus, unable to 
produce stable adhesion on its own.199 The interaction of platelets with vWF does 
not require activation of GPIb which facilitates the capture of platelets and 
decrease their velocity allowing the formation of more stable adhesive bonds.161,190 
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Collagen 
In order to fully adhere and become activated platelets are required to bind directly 
to exposed collagen through specific platelet receptors, GPVI and integrin α2β1.
190 
There are several types of collagen within the extracellular matrix, types I-II-III-IV, 
and the conformation of these proteins influences the mechanism of interaction 
with platelets.200 The binding of platelets with these components produces a 
sequence of events that lead to platelet shape change, spreading, integrin 
expression, firm adhesion and activation. Integrin α2β1 is associated to Src family 
kinases and ultimately induces activation of PLA2 and PLCϒ.
201 The grade of 
contribution of α2β1 to collagen-dependent platelet responses is still under debate, 
whereas GPVI is established to be indispensable for full platelet adhesion and 
activation.190 Indeed, in vivo studies have shown that platelets depleted of the GPVI 
receptor under arterial blood flow display severe impairment of adhesion and 
aggregation at sites of vascular injury.202 GPVI is a member of the immunoglobulin 
superfamily composed of two IgG domains, a transmembrane and an 
intracytoplasmic domain.190 GPVI specifically recognizes the sequence Gly-Pro-Hyp, 
also known as collagen-related peptide (CRP), which is able to induce platelet 
activation as efficiently as collagen.203 This receptor is associated with the adapter 
protein FcRϒ and its binding to collagen leads to a signalling cascade of events 
characterised by tyrosine phosphorylation of PLCϒ2 and consequent activation of 
integrin αIIbβ3, increase of intracellular calcium levels, secretion of α and dense 
granules contents, synthesis and release of bioactive metabolites.181,204 Horm 
collagen is the most common collagen preparation experimentally used which 
consists of a fibril suspension formed by equine type I collagen and acts through 
both α2β1 and GPVI, whereas collagen-related peptide (CRP) activates only 
GPVI.181,201 
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Figure 1.11 Schematic representation of key ligands and receptors involved in 
primary platelet adhesion. Circulating platelets are captured at site of vascular 
injury through the binding of GPIb-IX-V to subendothelial vWF resulting in platelet 
translocation along the subendothelium. Stable adhesion requires the binding of 
GPVI to collagen fibrils and of different β1 integrins to their respective ligands 
exposed in the subendothelium (e.g. α2β1 integrin to collagen) as well as the binding 
of integrin αIIbβ3 to vWF. 
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Figure 1.12 Schematic representation of the signalling events following receptor 
ligation during primary platelet adhesion. Platelet adhesion leads to signalling 
cascade of events including Scr family inase (Scr), Syk and PI3-kinase (PI3K) leads to 
the activation of phospholipase Cϒ (PLCϒ) which hydrolyses the membrane 
phospholipids to generate IP3. The binding of IP3 with its receptor, IP3R, on the 
dense tubular system (DTS) stimulates Ca2+ mobilization leading to granule 
secretion, TXA2 generation, and the conversion of integrin αIIbβ3 to a high-affinity 
receptor for vWF and fibrinogen. The binding of integrin to subendothelium vWF 
contributes to stabilise platelet adhesion to the vessel wall, while its binding to 
fibrinogen promotes platelet aggregation. 
 
Once platelets become activated through binding to collagen, rearrangements in 
the platelet cytoskeleton occur resulting in shape change. This process involves 
reorganization of the actin-based cytoskeleton which leads platelets to lose their 
characteristic discoid shape, formation of filopodia which allow platelet spreading 
at the site of injury and centralization of α and dense granules within platelets prior 
to their release.205 It has been reported that Gq and G13  linked receptors are 
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involved in platelet shape change.34 Both thrombin and TXA2 are able to induce 
shape change by acting on such receptors, preferentially on G13, while ADP acts 
solely through Gq-linked processes.
34    
 
1.6.4.2 Aggregation 
In order to aggregate and develop a stable thrombus, activated platelets secrete, 
synthesize and release a vast range of metabolites able to recruit additional 
platelets and amplify the signals which sustain platelet activation and promote 
platelet-platelet interactions.161 Amongst platelet agonists, thrombin, collagen, ADP 
and TXA2 are able to activate integrin αIIbβ3, or GPIIb-IIIa, which plays a crucial role 
in the formation of platelet aggregates.182 Upon activation integrin αIIbβ3undergoes 
a conformational change, referred to as “inside-out signalling”, which increases its 
affinity to fibrinogen.182 Integrin αIIbβ3 is the most abundant integrin in platelets 
with 60,000 – 80,000 receptors on the platelet surface and further copies stored 
within the α-granules and expressed on the platelet surface upon 
activation.182,193,190 This integrin strongly binds proteins containing an RGD 
(arginine-glycine-aspartic acid) sequence, such as VWF, fibronectin and fibrinogen, 
and outside-in signalling leads to activation of the platelet through PLCϒ. 
161,193 
Fibrinogen and vWF are able to bridge integrin αIIbβ3 on the surface of adjacent 
platelets promoting thrombus growth. 161 Fibrinogen in particular is responsible for 
the development of stable thrombi through the formation of strong bonds between 
platelets decreasing the risk of embolism under flow conditions.  
 
Thrombin 
Thrombin activation is mediated by tissue factor which becomes exposed upon 
vascular injury and induces activation of a cascade of coagulation factors.206 As a 
result of this cascade of events, activated factor X, Xa, and Va are responsible for 
the cleavage of prothrombin to form thrombin which occurs on the platelet 
surface.207 Thrombin is the most potent platelet agonist and is involved in both 
aggregation and coagulation processes. At very low concentrations it is able to drive 
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strong aggregation responses inducing a rapid rise of intracellular calcium levels, 
cytoskeleton rearrangements, shape change, activation of integrin αIIbβ3, platelet 
activation, aggregation and also decreases the platelet cAMP levels directly via Gi-
coupled receptor or indirectly through the release of ADP.208,209 Thrombin acts on 
two protease activating receptors (PAR), human PAR-1 and PAR-4, which are 
members of the GPCRs.207 In particular, these receptors are activated by thrombin 
proteolytic cleavage of the N-terminal.210 Both these receptors are required for 
platelet aggregation responses. It has been shown that thrombin acts first on PAR-1 
and subsequently on PAR-4 where higher concentrations of the agonist are 
required.211,212 PAR-1 and PAR-4 are coupled to Gq and G12/13.
34 Gq-mediated 
signalling leads to PLCβ activation and generation of IP3 and DAG with the 
consequent rise in intracellular calcium levels which promote the activation of 
cytosolic phospholipases and, thus, the formation of TXA2.
34,207  
TXA2 
Thromboxane A2 is a short-lived (30 s) lipid mediator synthesized using AA as a 
substrate which is released from the membrane phospholipids through the activity 
of PLA2.
4,32 The 85-kDa cytosolic PLA2 (cPLA2) is the main isoform express in platelets 
and the main source of AA.213 COX-1 and TXA synthase are the platelet enzymes 
involved in the synthesis of TXA2.
26 It  has been reported that platelets expressed 
also the COX-2 isoform  which was found to increase in patients with a high platelet 
turnover (e.g. immune thrombocytopenia or peripheral blood stem cell 
transplantation)214 This prostanoid belongs to the class of platelet mediators, such 
as ADP, that promote second wave aggregation characterised by the amplification 
of platelet activation and recruitment of additional platelets in order to promote 
thrombus growth and stabilization. In particular TXA2 acts as a positive feedback 
regulator and leads to platelet activation, aggregation, integrin αIIbβ3 activation, 
secretion, and membrane lipid phosphorylation but affects only slightly platelet 
cAMP levels. Due to the chemical instability of this mediator, a TXA2 mimetic, 
U46619, is used experimentally.32,33 Both these agonists act on TP receptors of 
which two isoforms have been identified, TPα and TPβ. Platelets express only the TPα 
isoform which couples with Gq and G12/13, although platelets present both 
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transcripts.32,215,216 Gq stimulates PLCβ to increase the platelet intracellular calcium 
levels and activate PKC promoting platelet aggregation, while the G12/13-mediated 
Rho/Rho-kinase-dependent regulation of myosin light chain phosphorylation 
participates in receptor-induced platelet shape change.217 Lack of TP receptors in 
mouse platelets has been shown to cause a bleeding tendency which illustrates the 
importance of TXA2 in supporting platelet aggregation.
33 
 
ADP 
Along with TXA2, ADP represents a positive-feedback mediator and is secreted from 
the dense granules upon platelet activation.34,218 Damaged erythrocytes at the site 
of injury are also a source of ADP. This platelet agonist induces a cascade of events 
including TXA2 synthesis, increase of intracellular Ca
2+ levels, integrin αIIbβ3 “inside-
out signalling”, protein phosphorylation, platelet shape change, secretion and 
aggregation. ADP also decreases the platelet cAMP levels, which promotes platelet 
activation and aggregation. This platelet agonist acts on two different purinergic 
GPCRs, P2Y1 and P2Y12, both of which are required for a full platelet aggregation 
response.218 The P2Y1 receptor is coupled with Gqα which leads to the activation of 
PLC pathway, while the P2Y12 receptor is coupled with Gi inducing a decrease in 
cAMP levels.218 Although full aggregation responses require the activation of both 
these receptors, the lack of P2Y12 strongly impairs platelet aggregation and causes 
severe bleeding. Conversely, aggregation responses to different agonist are 
unaffected by the lack of P2Y1. Moreover, in the presence of serotonin, a weak 
agonist which activates PLC, ADP responses were preserved in P2Y1
-/- mice. 
Therefore, the anti-platelet therapy currently used for the prevention of secondary 
thrombotic events focuses upon P2Y12 as a therapeutic target. Also, the P2Y1 
receptor becomes selectively desensitized following ADP stimulation.218 P2X1 is a 
third platelet P2 receptor which acts on gated cation channels triggering increases 
in intracellular Ca2+ levels upon ATP stimulation. Activation of this receptor alone 
does not induce platelet aggregation, although it has been suggested it might 
support collagen-induced aggregation.218  
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Activated platelets are able to release a vast range of other agonists which indicate 
quite a high level of system redundancy. Although these mediators exhibit weak 
effects on platelet aggregation they are able to potentiate the effects induced by 
strong agonists (e.g. thrombin, TXA2, ADP). Epinephrine represents an example of 
mediator able to potentiate platelet aggregation through the activation of α2-
adrenergic receptors which couple to Gz (Gi type of G-protein).
34 Moreover, 5-TH 
(serotonin) is released from dense granules by activated platelets and acts on 5-
HT2A receptors which couple with Gq.
34,219  
 
1.6.4.3 Secretion 
As described above, platelet α-granules and dense granules store a vast range of 
mediators that play a crucial role in supporting thrombus formation. In particular, 
α-granules contain factors such as fibrinogen, vWF, integrin αIIbβ3, coagulation 
factors, and P-selectin, whereas dense granules store other agonists, such as ADP 
and serotonin. Therefore, secretion of these mediators represents a fundamental 
step of platelet activation and consequent aggregation. Both Gq and G13 signalling 
pathways are crucial for platelet secretion. Indeed, Gq stimulates secretion by 
increasing the intracellular calcium levels and PKC activation, whereas G13 acts by 
inducing the centralization of granules prior to their release.34  
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Figure 1.13 Schematic representation of platelet receptors activated by soluble 
agonists essential for platelet aggregation. Following primary adhesion platelets 
generate or release several agonists, in particular ADP, TXA2 and thrombin which 
induce biochemical and functional platelet responses such as intracellular Ca2+ 
mobilization, platelet shape change, and granule secretion which ultimately lead to 
the formation of stable platelet aggregates. ADP, TXA2 and thrombin bind to specific 
G-protein coupled receptors (ADP, P2Y1 and P2Y12; TXA2, TP; thrombin, PAR1 and 
PAR4) to amplify platelet activation. Receptors for ADP, TXA2 and thrombin are 
coupled to Gαq leading to the activation of PLCβ, and the hydrolysis of membrane 
phospholipids to generate IP3 and DAG which induce Ca
2+ mobilization and protein 
kinase C (PKC) activation, respectively. The P2Y12 receptor couples to Gαi leading to 
the inhibition of adenylyl cyclase (AC) and activation of PI3K. All these signalling 
pathways induce the integrin high-affinity state which is able to bind both 
fibrinogen and vWF, thus promoting thrombus growth.  
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1.6.4.4 Coagulation  
Upon vascular injury the key haemostatic processes induced are represented by the 
coagulation pathway involved in fibrin formation and, as previously described, by 
platelet activation, adhesion at the site of injury and thrombus growth. In normal 
conditions the endothelium provides several anti-coagulatory and anti-aggregatory 
factors (e.g. tissue factor pathway inhibitor, anti-thrombin, NO, PGI2) within the 
vascular system. Within the vascular wall tissue factor (TF) is highly expressed and 
represents the initiator of the coagulation pathway, also known as extrinsic 
pathway, when exposed to the blood stream.220 Coagulation can be also initiated 
through an intrinsic pathway which requires the activation of FX by the FVIIIa-FIXa 
complex.221 Once the vascular wall presents an injury, TF becomes exposed to the 
blood triggering the activation of a cascade of coagulation factors.220,222 The 
membrane protein TF binds factor VII and the active factor VIIa.220 Binding of TF to 
factor VIIa leads to the activation of factor IX and factor X.220,223 Factor VIIa, IXa and 
Xa are able to activate TF when bound to factor VII, thus promoting a positive-
feedback amplification of the system.220 Factor VII circulates in the blood stream 
bound to vWF and, once activated, it dissociates from the complex and binds factor 
IX to form the tenase complex on the negatively charged membrane which then 
activates factor X.220,223 Factor V is activated to Va by both the negatively charged 
membrane bound to factor Xa and thrombin.220 Factor Xa and factor Va form a 
prothrombinase complex which activates prothrombin to thrombin.223 Ultimately, 
thrombin activates fibrinogen to fibrin which plays a crucial role in stabilising the 
thrombus.220 Also, thrombin via a positive-feedback amplification mechanism 
activates factors V, VIII and XI, where factor VIII has been shown to stabilise the 
plug by crosslinking fibrin.220 The amplification of the system produces a notable 
increase in the plasma levels of these coagulation factors, such as factor VII and 
fibrinogen.220 As described before thrombin is a potent platelet agonist and plays a 
key role in both pro-/anti-coagulatory and pro-aggregatory processes. Once 
activated, both platelets and platelet microparticles express TF and exhibit 
negatively charged phospholipids providing a pro-thrombogenic surface where both 
tenase-complexes and prothombinase-complexes can be formed.220,222,224 
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Figure 1.14 a) Extrinsic coagulation pathway; b) Intrinsic coagulation pathway. PL: 
phospholipids; HMWK: high molecular weight kininogen; PK: prekallikrein. 
 
A number of circulating endogenous coagulation inhibitors physiologically circulate 
within the vasculature with the purpose of counteracting the pro-coagulatory 
processes during the development of the thrombus. Amongst these inhibitors, 
tissue factor pathway inhibitor (TFPI) prevents the amplification of the coagulation 
cascade by inhibiting the production of both FXa and FIXa through the TF-FVII/FVIIa 
complex.221 The optimal conditions for TFPI to elicit its inhibitory effects occur when 
the enzyme is in the prothrombinase complex which includes FXa, FV and 
calcium.221,223 In vivo 80% of the plasma TFPI is bound to plasma lipoproteins (e.g. 
LDL, HDL and VLDL) within the circulation, whereas free TFPI represent only the 5 – 
20%.221 The lipoprotein-bound TFPI exhibits weaker anti-coagulant effects 
compared to the unbound.221 Another crucial inhibitor of the coagulation cascade is 
represented by antithrombin (AT), a serine-protease inhibitor, which preferentially 
Introduction 
41 
 
inhibits unbound coagulation enzymes.220 The function of the enzyme is to limit 
coagulation processes at site of vascular damage by reducing the levels of the pro-
coagulatory enzymes released in the circulation.220 Circulating AT does not exhibit 
efficient protease activity and requires stimulation by heparin and heparine-derived 
molecules expressed on the surface of endothelial cells which accounts for the use 
of heparin as a therapeutic anticoagulant.220,225 Ultimately, the protein C system 
inhibits the coagulation pathway through a key component which is represented by 
protein C, a vitamin K-dependent zymogen (proenzyme) to an anticoagulant 
protease.220 Protein C is activated by thrombin bound to the membrane protein 
thrombomodulin I on the surface of intact endothelial cells which accounts for both 
pro- and anti-coagulatory role of thrombin.220,226 Activated protein C (APC) together 
with a cofactor, protein S, inhibits the pro-coagulatory activities of the cofactors 
involved in the tenase- and prothrombinase-complexes by cleaving peptide bonds 
of FVa and FVIIIa.226,227 
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Figure 1.15 Stages of plug formation. a) In physiological conditions platelets are 
maintained in a resting state by inhibitory factors released from vascular 
endothelial cells. These factors include prostacyclin (PGI2), nitric oxide (NO) and 
CD39, an ADPase expressed on the surface of endothelial cells. b) As a consequence 
of vascular injury extracellular matrix proteins, collagen-von Willebrand factor 
(vWF) complex, are exposed to the blood stream. These proteins together with 
thrombin capture and activate circulating platelets which then adhere and spread at 
the site of injury. c) Activated platelets release a range of agonists, such as TXA2 and 
ADP, which recruit and activate further platelets contributing to the development of 
the plug. Platelet-platelet interactions are mediated by bridges via the binding of 
fibrinogen, fibrin or vWF to activated integrin αIIbβ3. d) Platelet contacts together 
with fibrin formation contribute to stabilise the forming plug. 
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1.7 Thrombotic vascular events 
 
The development of a thrombus within the arterial vasculature, as previously 
described, can lead to partial or total occlusion of the vessel lumen with consequent 
depletion of oxygen supplies to organs and tissues. This pathological condition can 
manifest clinically as coronary artery syndrome, myocardial infarction or ischaemic 
stroke which are associated with a high risk of morbidity and mortality.184 In order 
to avoid the occurrence of such events prompt intervention is required.184 
 
1.7.1 Antiplatelet treatment  
Anti-platelet drugs are currently used as a therapeutical approach in the prevention 
of thrombotic events such as myocardial infarction and stroke. Currently the classes 
of anti-platelet drugs that are most wildly in use are aspirin, thienopyridines and 
GPIIbIIIa antagonists. Aspirin is considered the “gold standard” anti-platelet 
treatment because of the its history of use and the greater cost:benefit ratio 
compared to other drugs. Several clinical trials showed that that double antiplatelet 
therapy where aspirin (75 – 100 mg daily) and  ticlopidine, e.g. clopidogrel, are used 
in combination reduces the risk of myocardial infarction in patients with peripheral 
artery disease, produces beneficial effects in patients with unstable angina or MI 
without ST-segment elevation and significantly reduced the incidence of death, 
reinfarction or stroke.228,229 Also, double-dose clopidogrel significantly reduced 
secondary outcome of stent thrombosis in patients who underwent percutaneous 
coronary intervention (PCI). The ISAR study showed that treatment with ticlopidine 
plus aspirin, compared with oral anticoagulants plus aspirin, robustly decreased the 
incidence of death from cardiac causes or the occurrence of MI, aorto-coronary 
bypass surgery, or repeat angioplasty 30 days after the intervention.230,87,231 Among 
the ticlopidine prasugrel at 60 mg loading dose and 10 mg maintenance dose was 
proven in the TRITON TIMI-38 clinical trial to significantly reduced the incidence of 
cardiovascular events, particularly stent thrombosis as compared with 
clopidogrel.232 Moreover, phosphodiesterase (PDE) inhibitors increase the 
intracellular levels of cyclic guanine monophosphate (cGMP) and/or cAMP by 
Introduction 
44 
 
blocking the degradation of cyclic nucleotides with pleiotropic effects on platelet 
function and vasoreactivity.233 In particular, dipyridamole acts on both PDE3 and 
PDE5 and in combination with aspirin has been proven more effective than aspirin 
alone in secondary prevention of stroke and equally protective as compared with 
clopidogrel although with an increased risk of bleeding.234,235 
 
1.7.1.1 Aspirin 
Aspirin is established as a default anti-platelet treatment in the prevention of 
cardiovascular disease.236 Indeed, a reduction of about 30% in the occurrence of 
thrombotic events can be achieved by the use of low doses of aspirin (75-100 
mg).127,236 Aspirin irreversibly inactivates the cyclooxygenase activity of both COX-1 
and -2 isoforms through the acetylation of the Ser529 and Ser516 residue, 
respectively, in the active site.127,237 It is well established that platelets only express 
the constitutive COX-1 isoform and, thus, the presence of aspirin leads to the 
inability of the enzyme to synthetize AA-derived pro-thrombotic prostanoids, such 
as TXA2.
127 Conversely from COX-1, inhibition of the COX-2 enzyme requires higher 
concentrations of aspirin within the circulation since acetylation is determined by 
the oxidative state of the enzyme and is inhibited in cells with high peroxide tone.238 
Also, it requires a shorter dosing interval due to the fact that nucleated cells, 
differently from platelets, are able to rapidly resynthesize the enzyme. Aspirin is 
administered orally and rapidly absorbed in the stomach and upper intestine with a 
bioavailability of 50%.127 The plasma levels peak 30-40 min following ingestion of 
the uncoated formulation of the drug and the inhibition of TXA2-dependent platelet 
responses is evident by 1 hour.239 Aspirin has a half-life of 15-20 min and is 
characterised by rapid clearance from the circulation as it undergoes gastric and 
mucosal hydrolysis.239 As already mentioned, platelets are non-nucleated and, 
therefore, the effects of aspirin via irreversible inactivation of the COX-1 enzyme 
last for the life of the platelet.127 For this reason the only way to reverse these 
effects is normal platelet turnover. In patients affected by certain conditions that 
cause increased platelet turnover (e.g. diabetics) more frequent doses might be 
required to obtain the anti-thrombotic effects desired.240 Despite the rapid 
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clearance, platelets are inhibited by concentrated levels of aspirin within the 
hepatic portal circulation which accounts for the long lasting effects of once-a-day 
regimen of the drug.127 Meta-analysis recently established that administration of 
higher doses of aspirin, up to 500-1500 mg per day, are no more effective than low 
dose aspirin (75-100 mg per day) in the prevention of severe vascular events.241 The 
Antithrombotic Trialists’ Collaboration meta-analysis studies conducted in patients 
that already presented with ischaemic vascular events or at high risk of arterial 
thrombosis have demonstrated that aspirin treatment was able to reduce the 
occurrence of cardiovascular events (i.e. myocardial infarction and stroke) of about 
25%.241,242 It has been established that daily doses of aspirin (75-100 mg) lead to 
side effects such as gastrointestinal complications and increased risk of 
haemorrhagic stroke and extracranial bleeding which can be aggravated with higher 
dosage of the drug.127,243 Therefore, a safer but yet beneficial anti-platelet therapy 
would be desirable and investigations continue. 
 
 
 
1.7.1.2 Thienopyridine – P2Y12 blockers 
Thienopyridines are a class of drugs which selectively and irreversibly block the 
platelet P2Y12 receptor inhibiting the ADP-induced amplification of platelet 
aggregation and thrombus formation.244 Initially, these compounds were used as 
molecular tools to characterise platelet responses to ADP and the pro-thrombotic 
effects of this agonist.244 Currently, these drugs are used in combination with 
aspirin as a dual antiplatelet therapy in patients at risk of cardiovascular events.244 
Thienopyridines are pro-drugs and, hence, require hepatic metabolism in order to 
become pharmacologically active metabolites. By irreversibly blocking the P2Y12 
receptor, as in the case of aspirin, platelets are inhibited for all their remaining 
life.44 P2Y12 blockade leads to several intracellular effects and, in particular, 
inhibition of the ADP-mediated reduction of cAMP levels while preserving the 
calcium signalling pathways.236,245 The mechanisms by which these drugs 
pharmacologically inhibit platelet aggregation are 1) blockade of the P2Y12 receptor, 
2) inhibition of the TXA2 pathway of platelet activation and 3) sensitization to the 
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inhibitory effects of PGI2 and adenosine against platelet aggregation through 
disinhibition of the effects of P2Y12 activation on cAMP
236,246 4) conversion of ADP 
to adenosine which inhibits platelet aggregation in PRP and in whole blood when its 
uptake into red blood cells is inhibited, for instance in the presence of dipyridamole 
247 5) potentiation of the effects of  nitric oxide (NO) through a synergistic 
mechanism.248 Recently the interest in introducing oral drugs that reversibly 
inhibited the P2Y12 receptor led to the development of ticagrelor (or AZD6140), 
member of the new cyclopentyl-triazolo-pyridines class of drugs.236 Several reviews 
have emphasised the clinical relevance of the P2Y12 receptor as a target for 
antiplatelet drugs and have investigated blockers of the P2Y12 receptor.
218 Large-
scale clinical trials have demonstrated the beneficial effects of thienopyridines in 
the prevention of major cardiac events after coronary artery stent insertion and in 
the secondary prevention of major vascular events in patients with a history of 
cerebrovascular, coronary or peripheral artery disease.218 
 
Clopidogrel 
Clopidogrel is an oral pro-drug metabolised in the liver through cytochrome P450 
(CYP450), although recent studies have suggested that paraoxonase-1 might be 
involved in the generation of the active metabolite.249 Clopidogrel treatment 
inhibits ADP-induced platelet aggregation in a dose-dependent manner, although 
preserving shape change and transient week aggregation driven by P2Y1.
245 The 
clopidogrel active metabolite covalently binds cysteine residues of the P2Y12 
receptor, hence preventing binding with ADP.245 Administration of the drug at 
standard doses leads to partial and inter-individual variability (resistance” to 
clopidogrel).245 Clinical studies have suggested that patients that present 
“resistance” to the drug would perhaps benefit from a more personalised 
treatment.245 
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Prasugrel  
The variability of the effects following treatment with clopidogrel led to the 
development of new thienopyridines, and in particular prasugrel. Prasugrel is 
characterised by rapid and consistent inhibition of platelet aggregation.250 
Differently from clopidogrel, the new modifications introduced in the chemical 
structure of prasugrel allow this pro-drug to be metabolised to the active 
compound with less dependence on the CYP enzymes, therefore reducing the inter-
individual variability of the drug. In particular, a thiolactone is initially formed in the 
intestine through the activity of carboxylesterase (hCE)-2, then oxidised by 
intestinal and hepatic CYP3A and CYP2B6, with less contribution of CYP2C9 and 
CYP2C19. 251-253 Prasugrel, an oral pro-drug, peaks in the plasma after 30 min 
following ingestion and shows 10- to 100-fold more potency in inhibition of platelet 
aggregation ex vivo and in thrombus formation in vivo compared to other 
tienopyridines.250 Also, phase I clinical studies showed greater potency of prasugrel 
at 60 mg loading dose against the 300 mg of clopidogrel.254 In a phase III 
randomized, double-blind, parallel-group, multinational clinical trial (TRITON TIMI-
38) the effects of prasugrel (60 mg loading dose and 10 mg daily maintenance dose) 
were compared to those of clopidogrel (300 mg loading dose and 75 mg daily 
maintenance dose) on patients with moderate-to-high risk of acute coronary 
syndrome (ACS) who also required percutaneous coronary intervention (PCI).255,232 
As an outcome, prasugrel was associated with reduced ischaemic events, including 
stent thrombosis, although with an increased incidence of major and fatal 
bleeding.232 
 
1.7.1.3 Integrin αIIbβ3 inhibitors  
Integrin αIIbβ3 is a platelet-specific receptor and has been identified as a therapeutic 
target in the prevention or treatment of ischaemic cardiovascular disease because 
of the crucial role it plays in thrombus formation.256,257 As previously described, 
integrin αIIbβ3 , represents a fundamental and common element of the many 
pathways of platelet activation.256 Therefore, integrin αIIbβ3 has been targeted using 
monoclonal antibodies (e.g. abciximab) and peptides or peptidomimetics, based on 
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the arginine glycine-aspartic acid cell recognition sequence (RGD).256,257 The dose-
response curves of these drugs is very steep indicating the need to closely monitor 
the dose.257 As patients affected by Glanzmann thrombasthenia, where the 
expression of integrin αIIbβ3 is 50-60% of the normal number, rarely present with 
haemorrhagic diathesis, it appears most likely that pharmacological inhibition of 40-
50% of the receptor would not produce significant major bleeding.257 The pro-
thrombotic effects of integrin αIIbβ3 are mostly associated with platelet aggregation 
and thrombus formation, although this receptor is involved in other processes 
which may account for its beneficial effects.256 Indeed, it has been demonstrated 
that inhibition of this receptor reduces thrombin formation both quantitatively and 
qualitatively by decreasing the number of platelets in the thrombus and by 
decreasing platelet activation and release of FVa, respectively.256,258,259 
 
Abciximab 
Abciximab is a mouse/human chimeric monoclonal antibody 7E3 Fab fragment, 
which irreversibly blocks the integrin αIIbβ3  receptor with a high affininity (1 – 5 nM) 
Administration of a bolus (0.25 mg/kg) of abciximab produced 80% inhibition of 
both integrin αIIbβ3  and platelet aggregation to ADP in the majority of patients 
following percutaneous transluminal coronary angioplasty (PCI).258 The EPIC clinical 
trial also reported the beneficial effects of the drug in the prevention of ischaemic 
complications following PCI.260 The EPILOG study supported these data and showed 
that major bleeding was not increased by treatment with heparin and abciximab in 
combination during PCI. However, interindividual variations in the receptor 
blockade have been detected and suggested to be associated with differences in 
platelet count, integrin αIIbβ3  expression and presence of hepatic or kidney 
diseases.257 Human studies have reported that treatment with abciximab elicited a 
much more robust inhibitory effect on platelet function compared to treatment 
with aspirin.256 Also, phase III clinical trials in humans showed that administration of 
a bolus followed by 12h infusion of abciximab in combination with aspirin and 
heparin just before PCI reduced the risk of myocardial infarction, although major 
bleeding significantly increased.258  
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Low-molecular weight integrin αIIbβ3  inhibitors have been developed with the aim 
of overcoming the immunogenic complications and the irreversible inhibition of 
abciximab.  Eptifibatide, tirofiban, and lamifiban are members of this class of drugs 
which are commonly administrated intravenously as adjuvant therapy in situations 
of high risk of thrombosis where PCI is required.261 262 These molecules have been 
shown to have shorter durations of action and less affinity to integrin αIIbβ3 . 
261,262  
Several trials have shown that integrin αIIbβ3 are effective in patents with high risk 
of acute coronary syndrome (e.g. abciximab, tirofiban) and in those undergoing 
percutaneous coronary intervention (eptifibatide, tirofiban).233 However, their 
clinical use is limited as P2Y12 antagonists and new anticoagulants are the 
therapeutical strategies more broadly adopted.233,263 Generally, these drugs are 
now used only in refractory ischemia and high-risk PCI.263 
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1.8 HETEs and haemostasis/thrombosis 
  
1.8.1 HETEs and platelet aggregation 
Platelets possess different PLA2α isoforms including the cytosolic phospholipase A2 
(cPLA2α), the calcium-independent phospholipase A2 (iPLA2) and the inducible group 
II secretory phospholipase A2 (sPLA2), although the release of AA in platelets is 
dependent on cPLA2α, not sPLA2.
75,264 Upon platelet activation a link between cPLA2α 
and the integrin αIIbβ3 outside-in signalling was found in studies in which patients 
with a functional deficiency of cPLA2α demonstrated reduced platelet aggregatory 
and secretory responses when stimulated with ADP and collagen.75 Also, in cPLA2α-
deficient mice and human platelets treated with the selective cPLA2α inhibitor, 
pyrrophenone, no increase in integrin-associated cPLA2α activity in normal platelets 
occurred.75  
 
Alongside the platelet COX-1 enzyme, acute activation of the platelet-type 12-LOX 
has been reported in collagen- and thrombin-stimulated platelets leading to the 
production of 12(S)-HpETE/12(S)-HETE. However, the target receptor involved and 
intracellular signalling pathways of these metabolites are still not clear. There is 
evidence that collagen and collagen-related peptide (CRP) signalling via GPVI 
acutely promote the production of 12-HpETE in a dose and time dependent 
manner.75 Activating GPVI triggers P13-kinase turnover, leading to activation of 
phospholipase Cϒ2 (PLCϒ2). PLCϒ2 forms DAG and IP3, which then activate PKC and 
Ca2+ mobilization, respectively. Phosphorylation of PI3-kinase and stimulation of 
intracellular Ca2+ pools precedes activation of p12-LOX which involves 1) oxidation 
of the ferrous iron (Fe++) and 2) translocation of the cytosolic enzyme to plasma or 
nuclear membranes. It has been reported that in intact platelets the 12-LOX isoform 
is slowly activated and it remains active beyond the time required for platelets to 
aggregate, differently from the COX enzyme which is rapidly inactivated after a 
short burst of activity.76,265  
Multiple studies aiming at investigating the role these products played in regulating 
platelet responses have been reported. These studies have often used 12-LOX 
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inhibitors, but unfortunately their specificity is still debatable (as mentioned earlier) 
which may explain the lack of any consensus. It has been suggested that due to the 
high capacity of 12-LOX to oxygenate AA, the consequent oxygen depletion caused 
by its activity in a microenvironment represented by a mass of aggregated platelets 
during plug formation might render the system anaerobic. The reduction of the 
unstable 12-HpETE form involves a series of redox reactions and, ultimately, the 
oxidation of the gluthatione (GSH), the depletion of which was shown to cause 
inhibition of platelet aggregation and secretion.266 Thus, it has been hypothesized 
that 12-HpETE and other hydroperoxides might act as inhibitors of platelet 
activation. These findings are supported by studies in which both 12-HpETE and 15-
HpETE exhibited anti-aggregatory effects on human platelets at concentrations of 2-
6 µM.77 These inhibitory effects on platelet responses were suggested to be the 
consequence of the inactivation of free AA preventing the formation of pro-
aggregatory metabolites. Further studies that support an antiaggregatory effect of 
the 12-LOX pathway were conducted in 12-LOX-/- mice, which lacked the ability to 
synthetize 12-HETE from exogenous and endogenous AA, whereas TXA2 production 
remained unchanged.78 Platelets of these animals manifested a selective 
hypersensitivity to ADP ex vivo by both increasing the slope and the percentage of 
aggregation and by increasing the mortality in ADP-induced mouse model of 
thromboembolism.78 Therefore, these results suggest that the platelet-derived 12-
LOX pathway may play a role in inhibiting ADP-induced aggregation.  
Moreover, the cell membranes of inactivated platelets are rich in esterified AA and 
when platelet activation occurs the membrane structure is altered undergoing 
shape change, adhesion and secretion. Thus, it has been hypothesized that 12-LOX 
metabolises AA and consequently either promotes changes in the platelet 
activation processes and/or plays part in the structural changes the membrane 
undergoes upon activation.  
Conversely, Calzada et al. reported that physiologically relevant concentrations of 
lipid peroxides (e.g 12-HpETE), but not the reduced forms, potentiate platelet 
function when co-incubated with sub-threshold concentrations of AA.79 The 
inhibitory effect of HpETEs on platelet aggregation described in several studies were 
suggested to be linked to the high concentrations tested, whereas Calzada et al. 
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showed that hydroperoxides are able to potentiate platelet aggregation when used 
at concentrations closer to the physiological (i.e. 1-2 µM) and co-incubated with 
sub-threshold concentrations of AA.77,79 In particular, the addition of 
hydroperoxides, such as H2O2 and 12(S)-HETE (1-2 µM), to platelets primed with a 
non-aggregating concentration of AA resulted in an increased formation of TXB2 
supporting the hypothesis that the 12-LOX pathway might potentiate platelet 
aggregation through the enhancement of COX metabolism. Also nanomolar 
concentrations of 12(S)-HpETE were reported to potentiate aggregation of platelets 
co-incubated with sub-threshold concentrations of collagen and this was ascribed to 
activation of cPLA2α.
267
 
Platelet 12-LOX inhibitors, such as 5,8,11-eicosatriynoic acid (ETI) and baicalein 
(10µM), attenuated thrombin- and U46619-induced increases of platelet 
intracellular calcium and aggregation in washed human platelets.268 These results 
suggest that the platelet-derived LOX products are regulators of platelet 
intracellular calcium mobilization. The exogenous addition of 12-HETE was without 
effect on platelet intracellular calcium, whereas stimulation of 12-LOX with AA in 
ibuprofen-treated platelets did increase platelet calcium levels in response to 
thrombin suggesting  that an intermediate of the LOX pathway, and not 12-HETE, is 
responsible for this effect.268 LOX inhibition had no effect on platelet IP3 production 
suggesting that it may attenuate IP3-induced release of calcium from intracellular 
compartments or decrease the amount of calcium stored in IP3-sensitive 
compartments in platelets.268 Sekiya and al. reported that 12-HETE enhances 
thrombin-stimulated aggregation of bovine platelets and is able to prevent the 
elevation of cAMP levels induced by prostaglandin E1 (or prostacyclin in vivo) 
counteracting its inhibitory effect on platelet aggregation.80 The potentiating 
activity was also found in saturated hydroxyfatty acid, whereas polyunsaturated 
fatty acids without a hydroxyl group (e.g. linoleic acid) were not potentiating but 
rather inhibitory. Similarly to 12(S)-HETE, other naturally occurring HETEs, including 
12(R)-HETE, 5-HETE, 15-HETE and leukotriene B4, were also effective suggesting that 
the activity of 12-HETE might be attributable to the hydroxyl group within the 
molecule.80 This may raise the question on whether a potential interplay between 
all hydroxyl fatty acids might exist in acute conditions. 
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The divergent outcomes of the studies described might be linked to the non-
specificity of the inhibitors used which might have actions in addition to those 
caused by the inhibition of the platelet-type 12-LOX. Another possibility might lie in 
the differences between humans and mice in the p-12-LOX signalling pathway.78 
 
1.8.2 HETEs and vascular tone regulation 
Both the 12- and 15-LOX isoforms have been shown to play a role in modulating 
vascular tone and remodelling by acting on the vascular endothelium, smooth 
muscle cells, or both.55 In vitro studies reported that LOX and NO signalling 
pathways interact one with the other and that the former is involved in progression 
of vascular diseases.55 Indeed, LOX expressing cells were able to reduce NO 
bioavailability compared to LOX non-expressing cells and these data were 
supported by in vivo studies where 12/15-LOX knockout mice presented high levels 
of NO which prevented angiotensin II (AngII) signalling.269 Several reports suggested 
that inhibition of the 12-LOX enzyme was able to reduce both in vivo and in vitro 
responses to Ang II by altering intracellular calcium levels.82 Furthermore, the 
production of 12(S)-HETE from patients affected by essential hypertension was 
suggested to be greater than in normotensive control subjects and excreted higher 
amounts of 12(S)-HETE and lower amounts of PGI2 in the urine.
84 Animal 
experiments support the results obtained in humans showing that spontaneously 
hypertensive rats generated higher amounts of 12(S)-HETE than control Wistar-
Kyoto rats.85 However, it has to be taken into account that in many studies the 
inhibitors used are not specific for LOXs and, therefore, that LOX-independent 
biological responses may be involved in these effects on blood pressure.  
However, vasodilatory effects of HETEs on the coronary bed have been reported 
suggesting a role of these products in limiting or modulating the responses 
produced by the powerful vasoconstrictive action of TXA2 that could be released by 
aggregating platelets. In vitro and in vivo studies showed that both 12(S)-HETE and 
its precursor, 12(S)-HpETE, produced potent hyperpolarizing vasodilator effects in 
porcine coronary microvessels and smooth muscle cells, particularly in settings of 
oxidative stress. In these studies 12(S)-HETE was shown to potentially activate 
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large-conductance Ca2+-activate K+ currents in porcine coronary microvascular 
smooth muscle cell.83 
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1.9 Platelet-leukocyte interplay 
 
Leukocytes and platelets mutually interact and contribute to the development of 
thrombotic ischaemic events at sites of inflammation and vascular injury (e.g. 
rupture of an atherosclerotic plaque) where the release of local pro-inflammatory 
stimuli attracts both platelets and leukocytes to the luminal vascular endothelial 
surface.270 It has been suggested that platelets arrive early at sites of inflammation 
contributing to both coagulation and immune responses, partly by facilitating 
leukocyte-endothelium interactions.270 Platelets activated at the site of vascular 
damage play a key role in the polymorphonuclear leukocyte (PMNL) accumulation 
in a growing thrombus and the interaction between these two blood cell types is 
mediated by platelet P-selectin and leukocyte P-selectin glycoprotein ligand-1 
(PSGL-1). 271 Both endothelial cells and platelets express P-selectin which is stored 
in the Weibel-Palade bodies (WPBs) and α-granules, respectively.270 Once activated, 
the P-selectin released by both platelets and endothelial cells supports adhesion 
with several leukocyte types and induces their activation.272,273,274 It has been 
suggested that activated platelets at the site of vascular injury are crucial for 
initiating migration/activation of leukocytes, although there is also evidence that 
platelet-PMNL recruitment might be induced and/or amplified by PMN 
activation.270  Indeed, the inflammatory factors released by the injured vessel may 
activate PMNL causing further damage of endothelial cells and, thus, aggravating 
vascular injury.275 These events might trigger the activation of integrin integrin αIIbβ3 
promoting platelet binding to fibrinogen and, therefore, aggregation.276,277 Another 
study has shown that stimulated platelets are able to activate PMNL in a contact-
dependent manner which requires the exposure of fibrinogen on the platelet 
surface.278 Independent of the cell type that initiates haemostatic processes, it is 
evident that both platelets and leukocytes are involved in sustaining their mutual 
recruitment and activation in both physiological and pathological conditions.  
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1.9.1 HETEs and leukocytes in inflammation 
LOX metabolites have been shown to be crucial in inflammatory processes. In vitro 
experiments showed that HETEs possess chemotactic activity for human eosinophils 
and neutrophils, which was lost after treatment of these cells with the non-selective 
lipoxygenase inhibitor, NDGA.279,280,281 Several LOX metabolites were identified in 
supernatants from homogenates of human-derived neutrophils and, in particular, 
12-HETE, 11-HETE and 5-HETE.280 The human neutrophil chemotactic activity of 
these HETE products exhibited a rank-order of potency with 5-HETE>>11-HETE=12-
HETE.281 Therefore, these results suggest that the HETEs might influence the 
mobility of human neutrophils. It is already held that biosynthesis of prostaglandins, 
leukotrienes, and lipoxins occur during cell-cell interactions and there is evidence 
for AA serving as a transcellular biosynthetic intermediate.282 The interaction 
between 12-LOX and 5-LOX has been shown to promote the formation of 
leukotrienes (LT) or lipoxins (LXs) suggesting a cooperation between platelets and 
leukocytes in inflammatory responses.283 Indeed, co-incubation of leukocytes and 
platelets promotes the formation of fatty acids, such as 5-HETE, LTB4, 5,12-diHETE, 
known to be neutrophil chemotactic factors, via transcellular biosynthesis.283,282  In 
support of the idea of cell-cell interaction between platelets and neutrophils being 
important in the production of bioactive metabolites, studies have also shown that 
the great amounts of both arachidonate and of the 12-LOX metabolite, 12(S)-HETE, 
released by activated platelets are then used as a substrate by neutrophils for the 
synthesis of LTB4/5-HETE and DHETE, respectively.284 
 
1.9.2 HETEs and leukocytes in coagulation 
Tissue factor (TF) is a membrane glycoprotein associated with phospholipids, which 
triggers blood coagulation leading to fibrin formation.285 TF is constitutively 
expressed in extravascular cells, whereas vascular cells can express it when exposed 
to inflammatory-derived mediators, which can induce its synthesis and expression 
on their membrane. Indeed, activated blood monocyte highly express TF on their 
surface when exposed to ECs stimulated with inflammatory factors (e.g. TNF).286 It 
has been reported that 12-HETE released by AA-activated platelets is able to 
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enhance the expression of TF by endotoxin-stimulated leukocytes and that  this 
enhancement is more robust when platelets are treated with aspirin due to 
diversion of AA to the production of HETEs via the LOX pathway.287,71,76 Also, this 
effect was 12-HETE specific whereas leukocyte-derived 5-HETE and 5-LOX-derived 
leukotrienes were inactive, suggesting that platelets play a crucial role in this 
process.287 
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1.10 Platelets and angiogenesis 
 
Platelets, in addition of playing a fundamental role in haemostasis, are also known 
to be involved in the regulation of inflammation and neovascularization.288 In the 
late 1960s platelets were found to influence endothelial cells in the development of 
new vessels, a process referred to as angiogenesis. Although, physiologically 
revascularization, characterised by recruitment of endothelial cells and release of 
angiogenic regulators, is crucial in restoring the function of damaged and 
regenerating organs, angiogenesis also plays part in tumour growth and metastases 
allowing the invasion of other tissues and organs.179,289,290 Several in vitro and in 
vivo studies in animal models and patients have shown that platelets are a relevant 
source of factors with pro-angiogenic potential in both haemostatic and 
pathological conditions (e.g. tumour progression) and used for tissue regenerative 
purposes in clinical practice.291,288 Indeed, both platelets and megakaryocytes 
regulate angiogenesis by storing in α-granules both pro-angiogenic factors, such as 
vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF) 
and fibroblast growth factor (FGF), and anti-angiogenic factors, such as endostatin 
and thrombospondin (TPO). VEGF it is known to play a key role in increasing vessel 
wall permeability and as a chemoattractant in endothelial cell sprouting. Recently, 
in vitro and in vivo studies have shown that the platelet-derived deoyribose-1-
phoaphate (dRP) stimulates HUVEC migration and angiogenesis.288 
 
Upon activation platelets release these factors in a differential manner depending 
on the receptor and, therefore, the pathway involved.179,289,292 By storing pro-/anti-
inflammatory and pro-/anti-angiogenic factors together with the high expression of 
integrins on their surface platelets may be considered as an optimal intermediary 
between resident endothelial cells and recruited cells. There is evidence that 
platelets influence all three of the steps of angiogenesis: a) the initial 
inflammatory/haemostatic phase; b) the proliferative phase where fibroblast and 
progenitor cells are recruited; c) the remodelling phase consisting of the 
reorganization of the collagen fibres.  
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Several studies have reported that TXA2, ADP or thrombin, through PAR1 and PAR4 
receptors, can differentially promote the release of both pro- and anti- angiogenic 
factors. In particular, TXA2 stimulates the release of α-granules containing 
endostatin, and ADP those containing VEGF. Moreover, PAR-1 and PAR-4 mediate, 
respectively, pro-angiogenic responses by promoting the release of alpha-granules 
containing VEGF and anti-angiogenic responses by promoting the release of those 
containing endostatin. Upon activation the net effect of platelets on endothelial cell 
angiogenic responses has been shown to be pro-angiogenic.179,293 Physiologically 
thrombin is one of the most potent platelet agonists enhancing the release of both 
TXA2 and ADP, although the mechanisms by which it modulates angiogenesis are 
still unclear.179 Also, the levels of thrombin are significantly elevated in pathological 
conditions, such as inflammation and cancer. In this respect animal models of 
metastasis have identified a link between fibrin formation by platelets through the 
proteolytic activity of thrombin and tumour spreading.294,295,296 This is suggestive of 
thrombin being a strong promoter of angiogenesis. Therefore, a better 
understanding of how this agonist can affect platelet function in the regulation of 
angiogenic responses might give further insight into the identification of new 
targets for the development of anti-cancer therapy.46  
 
Interestingly, in several studies the irreversible inactivation of platelets by aspirin 
led to a reduction in angiogenic processes via the inhibition of the release of VEGF 
from α-granules resulting in anti-metastatic effects.292 Also other anti-platelet 
treatments, such as P2Y12 blockers and integrin αIIbβ3 antagonists, produced the 
same outcome.292 Recently a study performed on human microvascular endothelial 
cells (HMEC-1) by Etulain’s group reported that the presence of aspirin in platelet 
releasates stimulated with thrombin strongly inhibited HMEC-1 angiogenic 
processes (e.g. migration and tube formation).297 Based on these outcomes aspirin 
has been suggested as a potential adjuvant therapy for cancer due to its inhibitory 
effects on the proangiogenic activity of thrombin-stimulated platelets.297 Data from 
randomized trials reported that daily aspirin is able to delay (5 years) the deaths of 
different cancers, such oesophageal, pancreatic , brain and lung cancer which were 
even more delayed for colonrectal, stomach and prostate cancer.298,299 Moreover, 
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analysis of five large randomised trials of daily aspirin have shown that patients 
diagnosed with cancer taking low doses of aspirin (75 mg) used for secondary 
prevention of vascular events, had a reduced risk of metastatic adenocarcinoma.300 
In particular, aspirin has been recognised to be beneficial against the development 
of colorectal cancer289,297,301,300 Therefore, aspirin in addition to its already known 
beneficial effects in cardiovascular disease can also be considered as an adjuvant to 
conventional chemotherapeutic and hormonal therapies.289 
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Figure 1.16 A schematic representation of the multiple bidirectional interactions 
between platelets and tumor cells. Platelets and tumour cells express many of the 
same receptors, such as GPIb and integrin αIIbβ3, which may participate in tumour 
cell induced platelet aggregation (TCIPA) by promoting arrest of tumour cells in the 
vasculature and by promoting interactions with bridging proteins such as VWF, 
fibronectin and fibrinogen. Tumour cells are able to both up-regulate the expression 
of TF leading to thrombin formation and to directly secrete platelet agonists, such 
as ADP and thrombin, which then activate platelets in the tumour 
microenvironment. In turn, activated platelets secrete growth factors and 
proteinases that can regulate tumour growth and invasion. Activated platelets also 
shed microparticles, which promote cell invasion and angiogenesis.  
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1.10.1 COX-derived 15(S)-HETE 
Studies have reported that 15-HETE, in addition to being a 15-LOX product, can also 
be generated via the lipoxygenase activity of the COX enzyme in several cell types 
within the vascular system. Cultured human umbilical endothelial cells (HUVEC) 
generate prostaglandins and mono-/di-HETEs with 15-HETE being the major 
lipoxygenase metabolite but also a minor cyclooxygenase product (20%), together 
with 11-HETE.302,303 Moreover, experiments conducted on rat smooth muscle cells 
stimulated with thrombin released great amounts of PGI2 together with 11-HETE 
and 15-HETE via the cyclooxygenase pathway.304 Smith et al. demonstrated that 
isolated and purified native forms of ovine COX-1 enzyme exhibit lipoxygenase 
activity by producing, in addition to PGG2, also 11(R)-HETE, 15(S)-HETE and 15(R)-
HETE; this follows from the ability of AA to assume three catalytically productive 
rearrangements within the cyclooxygenase site of the enzyme.26 Aspirin acetylation 
of the COX-2 enzyme, although causing the loss of the cyclooxygenase activity, yet 
permits lipoxygenase activity from which 15(R)-HETE is produced.305 Abnormalities 
in platelet-vascular AA metabolism that may contribute to the development of 
atherosclerotic or vascular disease have been observed in both humans with 
diabetes mellitus and animal models.302 These include enhanced platelet 
production of proaggregatory TXA2 and concomitant decrease in vascular PGI2 
generation. 15-HETE caused both inhibition of PGI2 biosynthesis and formation of 
other COX metabolites in isolated microsomes from human umbilical arteries and in 
endothelial cells.302 Moreover, studies performed on the vasculature from infants of 
diabetic mothers produce significantly more 15-HETE and less 6-keto-PGF1α 
compared to control tissues.302 15-HETE enhanced endothelial cell migration in vitro 
and elicited neovascularization in an in vivo angiogenic system using the rabbit 
corneal pocket assay.306 Therefore, an increase of 15-HETE production in diabetes 
mellitus could both modulate endogenous vascular PGI2 production and play a role 
in the abnormal neovascularization which occurs in pathological states associated 
with vascular changes.302 The studies of Vanderhoek et al. recently suggested a 
possible regulatory role of 15-HETE in the lipoxygenation of AA-derived metabolites 
in platelets, PMNs and T lymphocytes and in particular this fatty acid has been 
shown to act as a selective inhibitor of platelet lipoxygenase.302  
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1.10.2 15(S)-HETE and angiogenesis  
Interestingly, AA-derived 15-LOX metabolites, 15(S)-HpETE and 15(S)-HETE, have 
been shown to elicit opposing angiogenic effects.307 In particular, 15(S)-HETE 
stimulates angiogenesis in both HDMVECs and HUVECs by up-regulating VEGF 
through the PI3K/Akt and p38MAPK signalling pathways.308,94,307,309 In contrast, 
15(S)-HpETE elicits anti-angiogenic effects by down-regulating the expression of 
VEGF and FGF, although the mechanism through which this is caused is not 
understood.307 The relative rate of conversion of 15(S)-HPETE to 15(S)-HETE during 
inflammation might affect angiogenesis depending on the cellular levels of 
peroxides which catalyse the reduction of 15(S)-HpETE to 15(S)-HETE. Similar 
opposing effects have also been identified for COX metabolites. For instance, PGE2 
showed pro-angiogenic effects while PGD2 displayed anti-angiogenic ones.
310 
 
Anti-platelet levels of aspirin are clinically used with the aim of controlling the state 
of activation of platelets in order to prevent the occurrence of cardiovascular 
events (e.g. heart attack and stroke). Aspirin elicits its therapeutic effect by 
irreversibly inhibiting the platelet COX-1 enzyme and, therefore, by reducing the 
production of pro-thrombotic mediators, such as TXA2. However, chronic use of this 
treatment may lead to side effects, such as gastrointestinal and intracranial 
bleeding, which are harmful for patients. Thus, new strategies able to improve 
current therapies are desirable. Furthermore, anti-platelet levels of aspirin have 
been shown to have benefits beyond inhibition of acute thrombosis and notably to 
be associated with a reduction in risk for cancer, in particular colorectal cancer, 
which is consistent with the drug having anti-angiogenic properties. As described 
previously, AA-derived prostanoids and HETE isoforms have been shown to be 
involved in different vascular processes, such as haemostasis, inflammation and 
angiogenesis and, upon activation, platelets, along with producing TXA2 and 
prostaglandins through the COX-1 enzyme, generate high amounts of 12(S)-HETE, 
the role of which is still unclear and matter of controversy, as elucidated previously. 
Based on this knowledge the aim was to study the roles these AA-derived 
eicosanoids of platelets play within the vasculature and their potential associations 
with the protective effects of aspirin in both thrombosis and cancer with the 
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ultimate goal of identifying potential targets for the development of novel 
therapeutics. 
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Aims of the research 
 
Based on the evidence that aspirin has protective effects in both thrombosis and 
cancer, I was interested in studying the AA-derived products generated by activated 
platelets and their sensitivity to anti-platelet levels of aspirin with the ultimate goal 
of identifying potential targets for the development of treatments able to 
ameliorate current anti-platelet or anti-cancer treatments. In particular, attention 
was addressed to those AA-derived products generated through the platelet COX-1 
(prostanoids) and LOX enzymes (HETEs) in order to study the interplay between 
these products, their function within the vasculature and their potential association 
with the protective properties of aspirin in both thrombosis and cancer. Hence, the 
aims of the project were the following: 
 
1) To qualitatively and quantitatively determine via LC-MS/MS analysis the 
production of AA-derived eicosanoids in blood stimulated in vitro, with 
particular attention to prostanoids and HETEs, respectively COX and LOX 
products. 
 
2) To establish whether platelets or platelets in association with other blood 
cells represent the source of AA-derived prostanoids and HETEs in blood 
stimulated in vitro. 
 
3) To elucidate the enzymatic pathways involved in the production of 
eicosanoids by using blood samples from patients affected by a homozygous 
deletion for the cPLA2α isoform. 
 
4) To evaluate how the COX inhibitor, aspirin, the P2Y12 blocker, prasugrel, or 
the combination of aspirin and prasugrel, which represents the anti-platelet 
therapy used for secondary prevention of cardiovascular events, might 
affect the production of eicosanoids in stimulated whole blood and platelet-
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rich-plasma (PRP) in vitro using LC-MS/MS analysis. These results might 
elucidate the enzymatic pathways downstream of cPLA2α involved in the 
production of prostanoids and HETEs. 
 
5) To establish the biological/physiological roles the different HETE isoforms 
play within the vasculature by investigating whether these produced 
autocrine effects on platelet responses, hence regulating 
haemostasis/thrombosis. I furthermore aimed at determining whether an 
interplay between platelet-derived prostanoids and HETEs in regulating 
platelet responses existed. 
 
6) To study whether the different HETE isoforms identified via LC-MS/MS 
analysis elicited paracrine effects on leukocytes, in particular PMNLs, in 
regulating or modulating inflammatory processes, with particular focus on 
neutrophil chemotaxis and expression of adhesion molecules. 
 
7) To investigate whether the 15(S)-HETE stereoisomer affected angiogenic 
processes of human microvascular endothelial cells (HMEC-1) through the 
assessment of tube formation and cell migration in vitro. Angiogenesis was 
also studied ex vivo through the measurement of sprouts produced by 
sections of rat aorta.
Materials and methods 
 
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Material and Methods 
 
 
 
 
Material and methods 
69 
 
Materials 
 
12(S)-HETE      Cayman Chemicals Company, USA 
5-HETE      Cayman Chemicals Company, USA 
11-HETE      Cayman Chemicals Company, USA 
15-HETE      Cayman Chemicals Company, USA 
11(R)-HETE      Cayman Chemicals Company, USA 
15(S)-HETE      Cayman Chemicals Company, USA 
15(R)-HETE      Cayman Chemicals Company, USA 
Abciximab     Lilly, USA 
Acetylsalicilic acid (aspirin)   Sigma, UK 
Adenosine Diphosphate    Labmedics, UK 
Arachidonic acid    Sigma, UK 
Ascorbic Acid     Sigma, UK 
Baicalein     Sigma, UK 
BME reduced growth factor    Amsbio 
Calcein     Invitrogen, USA 
Calcium ionophore (A23187)   Sigma, UK 
CD11b/isoCD11b    eBioscence 
CD62L/isoCD62L    eBioscence 
Dimethyl Sulfoxide     VWR, UK 
Epinephrine     Labmedics, UK 
Ethanol     VWR, UK 
FACS Lysis Buffer Solution   BD Bioscence 
Fetal Bovine Serum (FBS)   Life Technologies, UK  
ϒ-Globulins from human blood   Sigma, UK 
Horm collagen    Nycomed, Switzerland 
Hirudin (Refludan®)    Celgene, UK 
HMEC-1      CDC, Atlanta, USA 
Leukotriene B4    Cayman Chemicals Company, USA 
Mepacrine     Sigma, UK 
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N-Formyl-Met-Leu-Phe   R&D Systems, USA 
Nordihydroguaiaretic acid    Sigma, UK 
Penicillin/Streptomycin    Sigma, UK 
PGD2      Cayman Chemicals Company, USA 
PGE2      Cayman Chemicals Company, USA 
Phosphate buffer saline   Sigma, UK 
Prasugrel active metabolite    AstraZeneca, Sweden 
Prostacyclin     R&D Systems, USA 
Recombinant Human CXCL8/IL-8  R&D Systems, USA 
RPMI1640 medium + L-glutamine  APP, UK 
TRAP-6 amide     Bachem, UK 
Trypsin/EDTA solution    Sigma, UK 
Tri-sodium citrate    Sigma, UK 
U46619     Cayman Chemicals Company, USA 
VEGF 164 (murine)    R&D Systems, USA 
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Methods 
In this chapter are detailed the common experiments and analytical methods used 
in the following chapters of the thesis. 
 
3.1 Ethics and consent 
For the two patients affected by a homozygous deletion of the cPLA2α enzyme blood 
samples were taken as part of clinical analysis and care following patient consent. 
 
3.2 Screening of healthy blood donors 
After proving written consent potential blood donors were screened based on 
answers to a structured questionnaire, previous and current medical history, 
current medication and physical examination of temperature, pulse rate, heart 
rhythm and blood pressure to determine health status. Donors were aged 18 – 40 
and both female and male donors were included in the studies of my thesis. 
Approval for these studies was obtained from St. Thomas’s Hospital Research Ethics 
Committee (reference 07/Q0702/24). 
 
3.3 Venepuncture 
Venepuncture was performed in the ante-cubital fossa using a 19 gauge butterfly 
needle. Blood was drawn into a syringe containing an anticoagulant to prevent 
blood clotting. The anticoagulants used were either 3.2% of the dehydrate form of 
trisodium citrate or 250 µg/ml lepirudin, as specified in each chapter, in order to 
obtain as final concentrations at the end of the venepuncture 0.109 M and 25 
µg/ml, respectively. Lepirudin was generally used as the anticoagulant of choice for 
all the experiments. Blood was taken into lepirudin or trisodium citrate solution to 
determine whether the use of different anticoagulants might influence the effect of 
12-LOX inhibition on platelet aggregation.   
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3.4 Preparation of PRP and PPP from whole blood 
Platelet rich plasma (PRP) was obtained by the centrifugation of whole blood at 175 
x g for 15 minutes. Subsequently, the PRP was removed paying attention not to 
extract the buffy coat. Platelet poor plasma (PPP) was obtained by the 
centrifugation of PRP or whole blood at 1300 x g for 2 minutes. 
 
3.5 Isolation of platelets 
Human blood from healthy volunteers was collected by venepuncture into tri-
sodium citrate (3.2% w/v final) and centrifuged (175 g, 15 min) to obtain platelet-
rich plasma (PRP). The PRP was centrifuged (1000 g, 10 min), following addition of 
apyrase (0.02 U/ml) and PGI2 (2 µg/ml) in order to inhibit platelet adhesion and 
aggregation. Platelets were gently suspended in Modified Tyrodes Hepes buffer pH 
7.4 (glucose 5mM; BSA 1 mg/ml; NaCl 134 mM; HEPES 20 mM; KCl 2.9 mM; 
Na2HPO4 0.34 mM; MgCl 1 mM; apyrase 0.02 U/ml) and PGI2 (2 µg/ml) was added. 
Platelets were then centrifuged (1000 g, 10 min) and resuspended in MTH buffer.311 
Washed platelets were diluted to the concentration of 1x108plt/ml.  
 
3.6 Treatment of PRP or whole blood with antiplatelet drugs 
Aspirin was prepared at a concentration of 100 mM in 100% ethanol and then 
diluted in PBS to a concentration 100-200 times the required final concentration 
before addition at 1:100 or 1:200 to PRP or whole blood. Prasugrel active 
metabolite (PAM) was prepared to a concentration of 10 mM in DMSO and then 
diluted to a concentration of 100-200 times the required final concentration before 
being added 1:100 or 1:200 into PRP. Abciximab was provided as a solution (2 
mg/ml in dH2O) and added to PRP or whole blood in order to obtain 10 µg/ml as a 
final concentration. After addition of the treatments, PRP was incubated in a water 
bath at 37°C for 30 minutes before use in platelet assays. The concentrations of the 
drugs used in vitro represent the anti-platelet levels achieved clinically.  
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3.7 Treatment of PRP or whole blood with LOX or cPLA2α inhibitors 
Baicalein was prepared at a concentration of 100 mM in 25% DMSO and 75% PBS 
and then diluted in PBS to a concentration 200 times the required final 
concentration (10 µM) before addition at 1:200 to PRP. NDGA was prepared at a 
concentration of 100 mM in ethanol and diluted to a concentration 100 times the 
required in PBS before addition at 1:100 to PRP (final 10 µM). Pyrrophenone was 
prepared at a concentration of 25 mM in DMSO and directly added to PRP or whole 
blood in order to obtain a final concentration of 40 µM, minimizing the % of DMSO. 
The therapeutic concentrations of both baicalein and NDGA were chosen based on 
previous reports.268,312 The inhibitory concentration of pyrrophenone was identified 
by performing a dose-response curve using collagen at aspirin-sensitive 
concentrations as a stimulus. After addition of the treatments, PRP was incubated 
in a water bath at 37°C for 30 minutes before use in platelet assays. 
 
3.8 Preparation of platelet agonists 
ADP, TRAP-6 and U46619 were all prepared from 1 mM stocks diluted in PBS. Horm 
collagen 1 mg/ml was diluted in isotonic glucose buffer supplied with the agonist. 
Arachidonic acid was prepared at 100 mM stock in 100% ethanol and epinephrine 
at 1 mM stock and both diluted in 0.1% ascorbic acid in PBS. Calcium ionophore 
(A23187) was prepared from 50 mM stock and diluted in PBS. All agonists were 
prepared at a concentration 10 times that required and added 1:10 to PRP or whole 
blood in platelet assays.  
 
3.9 Preparation of HETE isoforms 
All HETE (25 µg) isoforms were provided dissolved in 250 µL ethanol and stored 
at -20°C. HETEs were all prepared diluted in PBS and kept on ice prior to use. All 
isoforms were prepared at a concentration 10 times that required and added 1:10 
to PRP or whole blood in platelet assays. 
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3.10 Preparation of human blood samples for LC-MS/MS analysis 
Whole blood or PRP from cPLA2α-deficient patients and healthy volunteers was 
incubated in a 24-well plate for 30 min at 37°C in the presence of collagen (30 
µg/ml), TRAP-6 (30 µM), calcium ionophore (A23187; 50 µM), or vehicle. The high 
concentrations of collagen and TRAP-6 were used to induce strong platelet 
activation and thus to mimic in vitro an acute scenario in vivo. The stimulatory 
concentration of A2387 was chosen based on results obtained from previous 
work.313 Plasmas were separated from the samples by centrifuging the plates at 
3,000 rpm for 2 min at 4°C. Supernatants (250 µL) were transferred into pre-
labelled eppendorfs kept on dry ice and immediately stored at -80°C. A lipidomic 
analysis of these samples was then performed by our collaborator, Dr. Darryl Zeldin 
(National Institute of Environmental Health Sciences, Research Triangle Park, 
NC27709, USA). 
 
3.11 LC-MS/MS analysis 
This is an analytical chemistry technique which employs negative mode electrospray 
ionization and HPLC with tandem quadrupole mass spectrometry (LC-MS/MS), as 
described previously.314 his method was used by Dr. Darryl Zeldin (National Institute 
of Environmental Health Sciences, Research Triangle Park, NC27709, USA), with 
whom we established a collaboration, in order to identify AA-derived eicosanoids in 
plasmas obtained from stimulated blood or PRP in vitro of patients or healthy 
volunteers. 
 
3.12 96-well plate light transmission aggregometry 
This method is a modification of standard light transmission aggregometry to allow 
a high throughput assessment of platelet aggregation. 315 Samples of PRP, 100 µL, 
were placed into the individual wells of a 96-well plate containing 10 µL volumes of 
agonists at 10X final concentration. On the top row of the plate four wells were 
reserved for PRP and other four wells for PPP as controls. The plate was then placed 
in a Tecan Sunrise 96-well plate reader, pre-warmed to 37°C, and the absorbance of 
595 nm light was measured every 15 seconds for 16 minutes for a total of 64 
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measurements, with lateral shacking at 738 rpm for 7 seconds between readings. 
Percentage aggregation was calculated with reference to the absorbance of PPP as 
a surrogate for 100% aggregation. An example of standard layout of the 96-well 
plate light transmission aggregometry is represented below: 
 
               PPP    PRP                                PBS 
             
            ADP 
            Arachidonic acid 
             Collagen 
            Epinephrine 
            TRAP-6 amide 
            U46619 
            Calcium ionophore  
                Treatment 1                                      Treatment 2 
→   Increasing concentrations of the agonist 
 
Figure 3.1 Standard layout of 96-well plate light transmission aggregometry. 
Measurement of platelet aggregation to increasing concentrations of seven 
different agonists. 
 
3.13 Light transmission aggregometry (LTA) 
Platelet aggregation was measured using PAP-8E aggregometry (BioData 
Corporation, USA). A blank reference reading was made using a 250 µL sample of 
PPP obtained from each donor. When performing the aggregation test, 225 µL 
samples of PRP were placed into individual cuvettes containing siliconised magnetic 
stir bars (Alpha Laboratories, UK) and incubated for 2 min at 37°C with continuous 
stirring at 1200 rpm. The platelet agonists were prepared 10 times final 
concentration and 25 µL aliquots added to the PRP samples. Aggregation responses 
followed for 5 min at 37°C with continuous stirring. The percentage aggregation 
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within each cuvette was calculated internally by the instrument, using the 
absorbance of the blank PPP or buffer as a surrogate for 100% aggregation. 
 
3.14 Platelet adhesion under flow conditions 
Platelet labelling 
Mepacrine is a fluorescent dye uptaken by the dense granules of platelets and was 
dissolved in dH2O at a concentration 100 times that required and then added to 
whole blood samples (10µM final concentration) and incubated for 30 min at 37°C.   
 
Flow chamber and perfusion system 
The flow system consisted of a chamber provided with six channels (IBIDI chamber; 
height 0.01 cm; width 0.1 cm), five of which were pre-coated overnight (37°C; 100% 
humidity) with 100 µg/ml Horm collagen (Type I) and one with PBS as control. The 
following day BSA 2% was added to each channel (100 µL/channel), incubated for 2 
hours (37°C; 100% humidity) and washed with PBS. The chamber was positioned on 
a fluorescent microscope (20X) connected to a camera. The software used to 
capture images was spot advance software (green emission wavelength; gain 4). A 
20 ml syringe was mounted on a Harvard pump and used to withdraw blood at 1000 
s-1 shear rate (flow rate (Q): 0.1 ml/min). The sample tubes and the syringes 
allocated on the pump for blood withdrawal were connected to the chamber using 
VWR-Tygon tubing (S-50-HL). Platelet adhesion was measured by fluorescent video-
microscopy. After 5 min of blood flow 8 images/channel were taken from different 
fields of the channel, stacked and consequent mean fluorescent intensity quantified 
using Image J software. 
 
3.15 Platelet adhesion under static conditions (acid phosphate assay) 
 
96-well plate collagen-coating 
Collagen plays a fundamental role in the first phases of plug formation. In order to 
validate this assay method a range of collagen concentrations able to stimulate a 
concentration dependent response of platelet adhesion was assessed. Thus, a flat 
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bottomed 96-well plate was coated with increasing concentrations of collagen type 
I (0.1 μg/ml – 20 μg/ml) and kept overnight at +4°C. The 96-well plates were then 
washed two times with PBS and incubated for 2 hours with 2% BSA. After a further 
two washes with PBS, plates were stored at +4°C to avoid evaporation.311  
 
Acid phosphate assay 
Washed platelets were added to the 96-well plate, leaving the wells for the 
controls, and incubated for 30 min in a humidified thermostat at 37°C. After 
incubation, wells were washed with saline and rapidly supplemented with 140 µl of 
0.1 M citrate buffer, pH 5.4, containing 5 mM p-nitrophenyl phosphate (acid 
phosphate substrate) and 0.1 Triton X-100 for 40 min at room temperature. Triton 
X-100 causes lysis of platelets without affecting the acid phosphatase activity. The 
number of platelets adhered was assessed by measuring the activity of acid 
phosphatase. The percentage of adhesion was calculated by reference to platelet 
standards for each experiment. There is a linear relationship between platelet 
number, with the top number of 1x108  plt/ml representing 100% adhesion, and 
absorbance at 405 nm. As a result in each experiment 10% of 1x108 platelet 
standard was used, chosen due to the expected level of platelet adhesion, so that 
the adhesion percentages per well were calculated from this known standard. 
 
3.16 Statistical analysis 
Statistical analysis were conducted using GraphPad Prism v5 (GraphPad Software 
Inc, CA, USA). Concentration-response curves were compared by two-way ANOVA. 
Differences were taken to be significant at P values of less than 0.05. Different 
statistical analyses will be specified in each chapter.
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4.1 Phospholipase A2 (cPLA2α)-deficient patients 
 
4.1.1 Introduction 
Two siblings affected by a homozygous deletion of the cytosolic phospholipase A2 
(cPLA2α), which supplies AA to the COX and LOX enzymes, were identified at the 
Department of Clinical Immunology, Barts Health NHS Trust of London, where these 
patients were under care.316 These patients were affected by cryptogenic multifocal 
ulcerous stenosing enteritis (CMUSE), a disease that presents symptoms such as 
bowel ulceration and stenosis, which closely resemble the side effects associated 
with chronic use of NSAIDs. Whole exome sequencing studies were performed and 
the deletion of the gene encoding for the constitutive phospholipase A2α (cPLA2α), 
which underpins much eicosanoid production (see Introduction) was found. 
Functional platelet studies showed a drastic impairment of the platelet responses of 
these patients due to their inability to synthetize pro-thrombotic AA-derived 
eicosanoids (e.g. TXA2).
316 The purpose of the experiments reported here was to 
analyse how the lack of the cPLA2α enzyme could affect the broader range of 
eiscosanoid production within the blood. 
 
The LC-MS/MS analysis established that stimulated blood generates great amounts 
of both COX- and LOX-derived eicosanoids, the production of which depends on the 
activity of the constitutive cPLA2α isoform. Of particular interest was the significant 
increase in the levels of both prostanoids and HETEs in blood stimulated with 
specific platelet stimuli, i.e. collagen and TRAP-6. The aim was, therefore, to 
qualitatively and quantitatively using LC-MS/MS whether the source of eicosanoids 
in acute conditions might be platelets or platelets in association with other blood 
cells, such as leukocytes.  
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4.1.2 Methods  
LC-MS/MS analysis of human blood samples 
The preparation of blood and PRP samples from the cPLA2α-deficient patients and 
healthy volunteers along with the LC-MS/MS analysis were performed as described 
in the Methods section of Chapter 3.  
 
4.1.3 Results 
LC-MS/MS analysis of stimulated-blood from cPLA2α-deficient patients and healthy 
volunteers 
The LC-LC/MS analysis was performed on blood samples of the cPLA2α-deficient 
patients and healthy volunteers using high concentrations of stimuli in order to 
determine eicosanoid production in vitro in conditions that mimicked those during 
an acute event. The results showed that blood stimulated in vitro with A2387, 
collagen or TRAP-6, but not vehicle, produced a vast range of eicosanoids. Among 
these, AA-derived prostanoids and HETEs were found in particularly high 
concentrations and were selected for further analyses as they represented the focus 
of my research (Figure 4.1). Interestingly, no increase in the levels of prostanoids 
and HETEs was found in blood from the patients, whereas stimulated blood from 
healthy volunteers showed a robust production of both.  Interestingly, high levels of 
11-, 12- and 15-HETE were found when blood was stimulated with platelet selective 
agonists or A23187, whereas 5-HETE was strongly produced only when A21387 was 
used as a stimulus. This is consistent with 5-HETE being a neutrophil product 
through the activity of the 5-LOX enzyme.. Overall these are very interesting 
findings which establish that AA-derived prostanoids and HETEs produced in blood 
cells mainly derive from the activity of the constitutive cPLA2α enzyme. Thus, blood 
of these unique “human knockouts” for the cPLA2α isoform represented a useful 
human model  to show that this specific enzyme is essential for the production of 
prostanoids and HETEs from blood cells (Figure 4.1). 
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LC-MS/MS analysis of eicosanoid formation from stimulated-whole blood and PRP 
The LC-MS/MS data showed that TXA2, PGs and HETEs were highly produced in both 
stimulated-whole blood and PRP indicating that all these AA-derived products are 
mainly generated by platelets. Among these eicosanoids, 5-HETE was the only 
product uniquely detected in whole blood after stimulation with A23187. Thereby, 
these data established that stimulated platelets are the main source of COX and 
LOX products in these experimental conditions, with the exception of 5-HETE which 
was only produced in whole blood stimulated with A23187, consistent with it being 
a neutrophil product (Figure 4.2). The levels of prostanoids and HETEs identified 
differ from the previous analysis (Figure 4.1) due to the variability among 
individuals. However, the results clearly show that both prostanoids and HETEs are 
the major products of platelets activated with collagen or TRAP-6 as the levels 
produced do not differ significantly between blood or PRP. 
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Figure 4.1 LC-MS/MS analysis of eicosanoid levels in whole blood from cPLA2α-
deficient patients and healthy volunteers. LC-MS/MS analysis of plasmas obtained 
from whole blood of cPLA2α-deficient patients and healthy volunteers (n=4) 
incubated for 30 min at 37°C in the presence of collagen (30 µg/ml), TRAP-6 (30 
µM), calcium ionophore (A23187; 50 µM), or vehicle. Blood from healthy volunteers 
showed no increase of eicosanoid levels in the presence of a) vehicle; a robust 
increase of TXB2, PGD2, 5-, 11-, 12-, 15-HETE in the presence of b) A23187; an 
increase of TXB2, PGD2, 11-, 12-, 15-HETE levels in the presence of c) collagen or   d) 
TRAP-6. Blood from the patients did not show any increase in the levels of 
eicosanoids.  
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Figure 4.2 LC-MS/MS analysis of TXB2, PGE2, PGD2, 11-HETE, 15-HETE, 12-HETE and 
5-HETE in stimulated blood and PRP obtained from healthy volunteers. LC-MS/MS 
analysis of plasmas obtained from whole blood and PRP of healthy volunteers 
incubated for 30 min at 37°C in the presence of calcium ionophore (A23187; 50 
µM), collagen (30 µg/ml), TRAP-6 (30 µM), or vehicle. A significant increase of the 
levels of TXB2, PGE2, PGD2, 11-HETE, 15-HETE and 12-HETE was found in both PRP 
and whole blood stimulated with A23187, collagen or TRAP-6 compared to vehicle. 
No significant difference between PRP and whole blood in the production of these 
metabolites was detected. The levels of 5-HETE increased exclusively in whole blood 
stimulated with A23187.  Differences were taken to be significant at P values of less 
than 0.05 (***p˂0.01) by two-way ANOVA; n=5. 
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4.1.4 Conclusions 
The opportunity to test blood samples from two “human knockouts” for the cPLA2α 
enzyme allowed me to acquire very useful information via LC-MS/MS regarding the 
eicosanoids that are qualitatively and quantitatively produced in stimulated whole 
blood. Compared to healthy volunteers blood of cPLA2α-deficient patients did not 
generate any AA-derived prostaglandins (PGs) or HETEs when stimulated in vitro 
with very high concentrations of platelets agonists, collagen and TRAP-6, or calcium 
ionophore. Conversely, blood from healthy volunteers produced high levels of both 
prostaglandins and HETEs. The levels of prostaglandins measured by LC-MS/MS, in 
particular TXB2 and PGE2, are consistent with those obtained in our laboratory using 
enzymatic-immune assay (EIA) which gave further validation to the lipidomic 
analysis. Among the AA-metabolites, 12-HETE was the most abundant product, 
almost one order greater than TXB2. Platelets express the 12-LOX enzyme isoform 
and the production of very high levels of 12(S)-HETE is already established. 
Curiously, great amounts of 15-HETE and 11-HETE were also found and I was, 
therefore, interested in further investigating whether these products derived from 
platelets alone or in association with other blood cells. To address these questions a 
LC-MS/MS analysis was performed through a collaboration with Dr. Darryl Zeldin 
(NIEH, USA) on the releasates obtained from whole blood and platelet-rich plasma 
(PRP) of healthy volunteers incubated with collagen, TRAP-6 or A23187. 
Interestingly, the production of prostaglandins, 11-HETE, 12-HETE and 15-HETE 
didn’t differ significantly between blood and PRP suggesting that platelets are the 
main source of these products in human stimulated blood. It is already known that 
5-HETE is a leukocyte-derived product through the activity of the 5-LOX enzyme.56 
Indeed, 5-HETE represented an optimal control for my analysis since it is produced 
only in whole blood in the presence of calcium ionophore but not collagen or TRAP-
6 confirming that it is not a platelet metabolite. The differences between the two 
eicoisanomic analyses were adressed to the variability among the individuals from 
which we obtained the blood samples. 
In conclusion, the LC-MS/MS data established that the 85-kD constitutive cPLA2α 
isoform is the enzyme in charge of initiating the synthesis of AA-derived fatty acids, 
and platelets represent important contributors in the production of both 
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prostaglandins and HETEs in stimulated human blood. Moreover, these results 
revealed that platelets generate great amounts of 11-HETE and 15-HETE in addition 
to 12-HETE. Therefore, my next aim was to determine the enzymatic pathways that 
support the synthesis of these platelet metabolites and whether they play a role in 
regulating haemostasis/thrombosis. 
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Chapter 5: Effect of lack of COX-1 or 
cPLA2α  activity on platelet aggregation 
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5.1 Effect of COX or cPLA2α inhibitor on platelet aggregation 
 
5.1.1 Introduction 
The data of the previous chapter indicate that the cytosolic cPLA2α isoform is crucial 
for eicosanoid production by catalysing the release of AA from the membrane 
phospholipids and platelets are the principal source of these hormones in 
stimulated blood. I was, therefore, interested in better understanding whether 
platelet aggregation is mainly driven by the COX-1-derived TXA2 with its already 
known prothrombotic and vasocontrictive effects, or whether other pathways 
might be involved. In particular, the aim was to determine whether a window of 
aggregation that was COX-independent could be identified by comparing platelet 
aggregation responses of blood from the cPLA2α-deficient patients and blood from 
healthy volunteers treated in vitro with the selective cPLA2α inhibitor, pyrrophenone 
(40 µM), with those of blood from healthy volunteers treated with aspirin (100 µM). 
These experiments would indicate whether there was an eicosanoid pathway, other 
than that dependent upon COX-1, involved in the regulation of platelet activation 
and aggregation. 
The effects of the lack of cPLA2α or COX activity on platelet aggregation were next 
investigated under shear conditions. Flow chambers allow studies at shear rates 
throughout the physiological and pathophysiological ranges and also the precise 
control of rheological parameters, such as shear rate and shear stress. These 
chambers are coated with agents such as collagen and fibronectin to which 
platelets adhere, and consequently platelet adhesion under shear can be assessed. 
The system allows one to flow whole blood, reconstituted blood or PRP and to take 
under consideration physiological elements (e.g. convective and diffusive forces) 
that play a fundamental role in platelet adhesion and activation. Another important 
advantage of using whole blood in flowing systems is the possibility to take into 
account the eventual influence/interference of other blood cells and plasma factors 
while assessing platelet reactivity. Here these studies were performed using whole 
blood of the patients and healthy volunteers in which platelets were labelled with 
mepacrine (quinacrine dihydrochloride), a fluorescent dye up-taken by the platelet 
   Results 
89 
 
dense granules and leukocyte granules, which has no effect on normal platelet 
function at the concentration of 10 µM.317,318 Platelets and leukocytes are clearly 
distinguished by epifluorescence microscopy. It has been established that any 
fluorescence from within erythrocytes is quenched by haemoglobin and that 
leukocytes do not adhere to collagen-coated surfaces at the relatively high shear 
rates used in the studies here reported (i.e. 1000 s-1).317,319 Platelet secretion from 
the dense granules following adhesion is sufficiently limited in rate and extent that 
platelet fluorescence does not decrease detectably during adhesion and 
aggregation under the experimental conditions used.317  
 
5.1.2 Methods 
96-well plate aggregometry 
PRP was treated with the COX inhibitor, aspirin (100µM), the PLA2α inhibitor, 
pyrrophenone (40µM), or vehicle. All treatments were incubated for 30 min (37°C). 
Platelets were activated by a range of agonists, in particular by collagen (0.1 – 30 
µg/mL), TRAP-6 amide (0.1 – 30 µM), ADP (0.1 – 30 µM), U46619 (0.1 – 30 µM), 
epinephrine (0.001 – 100 µM) or A23187 (0.125 – 40 µM). Platelet aggregation was 
determined by 96-well plate light transmission aggregometry (Tecan Sunrise) as 
described in the methods section of Chapter 3.  
 
Statistical analysis 
Statistical analysis was conducted using GraphPad Prism v5 (GraphPad Software Inc, 
CA, USA). Agonist concentration-response curves were plotted and analysed by the 
equation: Y=Bottom + (Top-Bottom)/(1+10^(LogEC50-X)*HillSlope)). Concentration-
response curves were compared by two-way ANOVA. Differences were taken to be 
significant at P values of less than 0.05. 
 
 
Platelet adhesion under flow condition 
Blood from both the cPLA2α-deficient patients and healthy volunteers was collected 
into lepirudin. Whole blood from healthy volunteers was treated with abciximab (10 
µg/ml), aspirin (100 µM), pyrrophenone (40 µM) or vehicle (30 min; 37°C). 
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In order to distinguish platelet adhesion from platelet aggregation, blood samples 
was treated with abciximab (10 µg/ml), an inhibitor of integrin αIIbβ3. The 
fluorescent signal given by blood treated with abciximab was associated with 
platelet adhesion only and used as the threshold to separate the two processes, 
adhesion from aggregation. Therefore, platelet aggregate size was measured by 
subtracting the signal given by blood in the presence of abciximab from that given 
by blood of the patients and that by blood of healthy volunteers treated with 
aspirin, pyrrophenone or vehicle. Platelet aggregation was determined using a 
perfusion system as described in the methods section of Chapter 3.  
 
Statistical analysis 
Statistical analysis was conducted using GraphPad Prism v5 (GraphPad Software Inc, 
CA, USA). Data shown as mean ± SEM; ANOVA with Dunnett post-test was used for 
comparison of all columns to vehicle column. Differences were taken to be 
significant at P values of less than 0.05; n=4. 
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5.1.3 Results 
Effect of aspirin and pyrrophenone on platelet aggregation  
Aspirin and pyrrophenone inhibited platelet aggregations to collagen and A23187, 
but not those to TRAP-6, ADP, U46619 and epinephrine (Figure 5.1). 
 
Platelet aggregation under shear from blood of cPLA2α-deficient patients and 
healthy volunteers treated with aspirin or pyrrophenone 
Platelet aggregation under shear to collagen was strongly impaired in blood of the 
cPLA2α-deficient patients compared to control. During the first minutes of flow 
platelets formed a thin layer by weakly adhering to collagen, but over time were 
carried away by the shear unable to stick one to the other and generate stable 
aggregates. Blood from healthy volunteers, instead, formed dense and stable 
aggregates which were significantly reduced by pre-treatment with aspirin or 
pyrrophenone. The pattern of aggregating platelets of both the patients and 
volunteers treated with pyrrophenone differed from that of volunteers treated with 
aspirin. Indeed, pyrrophenone showed a pattern similar to that described for the 
patients, whereas platelets treated with aspirin were able to form small islands of 
aggregates suggesting that their ability to aggregate was not fully impaired. These 
data showed that the lack of cPLA2α enzyme leads to a fuller impairment of platelet 
aggregation in this particular system compared to aspirin alone, although the 
responses are probably mainly driven by TXA2.  Treatment with abciximab allowed 
analysis of the basal level of signal seen in the absence of platelet aggregation 
(Figure 5.2). 
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Figure 5.1 Effect of aspirin and pyrrophenone on platelet aggregation. 
Concentration-aggregation curves to a) collagen (0.1 – 30 µg/ml), b) TRAP-6 (0.1 – 
30 µM), c) ADP (0.1 – 30 µM), d) U46619 (0.1 – 30 µM), e) epinephrine (0.001-100 
µM), f) A23187 (0.125 – 40 µM) in platelet-rich plasma (PRP) in the presence of 
aspirin (100 µM), pyrrophenone (40 µM), or vehicle. Treatment with pyrrophenone 
did not show greater inhibitory effects on platelet aggregation to collagen and 
A23187 compared to aspirin. This suggests that platelet responses in this particular 
system are mainly COX-1 driven. Data shown as mean± SEM. Differences were taken 
to be significant at P values of less than 0.05 (**p˂0.01, ***p˂0.001) by two-way 
ANOVA; n=4.  
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Figure 5.2 Adhesion/aggregation to collagen (100 µg/ml) under shear (1000 s-1) of 
mepacrine-labelled platelets from cPLA2α-deficient patients and from healthy 
volunteers treated with abciximab (10 µg/ml), aspirin (100 µM), pyrrophenone (40 
µM) or vehicle. Time-lapse epifluorescent microscopy (20 X) was used to measure a) 
platelet aggregate size during 5 min of blood flow and b) platelet aggregate size of 
stacks of 8 images per sample from different fields of each channel following the 5 
min aggregation. The aggregation response of cPLA2α-deficient patients was 
significantly impaired and similar to that elicited by blood from healthy volunteers 
treated with pyrrophenone or aspirin. Data shown as mean ± SEM; ANOVA with 
Dunnett test was used for comparison of all columns to vehicle column. Differences 
were taken to be significant at P values of less than 0.05 (***p˂0.001); n=4. 
 
a) 
b) 
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Figure 5.3 Images taken by epifluorescent microscopy (20 X) of mepacrine-labelled 
platelets aggregating to collagen (100 µg/ml) under shear (1000 s-1 shear rate) in 
lepirudinized-blood from the cPLA2a-deficient patients and blood from healthy 
volunteers treated with abciximab (10 µM), aspirin (100 µM), pyrrophenone (40 
µM), or vehicle. After 5 min of blood flow, in blood treated with vehicle, collagen 
produced a robust stimulation of platelet aggregation which was strongly impaired 
in the patients and inhibited by both aspirin and pyrrophenone. 
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cPLA
2α
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5.1.4 Conclusions 
The results obtained from these functional studies showed that platelets of the 
cPLA2α-deficient patients and those of healthy volunteers treated with the selective 
cPLA2α inhibitor, pyrrophenone (40 µM), were fully inhibited and unable to form 
platelet-platelet interactions under shear, whilst untreated platelets from healthy 
volunteers developed dense and stable aggregates. Interestingly, both blood from 
the patients and blood from volunteers treated with pyrrophenone showed the 
same pattern of aggregation in which platelets weakly adhered to the collagen-
coated surface forming a thin layer and further circulating platelets  were carried 
away by the blood stream unable to form aggregates. Similarly, aspirin treatment of 
blood from healthy volunteers strongly inhibited platelet aggregation in these 
conditions, although the pattern slightly differed from that of blood where the 
activity of cPLA2α was inhibited or absent. In particular, platelets in the presence of 
aspirin were able to form islands of aggregation, although highly unstable. This was 
visually apparent but difficult to capture for statistical analysis. Therefore, the lack 
of cPLA2α or COX-1 activity produced slightly different patterns of platelet 
aggregation, but the overall inhibitory effect on platelet responses did not differ 
significantly. This outcome suggested that platelet aggregation in these systems is 
mainly driven by the COX-1 product, TXA2, and that inhibition of the more upstream 
cPLA2α enzyme does not produce further significant inhibition on platelet 
aggregation. 
My next aim was to investigate whether downstream pathways of AA metabolism, 
particularly the COX and LOX pathways, might underpin these pattern differences 
and whether an interplay between the products of these enzymes in modulating 
platelet responses existed. The high levels of HETEs, in addition to prostanoids, 
found via LC-MS/MS analysis suggested that these might represent bioactive 
products that could play roles in these responses. 
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Chapter 6: Effect of AA-derived HETE 
isoforms on platelet aggregation 
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6.1 Effect of platelet COX-1 or LOX inhibition and prostanoids or HETE 
isoforms on platelet aggregation 
 
6.1.1 Introduction 
The results obtained up to this point established that platelets release a range of 
AA-derived eicosanoids and, in particular, produce large amounts of TXA2 and 12(S)-
HPETE/12(S)-HETE, as described in the Introduction. It is also well established that 
platelets express the 12-LOX enzyme which, upon activation, synthetizes large 
amounts of 12(S)-HETE. Platelet COX-1 underpins the generation of prostanoids 
other than TXA2, such as PGD2 and PGE2, which have been shown to play an 
important role in modulating platelet activation and function. Indeed, studies have 
reported that PGD2 elicits a strong inhibitory effect on platelet activation, whereas 
PGE2 has both pro- and anti-thrombotic effects depending on the receptors through 
which this acts. Here in vitro platelet function testing was performed to investigate 
whether the 12-LOX product, 12(S)-HETE, or 12-LOX inhibition affect platelet 
function by modulating the already established pro-thrombotic effect of the COX 
product, TXA2. Initially, platelet function was investigated under shear comparing 
citrated- or lepirudinized-blood as it is established that citrate enhances TXA2-driven 
adhesion/aggregation and, therefore, the effects of aspirin on platelet function are 
overestimated.320 Citrate produces its anticoagulant effect by chelating extracellular 
calcium, while lepirudin directly inhibits thrombin. Use of lepirudin may render a 
more physiological system and allow one to study better potential effects on ion 
mobilization (e.g. calcium mobilization). Alongside, platelet adhesion was assessed 
also under static conditions using an assay designed to mimic the exposure of 
collagen but to highly discourage aggregation, although these two phases coexist in 
physiological conditions. Moreover, platelet aggregation tests were performed to 
study the effects of COX-1 or 12-LOX inhibition and of TXA2, PGD2, PGE2 or 12-LOX 
metabolites in order to predict the net effect produced by the interplay between 
prostanoids and HETEs on platelet aggregation in acute conditions. 
The LC-MS/MS data showed that activated platelets are the main source of 
different HETE isoforms in stimulated blood in vitro. In addition to 12-HETE, 
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established as a major platelet product, also 11-HETE and 15-HETE were produced 
at high concentrations by platelets. I was, therefore, interested in investigating 
whether exogenous addition of 11-HETE, 15-HETE and 12(S)-HETE, which represents 
the enantiomer produced by activated platelets through 12-LOX, or inhibition of 
HETE production with the non-selective LOX inhibitor, NDGA (10µM), affected 
platelet aggregation in vitro. The LC-MS/MS analysis identified also 5-HETE as a 
product of stimulated blood and, although it is known to be a neutrophil product, 
its effect on platelet aggregation was assessed along with the other HETE isoforms. 
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6.1.2 Methods 
Platelet adhesion under flow conditions 
Citrated- or lepirudinized-blood was taken from healthy volunteers and treated 
with prostacyclin PGI2 (2 µg/ml), aspirin (30 µM), baicalein (10 µM), or vehicle and 
incubated for 30 min at 37°C. Because of their short t1/2, PGI2 (2 µg/ml), positive 
control was added to whole blood immediately before starting the flow. Platelet 
adhesion was assessed using the flow system described in the Methods section of 
Chapter 3. 
 
Statistical analysis 
Statistical analysis was conducted using GraphPad Prism v5 (GraphPad Software Inc, 
CA, USA). Data shown as mean ± SEM; ANOVA with Dunnett test was used for 
comparison of all columns to vehicle column. Differences were taken to be 
significant at P values of less than 0.05; n=4. 
 
Static adhesion/aggregation of isolated platelets to collagen-coated 96-well plate  
Washed platelets were treated with prostacyclin, PGI2 (2 µg/ml), 12(S)-HETE (1 μM), 
12(S)-HpETE (1.5 μM), the COX inhibitor, aspirin (30 µM), the 12-LOX inhibitor, 
baicalein (10 µM), or vehicle. Platelet adhesion was assessed by acid phosphate 
assay as described in the Methods section of Chapter 3. 
 
96-well plate aggregometry 
PRP was treated with prostacyclin, PGI2 (2 µg/ml), the COX inhibitor, aspirin (30 
µM), the 12-LOX inhibitor, baicalein (10 µM), or vehicle. All treatments were 
incubated for 30 min (37°C) except for PGI2, which was added right before 
aggregation measurement (t1/2=2-3 min). 12(S)-HETE (0.1 µM - 1µM) was kept on 
ice and added right before aggregation measurement. Platelets were activated by a 
range of agonists, in particular by adenosine diphosphate (ADP, 0.1 – 30 µM), 
collagen (0.1 – 30 µg/mL), TRAP-6 amide (0.1 – 30 µM), U46619 (0.1 – 30 µM), 
epinephrine (0.001 – 100 µM), arachidonic acid (AA, 0.03 – 1 mM).  PGD2 (0.01nM – 
30 µM) was added to PRP stimulated with ADP, collagen, TRAP-6 amide, U46619, 
epinephrine and AA at both 0.3 µM and 3 µM, while PGE2 (0.1 – 10 µM) was added 
   Results 
100 
 
to PRP stimulated with ADP (0.3 – 3µM), collagen (0.3 – 3µg/ml), TRAP-6 amide (0.3 
– 3µM), U46619 (0.3 – 3µM), epinephrine (0.001 – 100 µM) and AA (0.03 – 0.3mM). 
Platelet aggregation was determined by 96-well plate light transmission 
aggregometry (Tecan Sunrise) as described in the methods section of Chapter 3.  
 
Statistical analysis 
Statistical analysis was conducted using GraphPad Prism v5 (GraphPad Software Inc, 
CA, USA). Agonist concentration-response curves were plotted and analysed by the 
equation: Y=Bottom + (Top-Bottom)/(1+10^(LogEC50-X)*HillSlope)). Concentration-
response curves were compared by two-way ANOVA. Differences were taken to be 
significant at P values of less than 0.05. 
 
96-well plate aggregometry 
PRP was treated with NDGA (10 µM) for 30min at room temperature. Platelets were 
then activated by a range of agonists, in particular by adenosine diphosphate (ADP, 
0.1 – 30 µM), collagen (0.1 – 30 µg/mL), TRAP-6 amide (0.1 – 30 µM), U46619 (0.1 – 
30 µM), epinephrine (0.001 – 100 µM), arachidonic acid (AA, 0.03 – 1 mM), calcium 
ionophore (A23187; 1.6 – 50 µM). Aggregation was then measured with a 96-well 
plate reader (Tecan Sunrise) as previously described in the Methods section of 
Chapter 3. 
 
Statistical analysis 
Statistical analysis were conducted using GraphPad Prism v5 (GraphPad Software 
Inc, CA, USA). Agonist concentration-response curves were plotted and analysed by 
the equation: Y=Bottom + (Top-Bottom)/(1+10^(LogEC50-X)*HillSlope)). 
Concentration-response curves were compared by two-way ANOVA. Differences 
were taken to be significant at P values of less than 0.05. 
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6.1.3 Results 
Effect of COX-1 and 12-LOX inhibition on platelet adhesion under shear  
Platelet adhesion to collagen under shear after 5 min of blood flow was strongly 
inhibited by PGI2 in both citrated- and lepirudinized-whole blood and partly 
inhibited (50%) by aspirin only in citrated blood, which is consistent with citrate 
enhancing TXA2-driven aggregation. In lepirudinized-blood aspirin reduced platelet 
adhesion but not significantly. In contrast, baicalein did not alter platelet adhesion 
compared to control in the presence of either anti-coagulant. The aggregation and 
adhesion assays failed to demonstrate any effect of 12-LOX inhibition on platelet 
function (Figure 6.1) (Figure 6.2). 
 
Effect of COX-1 and 12-LOX inhibition and 12-LOX metabolites on platelet 
adhesion/aggregation under static conditions 
The effect of aspirin, baicalen, 12(S)-HETE and PGI2 (positive control) on platelet 
adhesion was determined under static conditions using an acid phosphate assay. 
Collagen at the different concentrations assessed induced platelet 
adhesion/aggregation in a concentration-dependent manner which was robustly 
inhibited by PGI2, as expected, and little inhibited by aspirin, whereas no effect was 
shown by either baicalein or the exogenous addition of 12(S)-HETE. (Figure 6.3). 
 
Effect of COX-1 and 12-LOX inhibition on platelet aggregation 
PGI2 produced a strong inhibitory effect on platelet aggregation to all agonists 
(Figure 6.4), whereas aspirin inhibited only those to collagen, ADP, epinephrine and 
AA (Figure 6.5). In contrast the 12-LOX inhibitor, baicalein, did not affect 
aggregation in response to any agonists (Figure 6.6). 
 
Effect of TXA2 and 12(S)HETE on platelet aggregation 
There is a much controversy in the literature as to whether 12(S)-HETE exhibits a 
pro- or anti-aggregatory effect on activated platelets. My aim was to determine 
whether the exogenous addition of the 12-LOX product, 12(S)-HETE, could 
modulate the pro-aggregating effects induced by TXA2. Platelet aggregation to both 
AA (0.03 – 1 mM) and U46619 (0.1 – 30 µM) was assessed in the presence of 12(S)-
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HETE (0.1 µM – 1 µM). 12(S)-HETE at the concentrations tested did not elicit any 
effect on platelet aggregation(Figure 6.7). 
 
Effect of PGD2 on platelet aggregation 
PGD2 produces strong inhibitory effects on platelet aggregation through DP 
receptors, activation of which stimulates adenylyl cyclase within the cell. All 
agonists at the highest concentrations caused full aggregation responses that were 
robustly reduced by PGD2 at nanomolar concentrations (Figure 6.8). 
 
Effect of PGE2 on platelet aggregation 
High concentrations of PGE2 inhibit platelet aggregation through non-specific 
activation of IP receptor, whereas low concentrations stimulate platelet aggregation 
through EP3 receptors. Indeed, the results showed that PGE2 at low concentrations 
was able to induce platelet aggregation, whereas at higher concentrations these 
responses were inhibited (Figure 6.9).  
Effect of exogenous HETEs on aggregation of activated-platelet in PRP 
The exogenous addition of 11-HETE, 12(S)-HETE, 15-HETE, 5-HETE (Figure 6.10) or 
non-selective LOX-inhibition by NDGA did not affect platelet aggregation compared 
to control (Figure 6.11).  
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Figure 6.1 Adhesion of mepacrine-labelled platelets to collagen (100 µg/ml) under 
shear (1000 s-1 shear rate) after treatment with prostacyclin, PGI2
 
(2µg/ml), aspirin 
(30 µM), baicalein (10 µM) or vehicle.  Data shown as mean ± SEM; ANOVA with 
Dunnett test used for comparison of all columns to vehicle column. Differences 
were taken to be significant at P values of less than 0.05 (*p˂0.05, **p˂0.01); n=4. 
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Figure 6.2 Images taken by epifluorescent microscopy (20 X) of mepacrine-labelled 
platelets aggregating to collagen (100 µg/ml) under shear (1000 s-1 shear rate) of 
citrated whole blood from healthy volunteers treated with aspirin (30 µM), PGI2 (2 
µg/ml), baicalein (10 µM) or vehicle. After 5 min of blood flow, collagen produced a 
robust stimulation of platelet aggregation which was strongly impaired in the 
presence of PGI2 and reduced with aspirin. In contrast, neither baicalein or 12(S)-
HETE altered the platelet responses compared to the vehicle control (n=4). 
 
vehicle aspirin 
PGI2 baicalein 
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Figure 6.3 Effect of 12-LOX products or 12-LOX inhibition on platelet 
adhesion/aggregation in static conditions. Concentration-adhesion curves to 
collagen (0.1 μg/ml – 20 μg/ml) in the presence of vehicle, PGI2 (2 µg/ml), 12(S)-
HETE (1 µM), aspirin (30 µM) or baicalein (10 µM). Differences were taken to be 
significant at P values of less than 0.05 (*p˂0.05; **p˂0.01) by two-way ANOVA; n=4  
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Figure 6.4 Effects of PGI2 on platelet aggregation. Concentration-aggregation curves 
to a) ADP (0.1 – 30 µM), b) TRAP-6 (0.1 – 30 µM), c) collagen (0.1 – 30 µg/ml) d) 
U46619 (0.1 – 30 µM), e) epinephrine (0.001-100 µM), f) AA (0.03 – 1 mM), in 
platelet-rich plasma (PRP) treated with prostacyclin (PGI2; 2 µg/ml). Aggregation to 
all agonists was strongly inhibited by PGI2 compared to vehicle. Differences were 
taken to be significant at P values of less than 0.05 (***p˂0.001) by two-way 
ANOVA; n=4. 
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Figure 6.5 Effect of aspirin on platelet aggregation. Concentration-aggregation 
curves to a) ADP (0.1 – 30 µM), b) TRAP-6 (0.1 – 30 µM), c) collagen (0.1 – 30 µg/ml) 
d) U46619 (0.1 – 30 µM), e) epinephrine (0.001-100 µM), f) AA (0.03 – 1mM) in 
platelet-rich plasma (PRP) treated with aspirin (30 µM).  Aggregation to AA was fully 
inhibited and aggregation to collagen, ADP and epinephrine partly inhibited by 
aspirin. Differences were taken to be significant at P values of less than 0.05 
(*p˂0.05; **p˂0.001; ***p˂0.001) by two-way ANOVA; n=4. 
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 Figure 6.6 Effect of baicalein on platelet aggregation. Concentration-aggregation 
curves to a) ADP (0.1 – 30 µM), b) TRAP-6 (0.1 – 30 µM), c) collagen (0.1 – 30 µg/ml) 
d) U46619 (0.1 – 30 µM), e) epinephrine (0.001-100 µM), f) AA (0.03 – 1 mM) in 
platelet-rich plasma (PRP) treated with baicalein (10 µM).  None of the aggregation 
responses were affected by baicalein (10 µM). Differences were taken to be 
significant at P values of less than 0.05 by two-way ANOVA; n=4. 
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a)                                                                               b) 
 
 
Figure 6.7 Effect of 12(S)-HETE on platelet aggregation. Concentration-aggregation 
curves to a) AA (0.03 – 1 mM) and b) U46619 (0.1 – 30 µM) in platelet-rich plasma 
(PRP) treated with 12(S)-HETE (0.1 – 1 µM) or vehicle. Aggregations to both agonists 
were not affected by the addition of 12(S)-HETE. Differences were taken to be 
significant at P values of less than 0.05 by two-way ANOVA; n=4. 
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Figure 6.8 Effect of PGD2 on platelet aggregation. Concentration-aggregation curves 
to a) ADP (3 – 30 µM), b) TRAP-6 (3 – 30 µM),  c) collagen (3 – 30 µg/ml), d) U46619 
(3 – 30 µM), e) epinephrine (0.1 – 10 µM), f) AA (0.2 – 0.6 mM) in platelet-rich 
plasma (PRP) in the presence of PGD2 (0.01 nM – 30 µM).  All agonists at their 
higher concentrations elicited platelet aggregations which were strongly inhibited by 
PGD2 in the nanomolar range of concentrations.  Differences were taken to be 
significant at P values of less than 0.05 (***p˂0.001) by two-way ANOVA; n=4.
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Figure 6.9 Effect of PGE2 on platelet aggregation. Concentration-aggregation curves 
to a) ADP (3 – 30 µM), b) TRAP-6 (3 – 30 µM),  c) collagen (3 – 30 µg/ml), d) U46619 
(3 – 30 µM), e) epinephrine (0.1 – 10 µM),  f) AA (0.2 – 0.6 mM) in platelet-rich 
plasma (PRP) in the presence of PGE2 (0.01 nM – 30 µM).  Low concentrations of 
PGE2 promoted platelet aggregation to all agonist, whereas high concentrations of 
PGE2 inhibited platelet aggregation to all agonists. Differences were taken to be 
significant at P values of less than 0.05 by two-way ANOVA; n=4. 
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Figure 6.10 Effect of 5-HETE, 11-HETE, 12-HETE and 15-HETE on platelet 
aggregation. Concentration-aggregation curves to a) ADP (3 – 30 µM), b) TRAP-6 (3 
– 30 µM),  c) collagen (3 – 30 µg/ml), d) U46619 (3 – 30 µM), e) epinephrine (0.1 – 
10 µM),  f) AA (0.2 – 0.6 mM), g) A23187 ( 0.125 – 40 µM) in platelet-rich plasma 
(PRP) in the presence of 5-HETE, 11-HETE, 12-HETE and 15-HETE (1 µM) or vehicle. 
Aggregations to all agonists were unaffected by the addition of HETEs. Differences 
were taken to be significant at P values of less than 0.05 by two-way ANOVA; n=4. 
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Figure 6.11 Effect of NDGA on platelet aggregation. Concentration-aggregation 
curves to a) ADP (3 – 30 µM), b) TRAP-6 (3 – 30 µM),  c) collagen (3 – 30 µg/ml), d) 
U46619 (3 – 30 µM), e) epinephrine (0.1 – 10 µM),  f) AA (0.2 – 0.6 mM, g) A23187  
0.125 – 40 µM) in platelet-rich plasma (PRP) in the presence of NDGA (10µM) or 
vehicle. Treatment with the LOX inhibitor did not alter platelet responses. 
Differences were taken to be significant at P values of less than 0.05 by two-way 
ANOVA; n=4.  
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6.1.4 Conclusions 
With this set of data I wanted to determine whether 12(S)-HETE, known to be a 
major platelet product following activation, or 12-LOX inhibition modulated platelet 
function by assessing platelet aggregation and adhesion, the two characteristic 
processes of plug formation. In the literature there is a lot of controversy regarding 
this topic and therefore the role of 12(S)-HETE is still unclear. Ultimately, by 
comparing these effects with those of prostanoids (i.e TXA2, PGD2 and PGE2) my 
goal was to estimate the effect all these metabolites combined might produce on 
platelet aggregation. Initially, I established whether 12-LOX metabolites or 
treatment with baicalein affected the initial processes of plug formation, i.e. 
platelet adhesion to collagen, both under static and shear conditions. PGI2 is one of 
the most potent physiological platelet inhibitors released by the vascular 
endothelium to maintain platelets in a resting state in normal conditions and was, 
thus, used as a positive control for functional testing studies. Experiments under 
shear were performed in both citrated- and lepirudinized-whole blood as citrate 
binds extracellular calcium, hence promoting TXA2-driven aggregation which leads 
to an over-estimation of the inhibitory effects of aspirin.320 By comparing the two 
anticoagulants the aim was to investigate whether an effect of the 12-LOX products 
could be detected in a system where aggregation was not exacerbated by the 
effects of TXA2. The results obtained in both static and shear conditions showed full 
inhibition of platelet adherence to collagen by PGI2 and a 50% inhibition in the 
presence of aspirin, whereas 12-LOX inhibition with baicalein did not produce any 
effect. Successively, 96-well plate aggregometry (light transmission aggregometry) 
was used to measure platelet aggregation to different agonists at a range of 
concentrations in order to examine the effect of 12-LOX inhibition with baicalein 
(10 µM) compared to that of COX inhibition with aspirin (30 µM).  As expected, PGI2 
fully inhibited platelet aggregation responses to all agonists, while aspirin inhibited 
those to collagen, ADP and epinephrine at the concentrations in which aggregation 
is mainly TXA2-driven. Baicalein, instead, did not show any effect on platelet 
aggregation compared to control.  
I failed to find any effect of exogenously added 12-LOX products on platelet 
aggregation in vitro. My results indicate that 12(S)-HETE, although a major platelet 
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metabolite, does not elicit autocrine effects on platelet function in terms of 
modulating platelet aggregation or adhesion in either static or shear conditions. 
Focus was then addressed in examining whether the other HETE isoforms identified 
as platelet products by my lipidomic analysis influenced platelet function. In 
particular, with this set of experiments I aimed to investigate whether the different 
platelet-derived HETEs, 11-HETE and 15-HETE, and the neutrophil-derived 5-HETE 
could exhibit an effect on platelet aggregation. Experiments were performed in 
lepirudinized-blood in order to limit the artefactual enhancement of TXA2-driven 
aggregation, which can be encountered in studies performed using citrated-blood. 
Platelets were activated with a range of concentrations of different agonists, in 
particular collagen, ADP, U46619, TRAP-6, A23187, AA or epinephrine, and 
aggregation measured using 96-well plate aggregometry. None of the HETE 
isoforms tested in vitro affected platelet aggregation in these conditions. 
 
Prior to investigating the functional role that platelet LOX products play within the 
vasculature, I was interested in determining whether anti-platelet therapy, 
represented by the combination of aspirin and prasugrel, affected the production of 
COX and LOX metabolites in in vitro stimulated whole blood and PRP. These results 
from these studies, performed by LC-MS/MS in collaboration with Dr. Darryl Zeldin 
(NIEH, USA), would allow me to clarify the pathways involved in the production of 
eicosanoids by platelets and how this production might be affected by currently 
used anti-platelet therapies. 
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Chapter 7: Effect of anti-platelet 
therapy on eicosanoid formation 
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7.1 Effect of anti-platelet treatments on eicosanoid production in 
whole blood and PRP 
 
7.1.1 Introduction 
LC-MS/MS analysis reported in earlier chapters established that the formation of 
PGs and HETEs, with the only exception of 5-HETE, depends on platelet activation, 
not other blood cells. My aim was then to study how anti-platelet therapy might 
affect eicosanoid production in both PRP and whole blood in order to gain more 
insight on the pathways involved in their synthesis. For this study eicosanoid 
production was assessed in both PRP and whole blood in the presence of aspirin, 
prasugrel, and the combination of aspirin with prasugrel, which matches the 
therapy used clinically for patients at risk of secondary thrombotic events. This assay 
allowed me to investigate how the interplay between platelets and other blood cells 
and the presence of clinically relevant anti-platelet therapy might affect the 
production of eicosanoids in acute conditions. 
 
7.1.2 Methods 
Sample preparation 
Platelets in both PRP and whole blood, prepared as previously described, were 
activated under stirring conditions at 37°C in a PAP-8E aggregometer in the 
presence of collagen (30 µg/ml) or TRAP-6 (30 µM) for 5 min. Plasma was then 
separated from the samples by centrifugation (12,000 rpm; -4°C) and analysed by 
LC-MS/MS as described in the Methods section in Chapter 3. 
 
Statistical analysis 
Statistical analysis were conducted using GraphPad Prism v5 (GraphPad Software 
Inc, CA, USA). ANOVA and Dunnett post-tests. Differences were taken to be 
significant at P values of less than 0.05.  
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7.1.3 Results 
LC-MS/MS analysis of eicosanoid levels in whole blood and PRP stimulated with 
TRAP-6 (30 µM) or collagen (30 µM) and treated with aspirin, prasugrel or the 
combination of aspirin and prasugrel  
As expected the productions of TXA2, PGD2 and PGE2 increased in the presence of 
TRAP-6 (30 µM) or collagen (30 µg/ml) under stirring conditions, which were 
significantly reduced by aspirin (100 µM), confirming that these are COX-derived 
products (Figure 7.1) (Figure 7.4). Alongside, the levels of 12-HETE strongly 
increased in the presence of both the platelet agonists, but were not affected by the 
presence of aspirin, establishing that it is not a COX product, consistent with what 
reported in the literature. Nevertheless, 12-HETE levels decreased in the presence 
of aspirin and prasugrel in combination. Particularly this reduction was significant 
when TRAP-6 was used as a stimulus (Figure 7.3) (Figure 7.6). This might suggest 12-
HETE could be a potential marker of platelet activation in acute conditions. Most 
interestingly,  both11-HETE and 15-HETE reached high levels upon stimulation with 
TRAP-6 or collagen and were fully inhibited by aspirin, suggesting that both 11-HETE 
and 15-HETE are COX, not LOX, products (Figure 7.2) (Figure 7.5).  The levels of 5-
HETE were not affected by the addition of platelet stimuli or by the addition of anti-
platelet treatments supporting the evidence that this represents a 5-LOX-derived 
neutrophil product (Figure 7.3) (Figure 7.6). In this set of data the levels of 
eicosanoids produced by activated platelets were quantitatively differ from those 
obtained in the previous LC-MS/MS analyses since for this study platelets were 
stimulated with the agonists under stirring conditions and, therefore, are also driven 
by platelet-patelet mechanical interactions which play an important role on platelet 
activation. 
 
 
 
 
 
   Results 
122 
 
LC-MS/MS analysis of TBX2, PGD2 and PGE2 in whole blood and PRP stimulated with 
TRAP-6 (30 µM) 
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Figure 7.1 LC-MS/MS analysis of TXA2, PGD2 and PGE2 levels in TRAP-6 (30 µM)-
stimulated PRP and whole blood of healthy volunteers in the presence of aspirin 
(100 µM), prasugrel (3 µM) or the combination of aspirin and prasugrel. The 
production of TXA2, PGD2 and PGE2 was fully inhibited by aspirin in both PRP and 
whole blood. Data shown as mean ± SEM; ANOVA with Dunnett test used for 
comparison of all columns to vehicle column. Differences were taken to be 
significant at P values of less than 0.05 (***p˂0.001); n=4. 
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Figure 7.2 LC-MS/MS analysis of 11-HETE and 15-HETE levels in TRAP-6 (30 µM)-
stimulated PRP and whole blood of healthy volunteers in the presence of aspirin 
(100 µM), prasugrel (3 µM) or the combination of aspirin and prasugrel. The 
production of 11-HETE and 15-HETE was fully inhibited by aspirin in both PRP and 
whole blood. Data shown as mean ± SEM; ANOVA with Dunnett test used for 
comparison of all columns to vehicle column. Differences were taken to be 
significant at P values of less than 0.05 (***p˂0.001); n=4. 
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Figure 7.3 LC-MS/MS analysis of 5-HETE and 12-HETE levels in TRAP-6 (30 µM)-
stimulated PRP and whole blood of healthy volunteers in the presence of aspirin 
(100 µM), prasugrel (3 µM) or the combination of aspirin and prasugrel. Aspirin and 
prasugrel in combination inhibited the production of 12-HETE in PRP. However, the 
levels of 5-HETE were not affected by any treatment in either PRP or whole blood. 
Data shown as mean ± SEM; ANOVA with Dunnett test was used for comparison of 
all columns to vehicle column. Differences were taken to be significant at P values of 
less than 0.05 (*p˂0.05); n=4. 
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LC-MS/MS analysis of whole blood and PRP stimulated with collagen (30 µg/ml) 
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Figure 7.4 LC-MS/MS analysis of TXA2, PGD2 and PGE2 levels in collagen (30 µg/ml)-
stimulated PRP and whole blood of healthy volunteers in the presence of aspirin 
(100 µM), prasugrel (3 µM) or the combination of aspirin and prasugrel. The 
production of TXA2, PGD2 and PGE2 was fully inhibited by aspirin in both PRP and 
whole blood. Data shown as mean ± SEM; ANOVA with Dunnett test used for 
comparison of all columns to vehicle column. Differences were taken to be 
significant at P values of less than 0.05 (***p˂0.001); n=4. 
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Figure 7.5 LC-MS/MS analysis of 11-HETE and 15-HETE levels in collagen (30 µg/ml)-
stimulated PRP and whole blood of healthy volunteers in the presence of aspirin 
(100 µM), prasugrel (3 µM) or the combination of aspirin and prasugrel. The 
production of 11-HETE and 15-HETE was fully inhibited by aspirin in both PRP and 
whole blood. Data shown as mean ± SEM; ANOVA with Dunnett test used for 
comparison of all columns to vehicle column. Differences were taken to be 
significant at P values of less than 0.05 (*p˂0.05, ***p˂0.001); n=4. 
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Figure 7.6 LC-MS/MS analysis of 5-HETE and 12-HETE levels in collagen (30 µg/ml)-
stimulated PRP and whole blood of healthy volunteers in the presence of aspirin 
(100 µM), prasugrel (3 µM) or the combination of aspirin and prasugrel. Aspirin and 
prasugrel in combination inhibited the production of 12-HETE in PRP and whole 
blood. However, the levels of 5-HETE were not affected by any treatment in either 
PRP or whole blood. Data shown as mean ± SEM; ANOVA with Dunnett test used for 
comparison of all columns to vehicle column. Differences were taken to be 
significant at P values of less than 0.05; n=4. 
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7.2 Effect of platelet COX-1-derived prostanoids and 11(R), 15(S,R)HETE on 
aggregation 
 
7.2.1 Introduction 
The LC-MS/MS analysis (Chapter 7) shows that platelet COX-1 is responsible for the 
synthesis of not only prostanoids but also 15-HETE and 11-HETE. Interestingly, the 
COX-1 derived 11-HETE, 15-HETE and TXA2 were produced in stimulated blood and 
PRP in the proportions of (1:1:2) suggesting that all three are major platelet 
bioactive metabolites and not COX-1 side products. The aim was then to investigate 
whether platelets in the presence of COX-derived prostanoids and HETEs in 
combination, using the concentrations and proportions identified via LC/MS/MS, 
might modulate platelet aggregation. Smith’s biochemical studies, have shown that 
11(R)-HETE, 15(R)-HETE and 15(S)-HETE are the major HETE enantiomers produced 
by semi-purified ovine COX-1 (oCOX-1) in the presence of AA.26 Thus, in the 
following set of experiments I examined the effects elicited by these three specific 
enantiomers. To assess whether the exogenous addition of COX-1 derived 
prostanoids and HETEs affected platelet responses, PRP was treated with aspirin in 
combination with prasugrel in order to increase the window of aggregation in which 
the effects of the metabolites could be tested and then stimulated with aspirin-
sensitive concentrations of collagen (1 – 3 µg/ml).  
 
7.2.2 Methods 
Incubation of PRP 
For this study PRP was prepared from lepirudinized-blood of healthy volunteers and 
treated with the combination of aspirin (100 µM) and prasugrel (3 µM) (30 min at 
37°C) in order to increase the aspirin-sensitivity in the system.  
 
Light transmission aggregometry  
Samples (6 per donor) were incubated under stirring (1200 rpm; 1 min) using light 
transmission aggregometry and stimulated for 1 min with collagen (1 µg/ml) in 
order to generate a wide window of aggregation. All eicosanoids were added to the 
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samples at the concentrations and proportions identified by LC-MS/MS analyses. 
U46619 (2 µM) was added after 1 min of collagen stimulation which represents the 
lag time required for TXA2 levels to increase and induce aggregation. The effects of 
PGD2/PGE2 (1 µM) in the presence or absence of the 11(R)-HETE, 15(S)-HETE and 
15(R)-HETE (1 µM) enantiomers on U46619-induced aggregation were studied. 
HETEs were prepared in EtOH since they are more stable in organic solvents and the 
final percentage of EtOH per sample was 0.96%, which was compared to a vehicle 
sample. Aggregation was then assessed over 7 minutes using light transmission 
aggregometry (LTA) as described in the Methods section of Chapter 3 and the area 
under the curve (AUC) was calculated using PAP-8E V2.1.0 software. 
 
Statistical analysis 
Statistical analysis was conducted using GraphPad Prism v5 (GraphPad Software Inc, 
CA, USA). Repeated measures ANOVA and Bonferroni post-tests. Differences were 
taken to be significant at P values of less than 0.05.  
 
 
 
Figure 7.7 Scheme of the aggregation study using LTA to test the effects of the 
combination of COX-1-derived prostanoids and HETEs on platelet aggregation 
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7.2.3 Results 
Aspirin and prasugrel in combination significantly inhibited aggregation in collagen 
stimulated PRP which was restored by the addition of U46619 (2 µM) alone. The 
addition of PGD2 and PGE2 on top of U46619 reduced platelet aggregation 
consistent with PGD2 being an inhibitory mediator of platelet activation. HETEs in 
combination with PGE2/PGD2 produced a small although significant inhibitory effect 
on platelet aggregation compared to the response elicited by platelets stimulated 
with U46619 alone. This might be suggestive of COX-1 derived HETEs being weak 
modulators of platelet aggregation. Based on the evidence that the HETE isoforms 
alone or in combination on platelet responses have weak effects on platelet 
responses I hypothesized that the effects of these metabolites need to be sought on 
neighbouring cells within the vasculature (e.g leukocytes or endothelial cells) (Figure 
7.8). 
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Figure 7.8 Effects of the combination of U46619, PGD2, PGE2, 11(R)-HETE, 15(S)-
HETE and 15(R)-HETE on platelet aggregation. PRP obtained from healthy 
volunteers was treated with the combination of aspirin (100 µM) and prasugrel (3 
µM) and stimulated with collagen (1 µg/ml). Samples were then also treated with 
U46619, PGD2, PGE2 (2:1:1) alone or in combination with 11(R)-HETE and 15(S,R)-
HETE (1:1:1). HETE stereoisomers in combination with PGE2/PGD2 produced a small 
although significant inhibitory effect on platelet aggregation compared to the 
response elicited by platelets stimulated with U46619 alone. Differences were 
assessed repeated measures ANOVA and taken to be significant at P values of less 
than 0.05 (*p˂0.05); n=4. 
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7.2.4 Conclusions 
This third LC-MS/MS analysis was performed on releasates obtained from both PRP 
and whole blood of healthy volunteers where platelets not only were stimulated 
with collagen or TRAP-6 but also kept under stirring conditions (1200 rpm; 37°C) 
using a standard aggregometer and aggregation measured over 5 min. Once again 
these results showed that platelets are the main source of prostaglandins and HETEs 
when blood is exposed to collagen and TRAP-6. Additionally, these data showed that 
11-HETE, 12-HETE and also 15-HETE are produced in significant amounts and, thus, 
are consistent with the previous lipidomic analyses. To investigate which pathways 
might be involved in the production of platelet-derived eicosanoids and how these 
might be affected by the presence of anti-platelet therapy, both PRP and whole 
blood were treated in vitro with aspirin and prasugrel (3 µM), or aspirin and 
prasugrel in combination, which represents the anti-platelet therapy currently used 
for secondary prevention of vascular events (e.g. heart attack). Interestingly, 
treatment with aspirin alone or in combination with prasugrel fully inhibited the 
production of both 11-HETE and 15-HETE in addition to prostaglandins, i.e. TXA2, 
PGE2, PGD2. Hence, this finding established that 11-HETE and 15-HETE are produced 
by activated platelets through the activity of COX-1 and not through a LOX activity. 
This is consistent with Smith’s biochemical studies performed on solubilized and 
partly purified ovine COX-1 which showed that the enzyme was able to display a 
lipoxygenase activity depending on the arrangements assumed by AA within the 
catalytic site.26,321 Conversely, the production of 12-HETE was not inhibited by 
aspirin or prasugrel alone, but was reduced when these were added in combination. 
This outcome suggested that the platelet-derived 12-HETE is a 12-LOX product and 
potentially represents a useful marker of platelet activation as the reduction of its 
levels correlates with the overall inhibitory state of the platelet.  
 
These results established that both 11-HETE and 15-HETE, in addition to 
prostanoids, are platelet COX-1 metabolites. Based on this knowledge, I was 
interested in assessing whether the combination of 11-HETE and 15-HETE was able 
to modulate the net aggregation responses induced by prostaglandins, in particular 
by TXA2 in combination with PGE2 and PGD2, using the concentrations and 
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proportion found in the lipidomic analysis. I used as a reference for my experiments 
biochemical studies conducted by Smith’s group in which isolated ovine COX-1 
metabolised AA into 15(S)-HETE, 15(R)-HETE and 11(R)-HETE enantiomers. In order 
to determine the effects of the exogenous addition of prostanoids together with 
15(S)-HETE, 15(R)-HETE and 11(R)-HETE on platelet responses, PRP was treated with 
aspirin in combination with prasugrel in order to obtain a bigger window of 
aggregation in which these effects could be assessed. Initially, the aim was to 
establish that the addition of the TXA2-mimetic, U46619, alone was able to restore 
platelet aggregation responses of aspirin-treated platelets and how these responses 
might be affected by further addition of PGE2 and PGD2 in combination. Ultimately, 
the three HETE enantiomers were added on top of prostanoids and the area under 
the curve (AUC) measured and used as the parameter to evaluate whether HETEs 
were able to modulate platelet responses over 7 min aggregation. This recapitulated 
the conditions seen in platelets responding to activation in the absence of aspirin. 
As expected, U46619 restored platelet aggregation which was partly inhibited by the 
presence of both PGE2 and PGD2 (TXA2:PGE2:PGD2 2:1:1), consistent with PGD2 being 
a strong platelet inhibitor. Further addition of the HETE enantiomers 
(TXA2:PGE2:PGD2:15(S)-HETE:15(R)-HETE:11(R)-HETE 2:1:1:1:1:1) did not alter the 
AUC measured in the presence of prostaglandins alone. These results proved once 
more that platelet-derived HETEs do not elicit autocrine effects on platelet function. 
The results also emphasise that it is not only TXA2 produced by platelet COX-1 that 
regulates platelet responses.  
 
The data collected up to this point provided important information regarding the 
qualitative and quantitative production of eicosanoids by activated platelets and 
clarified the enzymatic pathways involved. In particular, the cPLA2α enzyme has 
been identified as the isoform involved in the production of eicosanoids by 
platelets. Furthermore, both 11-HETE and 15-HETE were identified as platelet COX-
1, not LOX, major metabolites and produced in amounts comparable to those of 
prostaglandins, which is strongly suggestive of these being bioactive metabolites 
and not side products. These data also established that platelet-derived HETEs do 
not regulate or modulate platelet aggregation responses and, thus, my research 
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aimed at identifying the functional role of these metabolites by investigating their 
paracrine effects on neighbouring cells, such as leukocytes. 
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Chapter 8: Effect of HETE isoforms on 
neutrophil chemotaxis 
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8.1 Effect of platelet-derived HETEs on neutrophil chemotaxis 
 
8.1.1 Introduction 
In my studies reported in earlier chapters I had detected no significant effects of 
LOX products on platelet adhesion/aggregation. Therefore, I aimed to investigate 
whether these metabolites elicited paracrine effects on neighbouring blood cells 
other than platelets, particularly leukocytes, and so affected inflammatory 
responses or modulated leukocyte trafficking, recruitment and/or activation. It is 
already accepted that platelets and leukocytes mutually influence one another in 
both haemostatic and inflammatory responses.270 The presence of 
polymorphonuclear leukocytes (PMNL) and macrophages in platelet thrombi 
together with their ability to develop prothrombotic as well as thrombolytic 
activities suggests that leukocytes may be involved in localized modulation of both 
thrombotic and haemostatic processes in addition to the role they play in 
inflammation.270,271 Thus, the first step was to study whether the different HETE 
isoforms alone or in combination, generated by platelets at high concentrations in 
acute conditions, were involved in the recruitment of PMNL, in particular on 
neutrophil chemotaxis. LTB4 is a neutrophil 5-LOX product, along with 5-HETE, 
which I used as the positive control for my studies due to its potent chemotactic 
properties.322  
 
8.1.2 Methods  
Isolation of neutrophils from human blood 
Polymorphonuclear leukocytes (PMNL) were obtained by centrifugation (400 g; 30 
min) of citrated blood/RPMI (1:1) from healthy volunteers using a double density 
gradient media (Hystopaque 1109 – Hystopaque 1007). Following collection of the 
PMN layer, an equal volume of RPMI 1640 was added and cells were then 
centrifuged (300 g; 15 min). The supernatant was discarded and the pellet 
resuspended by gently flicking the tubes. Then, ice cold distilled water was added to 
induce lysis of contaminating erythrocytes and 3.6% of sodium chloride solution 
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was subsequently added to preserve PMNs. Cells were finally centrifuged (300 g; 10 
min). 
 
Cell counting  
For neutrophil counting, a 10 µL aliquot of cell pellet was diluted in 990 µL of Turk’s 
[0.01% (w/v) crystal violet in 3% (v/v) acetic acid]. This method allows one to 
distinguish between different cells (PMNs, monocytes, and lymphocytes based on 
nuclear morphology). Cells were finally resuspended in RPMI medium 
supplemented with 0.1% BSA to count (4x106 cells/ml). 
 
Preparation of LTB4 and HETEs 
LTB4 and HETEs were diluted in RPMI 1640 in the presence of 0.1% BSA. LTB4 was 
used as the positive control for this assay at final concentrations of 1 nM, 10 nM, 
and 100 nM. 5-HETE, 11-HETE, 12(S)-HETE and 15-HETE were prepared at the final 
concentrations of 0.3 µM and 3 µM. The vehicle containing 0.96% EtOH was also 
prepared and tested on neutrophil chemotaxis. 5-HETE and 12(S)-HETE were 
prepared at 1µM and singularly added on top of increasing concentrations (0.25 – 2 
µM) of 5-HETE, 11-HETE, 12(S)-HETE or 15-HETE. 
 
Chemotaxis assay 
For this assay I used commercially available chemotaxis plates (Neuroprobe; 
ChemoTx®; Disposable Chemotaxis System 3.2 mm dia. sites, 30 μL 96-well plate, 3 
μm), which consist of a 96-well microplate format with an upper filter (3 µm pore 
size) and lid. The chemoattractant (positive control and HETEs) and the medium 
alone (negative control) are pipetted (30 µL) into the bottom wells of the chamber 
while avoiding the development of air bubbles. The upper filter was then properly 
fixed in place at each corner with the membrane of the filter in contact with the 
fluid in the bottom compartment of every well. Care was taken to ensure that there 
were no bubbles between the filter and media in the bottom wells in order to avoid 
any false results. The cell suspension (25 µL/well) was then added onto the top 
wells and the lid put on the plate. The plate was then placed in a cell incubator in 
5% CO2 at 37°C for 1.5 hour. At the end of this time, the remaining cells/media were 
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removed from the top membrane using a cotton bud. Each well was then washed 
with 25 µL/well of PBS to remove any remaining cells. The plate and membrane 
were then centrifuged (312 g for 5 min) to pellet cells in the bottom well. The filter 
was then removed and the cell pellet resuspended. 
 
Neutrophil chemotaxis quantitation 
AlamarBlue is a fluorometric/coloumetric growth indicator used to detect metabolic 
activity.  From each sample/well 20 µL was taken and mixed with 30 µL of 
AlamarBlue, pre-diluted (1/10) in PBS, in a 96-well plate. Similarly, a standard curve 
was prepared using 20 µL of cell suspensions at different densities (4x106 cells/mL 
downwards in doubling dilution) and mixed with 30 µL of pre-diluted AlamarBlue. 
The indicator gives a blue colour to each well. The plate was incubated overnight in 
the incubator (5% CO2 at 37°C). After this time the colour should shift from blue to 
pink in the presence of cells. The plate was then read by fluorescent detection 
(excitation 540-570 nm, emission 580-610 nm). Unknown values were converted 
using the standard curve constructed with known PMN number. 
 
Statistical analysis 
Statistical analysis were conducted using GraphPad Prism v5 (GraphPad Software 
Inc, CA, USA). ANOVA and Bonferroni post-tests. Differences were taken to be 
significant at P values of less than 0.05.  
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8.1.3 Results 
Effect of 5-, 11-, 12(S)-, 15-HETE on neutrophil chemotaxis 
LTB4 is a potent neutrophil chemoattractant synthesized through the activity of the 
5-LOX enzyme which is expressed in these cells. As expected LTB4 at the low 
concentration of 10 nM produced a strong chemoattractant effect on neutrophils. 
5-HETE, similarly a product of the 5-LOX enzyme, at the highest concentration used 
produced a significant chemoattractant effect. Interestingly, 12(S)-HETE (3 µM) had 
a very robust effect on neutrophil chemotaxis comparable to that of LTB4.  In 
contrast, 11-HETE and 15-HETE were without effect (Figure 8.1).  
 
Effect of the combination of fixed concentrations of 5-HETE or 12HETE and 5-, 12(S),- 
11-, 15- HETEs on neutrophil chemotaxis 
The addition of 12(S)-HETE on top of a fixed concentration of 5-HETE increased 
neutrophil responses, whereas this did not occur in the reverse case. The addition 
of increasing concentrations of 11-HETE and 15-HETE to 5-HETE or 12(S)-HETE both 
at 1µM did not produce any alteration in responses (data not shown). This 
suggested that 5-HETE and 12(S)-HETE, but not the other HETEs tested, are able to 
produce chemoattractant effects on neutrophils (Figure 8.2). 
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Figure 8.1 Effects of LTB4 (1-10-100 nM), 11-HETE, 15-HETE, 5-HETE and the 12(S)-
HETE stereoisomer (0.3 – 3 µM) on neutrophil chemotaxis. The chemotactic 
responses of isolated neutrophils obtained from human blood and stimulated with 
11-HETE, 15-HETE, 5-HETE or 12(S)-HETE (0.3 – 3 µM) were studied using a 
disposable Chemotaxis System and compared to those produced by LTB4. LTB4 (1-10-
100 nM) significantly induced neutrophil chemotaxis, as did 5-HETE. 12(S)-HETE (3 
µM)
 
produced strong chemoattractant effect on neutrophils comparable to that of 
LTB4. In contrast, 11- and 15-HETE had no chemoattractant effects on isolated 
neutrophils.  Data shown as mean ± SEM; ANOVA with Dunnett post-test was used 
for comparison of all columns to vehicle column. Differences were taken to be 
significant at P values of less than 0.05 (*p˂0.05, ***p˂0.01); n=4 
 
LTB4 
5-HETE 
12(S)HETE 
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Figure 8.2 Effects on neutrophil chemotaxis of 12(S)-HETE or 5-HETE (1 µM) added 
singularly on top of increasing concentrations of 5-HETE and 12(S)-HETE (0.25 – 2 
µM) respectively. LTB4 robustly elicited chemoattractant effects on neutrophils. 
12(S)-HETE (1 µM)
 
alone produced a strong chemoattractant effect on neutrophil 
migration comparable to that of LTB4, while 5-HETE (1 µM) alone produced a weaker 
response. The addition of 12(S)-HETE (1 µM) to increasing concentrations of 5-HETE 
enhanced neutrophil chemotaxis, while in the reversed case this occurred only 
when 5-HETE was added at high concentrations (2 µM).  Data shown as mean ± 
SEM; ANOVA with Dunnett post-test was used for comparison of all columns to 
vehicle column. Differences were taken to be significant at P values of less than 0.05 
(*p˂0.05, **p˂0.01; ***p˂0.01); n=4. 
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8.2 Effect of platelet-derived HETEs on neutrophil activation 
8.2.1 Introduction 
After assessing the role the HETE products played on neutrophil chemotaxis and 
identifying 12(S)-HETE as a potent neutrophil cheoattractant, I wanted to study the 
effects these eicosanoids might exhibit on neutrophil activation. Neutrophils are 
captured at site of inflammation, followed by their arrest and migration between 
the endothelial junctions. This sequence of events is mediated by three different 
families of adhesive receptors: integrins, selectins and Ig gene superfamily.323 It is 
thought that selectins, such as L-selectin (CD62L) on neutrophils, E-selectin or P-
selectin on endothelial cells, mediate neutrophil capture and rolling.323 Neutrophil 
arrest and transmigration requires the expression of adhesive molecules on the 
neutrophil surface represented by the family of CD18 integrins, in particular 
CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac-1), which constitute useful markers of 
neutrophil activation.324 The expression of these integrins requires fluid shear, 
selectin-mediated signalling and stimulation by chemoattractants (e.g. fMLP, IL-8 
and LTB4).324-326 The integrin CD11b/CD18 (Mac-1) is an adhesion molecule stored 
in the secondary granules of neutrophils which translocates from the cytoplasm to 
the membrane upon activation.327 This integrin modulates neutrophil adhesion and 
migration on endothelial cells328 but is also involved in the immobilization of 
activated neutrophils to platelets or proteins such as albumin and fibrinogen.325,329 
There is evidence that neutrophil activation requires the expression of L-selectin 
(CD62L) which is also useful as a marker of neutrophil activation. Indeed, cross-
linking of L-selectin has been shown to up-regulate Mac-1 expression and, 
therefore, enhance neutrophil adhesion and transmigration across endothelial cells 
(e.g HUVECs) and adhesion to albumin and fibrinogen.323 Ultimately, this family of 
integrins is highly expressed by neutrophils following stimulation with potent 
chemoattractants such as fMLP, IL-8 released by endothelial cells, and LTB4 which is 
generated by neutrophils through the 5-LOX enzyme. I was, therefore, interested in 
establishing whether the platelet COX-1 dependent products (11(R)-HETE, 15(S)-
HETE and 15(R)-HETE and also the COX independent 12(S)-HETE, which I have 
shown to be involved in neutrophil chemoattractant responses, elicited effects on 
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neutrophil activation. In order to answer these questions human blood was 
stimulated with the different HETE isoforms and both CD11b and CD62L used as 
markers of neutrophil activation, the expression of which was then measured by 
flow cytometry. The effects of HETEs were compared to those produced by known 
strong neutrophil chemoattractants and activators, i.e. fMLP, IL-8 and LTB4.322,330,331  
 
8.2.2 Methods 
Treatment of human lepirudinized-blood 
Lepirudinized-blood from healthy volunteers (n=6) was treated with vehicle (0.32% 
EtOH+0.01% DMSO), fMLP (1 µM), IL8 (100 nM), LTB4 (10 nM), 5-HETE, 12(S)-HETE, 
11-HETE or 15-HETE HETE (1 µM). 
 
FACS analysis of CD11b and CD62L expression as markers of neutrophil activation 
To study the expression of the neutrophil markers of activation Mac-1 (CD11b) and 
L-selectin (CD62L) mouse monoclonal antibodies reacting with human Mac-1 (Anti-
human CD11b APC; 1 µg/ml) and with human L-selectin (Anti-human CD62-L PE-
cyanine5; 1 µg/ml) were used. To discard a non-specific background signal the 
isotypes CD11b and CD62L were used as controls. All blood samples containing the 
different tretaments were labelled with CD11b+CD62L in combination. Blood 
samples (vehicle) were labelled with isoCD11b+iso CD62L, CD11b or CD62L as 
controls for the assay. Monoclonal antibodies for CD11b and CD62L were diluted 
(2/100) in 1:1 ratio of PBS with 0.1% BSA and IgG blocker (1 mg/ml stock in HETEs 
buffer) to limit unspecific binding.  
 
Neutrophil isolation and labelling 
Samples were incubated for 10-15 min at 37°C, then spun (1200 rpm-; 5 min) and 
washed in ice cold PBS (1200 rpm; 5min). Red blood cells were lysed using cell lysis 
buffer (BD FACS lysis solution, 349202). Samples were spun at 1500 rpm and each 
pellet resuspended in 30 µL of the antibody solutions prepared and transferred in a 
round-bottomed 96-well plate, then incubated on ice for 30 min. After the 
incubation period, PBS (100 µL) was added to each well/sample to resuspend the 
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pellets. Each sample was then transferred into FACS tubes and the pellets were 
resuspended with 1% PFA (500µL) to fix the samples for flow cytometry analysis 
(FACS).  
 
Statistical analysis 
Statistical analysis were conducted using GraphPad Prism v5 (GraphPad Software 
Inc, CA, USA). ANOVA and Bonferroni post-tests. Differences were taken to be 
significant at P values of less than 0.05.  
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8.2.3 Results 
Effect of the combination 12(S)-, 11(R)-, 15(S,R) - HETEs on neutrophil activation. 
The positive controls, fMLP and IL-8, induced neutrophil activation as shown by 
increased expression of the adhesive protein MAC-1 (CD11b) and L-selectin (CD62L) 
activation, which requires shedding and, thus, a conformational change in order to 
be in the activate state. Therefore, the expression of the CD62L marker of the 
inactive selectin is inversely proportional to neutrophil activation. LTB4 also 
promoted neutrophil activation although not to the same level as fMLP and IL-8. 
12(S)-HETE slightly promoted neutrophil activation by increasing the expression of 
CD11b similarly to LTB4. All other HETEs were without effect on neutrophil 
activation (Figure 8.3). 
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Figure 8.3 Effect of HETEs on neutrophil activation. Neutrophil activation was 
assessed by flow cytometry using double staining with CD11b (MAC-1) and CD62L 
(L-selectin), as markers of neutrophil activation. fMLP, IL-8 and LTB4, potent 
neutrophil activators, were used as positive controls to stimulate human whole 
blood and their effects compared to those elicited by the different HETE isoforms. 
Both fMLP and IL-8 stimulated neutrophil activation as noted by increased 
expression of CD11b and decreased expression of CD62L. LTB4 produced a weak 
stimulatory effect on both markers of activation. 12(S)-HETE weakly increased the 
expression of the CD11b marker, whereas the other HETEs were without effect. 
These results did not show any significance due to the variability among subjects. 
One-way ANOVA; n=6.  
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8.2.4 Conclusions 
This set of data allowed me to determine whether the different isoforms of HETEs, 
that I had identified to be mainly platelet products in stimulated blood, played a 
role in regulating chemotactic responses on neutrophils. Indeed, there are studies 
suggesting that these products may interact with PMNL promoting their 
recruitment.281 Based on this knowledge I initially studied cell migration to establish 
whether HETEs elicited chemoattractant effects on neutrophils isolated from 
human blood. The effects of HETEs were compared to those of LTB4, a potent 
neutrophil chemoattractant, which is formed by neutrophils via the 5-LOX 
pathway.322 12(S)-HETE elicited strong chemoattractant effects similar to those 
elicited by LTB4. Also, it is held that there is a cross-talk between platelets and 
neutrophils underpinning the production of LTs and lipoxins through the platelet 
12-LOX and the neutrophil 5-LOX. Thus, it can be suggested that 12(S)-HETE might 
be an intermediate substrate for the synthesis of inflammatory mediators or 
perhaps that the similar structures of 12(S)-HETE and LTB4 might be reflected in the 
ability of both these products to elicit potent chemoattractant effects on 
neutrophils. 5-HETE, a neutrophil 5-LOX product, also significantly increased 
neutrophil chemotaxis, while all the other HETE isoforms did not show any effect on 
neutrophil migration.  
 
Based on the previous results I wanted to investigate whether HETEs were also 
involved in neutrophil activation by evaluating the expression of adhesive protein, 
MAC-1, and L-selectin. The responses were compared to those of strong neutrophil 
activators, in particular fMLP and IL-8.330 331 The results did not show any significant 
effect or trend of the different HETE isoforms on neutrophil activation. This may 
suggest that 12(S)-HETE and 5-HETE might be released by platelets and neutrophils, 
respectively, increasing the cross-talk between these two cell types and promoting 
neutrophil recruitment,  but not neutrophil activation.  Ultimately, based on the 
results reported so far the roles of 15-HETE and 11-HETE require further 
investigation as no convincing effects of these products on platelet or leukocyte 
function have been found. The role of these platelet COX-1 products might be in 
processes other than haemostasis/thrombosis and inflammation in which platelets 
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are major contributors, such as angiogenesis. Indeed, studies have shown (that 
15(S)-HETE promotes neovascularization.307 Therefore, I wanted to assess whether 
15(S)-HETE could influence/modulate angiogenesis. 
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Chapter 9: Effect of 15(S)HETE on 
HMEC-1 angiogenic responses 
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9.1 Production of the 15(S)HETE stereoisomer in whole blood and PRP 
 
9.1.1 Introduction 
The data obtained so far clearly established that 15-HETE is a major platelet COX-1 
metabolite, however I was interested in measuring the levels of the 15(S)-HETE 
enantiomer via enzymatic immune assay (EIA) in the same conditions used for the 
LC-MS/MS analysis. The aim was to confirm the results obtained by LC-MS/MS and 
determine the levels of this particular enantiomer in stimulated blood and PRP. In 
particular, it was important to establish the enantiomer produced by platelets as 
studies have shown that 15(S)-HETE represents the bioactive metabolite and able to 
elicit pro-angiogenic effects on human vascular endothelial cells.307 
 
9.1.2 Methods 
Incubation of PRP and whole blood 
Blood from healthy volunteers was taken into lepirudin. ¾ of the blood taken from 
each heathy volunteer was centrifuged (175 g; 15 min) in order to obtain PRP. Both 
PRP and whole blood were treated with aspirin (100 µM), prasugrel (3 µM) or the 
combination of aspirin and prasugrel and stimulated with collagen or TRAP-6 as 
previously described for the LC-MS/MS sample preparation.  
 
15(S)-HETE EIA assay 
The EIA assay was performed in accordance with the kit booklet. PRP and whole 
blood samples were diluted 1:10 and assayed in parallel to known 15(S)-HETE 
standards, a maximum binding control, non-specific binding control and blank on a 
96-well plate coated with goat anti-IgG antibodies. The plate was incubated for 18 
hours after the addition of 15(S)-HETE-acetylcholinesterase conjugate and 15(S)-
HETE rabbit antiserum. After washing, Elmann’ reagent was added, the plate was 
covered and allowed to develop for 60 minutes on an orbital shacking platform. 
Once developed, the absorbance of each well was determined at 405 nm. From the 
absorbance data, the percentage binding of known standards was calculated in 
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reference to the maximum binding control wells, plotted against the logarithm of 
concentration and analysed by non-linear regression using a four-parameter 
logistical fit model. Unknown samples were expressed in a similar fashion, 
interpolated from this standard curve and corrected for dilution. 
 
Statistical analysis 
Statistical analysis were conducted using GraphPad Prism v5 (GraphPad Software 
Inc, CA, USA). ANOVA and Bonferroni post-tests. Differences were taken to be 
significant at P values of less than 0.05.  
 
9.1.3 Results 
Production of 15(S)-HETE in TRAP-6 or collagen stimulated whole blood and PRP 
treated with aspirin, prasugrel or the combination of aspirin and prasugrel 
The results showed that the levels of 15(S)-HETE were comparable to those 
obtained from the LC-MS/MS analysis and were also in agreement with those 
reported in Smith’s study. Also, as shown from the LC-MS/MS data, the production 
of 15(S)-HETE was strongly inhibited in samples treated with aspirin which 
establishes once again that this eicosanoid is a COX-1 product. Further studies were 
then aimed at investigating the functional role that the platelet-derived 15(S)-HETE 
plays in angiogenesis (Figure 9.1). 
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Figure 9.1 EIA assay of 15(S)-HETE levels in collagen- and TRAP-6 stimulated 
lepirudinized PRP and whole blood of healthy volunteers in the presence of aspirin 
(100µM), prasugrel (3 µM) or the combination of aspirin and prasugrel. The levels of 
15(S)-HETE are similar to those identified by LC-MS/MS analysis. Aspirin alone and 
aspirin and prasugrel in combination significantly inhibited the production of 15(S)-
HETE in both PRP and whole blood consistent with it being a COX-1 product. Data 
shown as mean ± SEM; ANOVA with Dunnett post-test. Differences were taken to be 
significant at P values of less than 0.05 (**p˂0.01; *** p˂0.001); n=4. 
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9.2 Effect of 15(S)-HETE on HMEC-1 angiogenic responses 
 
9.2.1 Introduction 
Both my LC-MS/MS and EIA data established that upon stimulation 15(S)-HETE is a 
major platelet COX-1 product, together with TXA2. Studies have shown that 15(S)-
HETE produces pro-angiogenic effects on both HUVECs and HDMVECs by increasing 
endothelial cell migration and formation of tubular network-like structures and also 
promotes rat aortic ring sprouting.307,308 It is already held that platelets play a 
crucial role in modulating angiogenesis in both physiological and pathological 
conditions (e.g. tumour growth and metastases) through the release of pro- and 
anti-angiogenic mediators stored in α-granules.179 The differential release of these 
mediators is dependent on the platelet receptor and pathway involved and, thus, 
on the stage of the angiogenic process. Interestingly, several in vitro studies have 
reported that releasates from platelets stimulated with thrombin increased 
angiogenic responses in both HUVECs and HMEC-1, but that this effect was reduced 
when platelets were pre-treated with aspirin.297 These data were supported by 
clinical studies in which low doses of aspirin appear beneficial in limiting tumour 
progression in patients suffering from cancer.300 289  
 
I was, therefore, interested in investigating whether the great amounts of 15(S)-
HETE that were produced by platelets through the activity of the COX-1 enzyme 
were able to affect endothelial cell angiogenic responses. To do this I determined 
the effects of platelet releasates on in vitro tubular network-like structure 
formation on Matrigel, and measured migration of human microvascular 
endothelial cells (HMEC-1). For these angiogenic experiments HMEC-1 (CDC, 
Atlanta) were my model of choice as they were used by the Etulain et al. group. 
Thus my aim was to reproduce this in vitro model and evaluate whether addition of 
15(S)-HETE to aspirin-treated releasates would restore the angiogenic responses. 
Moreover, experiments were conducted ex vivo by measuring the formation of 
sprouts from rat aortic rings in order to support and give further relevance to the 
results obtained in vitro. 
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9.2.2 Methods 
Tube formation assay 
Human microvascular endothelial cells (HMEC-1 cells) 
HMEC-1 is a cell line obtained by immortalizing human dermal microvascular 
endothelial cells (HMEC) through their transfection with a PBR-322-based plasmid 
containing the coding region for the simian virus 40 A gene product, large T antigen. 
HMEC-1 represents the first immortalized microvascular endothelial cell line and 
maintains the same morphologic, phenotypic, and functional properties of normal 
human microvascular endothelial cells.332  
 
Passaging of HMEC-1 (30 min before start of the assay) 
Standard procedures to passage cells were used. Nearly confluent cultures of 
HMEC-1 were split and cells used when 80% confluent (generally, 5–8x106 cells per 
T75 flask). 
 
48-well cell culture plate coating with BME 
48-well plates were coated with 100 µL/well basement membrane extract, with 
sufficient wells to allow samples to be tested in duplicate. The plate was then 
transferred to a cell culture incubator and incubated for at least 30 min at 37° C to 
allow the basement membrane extract to gel. 
 
Harvesting 80% confluent HMEC-1 
When HMEC-1 reached 80% confluence in the T75 flask, the media (RPMI+10% 
FBS+10% steptomicyn/penicillin) was removed and the flask rinsed with sterile PBS. 
Trypsin-EDTA (3 ml) was added to the flask, briefly swirled and incubated at 37°C for 
a few minutes. Media was then added to the flask (1:1) and the cells resuspended. 
The cell suspension was transferred into a sterile 15 ml tube and centrifuged (800 g; 
5 min) to obtain a pellet. The cell number was determined using a haemacytometer 
(5 to 8x106 cells per T75 flask). 
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Plate layout 
 1 2 3 4 5 6 7 8 
1 
PBS PBS TRAP-6 TRAP-6 
TRAP6+ 
15(S)HETE 
TRAP6+ 
15(S)HETE 
TRAP6+ 
aspirin 
TRAP6+ 
aspirin 
2 TRAP6+ 
aspirin+ 
15(S)HETE 
TRAP6+ 
aspirin+ 
15(S)HETE 
collagen collagen 
collagen+ 
15(S)HETE 
collagen+ 
15(S)HETE 
collagen+ 
aspirin 
collagen+ 
aspirin 
3 collagen+ 
aspirin+ 
15(S)HETE 
collagen+ 
aspirin+ 
15(S)HETE 
                           
* In each well 40,000 cells/well solution (media+platelet releasates) was added. 
 
HMEC-1 addition to the Basement Membrane Extract (BME) 
HMEC-1 were resuspended with platelet releasates and RPMI medium+2% FBS (1:1) 
in order to have 40,000 cells/well final. Vehicle and 15(S)-HETE were added to each 
sample to a levels of 0.32% EtOH and 1µM, respectively. The HMEC-1 suspension 
(media+platelet releasates) was added onto the Matrigel-coated 48-well plate (200 
µL/well).  
 
Imaging-labelling/quantitate HMEC-1 tube formation 
Tube formation was visualized using time-lapse microscopy (4X magnitude) where 
images were taken in phase every 30 min for 16 hours (Mcell software). The 
imaging system was furnished as an incubator built around the microscope in order 
to keep the plate with HMEC-1 at 37°C and 5% CO2. The number of branching points 
was quantitated after 4h and 8h incubation (4X magnitude) and after 16h 
incubation (10X magnitude) using Image J software. After 16h incubation images 
were taken in phase (10X magnification) and, subsequently, calcein was added to 
each well and incubated for 10 min (37°C; 5%CO2) in order to take images in 
fluorescence (10X magnification), using a 485 nm excitation or 520 nm emission 
filter. 
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Migration assay  
Coating of 6-well cell culture plate with HMEC-1 
During passaging 1/3 of the cells in the T75 flask were plated onto 5 wells of 6-well 
plate and the rest split into two T75 flasks. The cells seeded on the 6-well plate 
were incubated (37°C; 5% CO2) until 100% confluence was reached.  
 
Scratch assay on HMEC-1 
HMEC-1 were ready for the assay when 100% confluent. A p200 tip was used to 
scrape the cells in a straight line in order to create a “scratch” of approximately the 
same size for each of the 5 wells.  
 
Preparation of platelet releasates+treatments  
Platelet releasates were prepared as explained in Chapter 6, then diluted with 
media (RPMI+10%FBS) (1:1). Vehicle and 15(S)-HETE were added to each sample in 
order to have 0.32% EtOH and 1 µM, respectively.  
 
Addition of the cells+releasates+treatments to the 6-well plate 
The media was removed from the wells and cells washed with PBS. The HMEC-1 
suspension was then added to each well (2 ml/well). Only 5 wells were used since 
one was required for the insertion of the CO2 probe for time-lapse microscopy 
imaging. 
 
6-well plate layout 
 1 2 3 
1 Platelet releasate+PBS 
 
Platelet releasate+TRAP-6 
 
Platelet releasate+TRAP-6 
+15(S)HETE 
2 
Platelet releasate+TRAP6 
+aspirin 
Platelet releasate+TRAP6 
+aspirin+15(S)HETE 
CO2 probe 
* The same layout was used for collagen-stimulated platelet releasates. 
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Imaging and quantitation of HMEC-1 migration 
HMEC-1 migration was visualized using time-lapse microscopy (10X magnitude) 
where images were taken in phase every 30 min for 20 hours using Mcell software.  
The imaging system included an incubator built around the microscope in order to 
keep the plate with HMEC-1 at 37°C and 5%CO2. Migration was measured by 
calculating the % of area covered the cells from time 0 to 20 h incubation. 
 
Rat aortic rings assay 
Thoracic aortas from 180-200 g Wistar rats (Charles River) were sliced into sections 
(0.5 mm) and incubated overnight in serum free OptiMEM (Invitrogen) at 37°C, 5% 
CO2. Animals were fed a standard chow diet and housed under a 12 hour light and 
dark cycle. Aortic rings were embedded in type I collagen (1 mg/ml) in E4 meda 
(Invitrogen). Platelet releasates were prepared as described in section in Section 3 
of the Methods and kept at -80°C. In order to have all samples equally treated for 
the assay releasates were thawed and collagen or TRAP-6 and/or aspirin were 
added to those samples in the absence of the respective treatments. Releasates 
were diluted in OptiMEM with 1% FBS (PAA) and those stimulated with PBS were 
then treated with VEGF (10 nM), 15(S)-HETE (1 µM) or vehicle, while those 
stimulated with TRAP-6 or collagen and in the presence of aspirin  were treated in 
the presence or absence of 15(S)-HETE (1 µM). The vehicle was added to all the 
remaining samples. Wells (5 per condition) were supplemented with the different 
conditions and incubated at 37°C, 5% CO2. After 4 days in culture, emergent 
angiogenic sprouts formed on the external portion of the rat rings were identified 
and counted using Olympus IX81 inverted microscope. All animal experiments were 
conducted in accordance with the British Home Office regulation (Scientific 
Procedures) Act 1986, United Kindom. Images were captured using Olympus IX81 
inverted microscope with Hamamatsu Orca-ER digital camera and image acquisition 
was performed using Cell M software (Olympus). Statistical analysis was performed 
using Graphpad Prism software Version 6.0. 
Statistical analysis 
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Statistical analysis was conducted using GraphPad Prism v5 (GraphPad Software Inc, 
CA, USA). ANOVA and Bonferroni post-tests. Differences were taken to be significant 
at P values of less than 0.05.  
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9.2.3 Results 
Effect of 15(S)-HETE on HMEC-1 tube-formation.  
Platelet releasates produced in response to high concentrations of TRAP-6 (30 µM) 
and collagen (30 µg/ml) robustly promoted tube formation compared to releasate 
from platelets stimulated with PBS (Figure 9.2) (Figure 9.5). Addition of 15(S)-HETE 
(1 µM) to both TRAP-6 and collagen platelet releasates produced no additional 
effects (Figure 9.2) (Figure 9.5). Aspirin pre-treatment of platelets greatly decreased 
the effects of TRAP-6 and collagen on formation of tube network-like structures, 
which were fully restored by the addition of 1 µM 15(S)-HETE (Figure 9.3) (Figure 
9.4) (Figure 9.6) (Figure 9.7).  
 
Effect of 15(S)-HETE on HMEC-1 migration 
Migration of HMEC-1 at the level of the scratch was slightly, although still 
significantly, increased in the presence of platelet releasates produced in response 
to TRAP-6 (30 µM) or collagen (30 µg/ml) compared to unstimulated platelet 
releasates. Aspirin pre-treatment of platelets reduced the effects of releasate on 
cell migration which was restored in the presence 15(S)-HETE (1 µM) (Figure 9.8). 
 
Effect of 15(S)-HETE on formation of sprouts from rat aortic rings  
The ex vivo rat aortic ring model of angiogenesis supported the findings obtained in 
vitro confirming the pro-angiogenic role of 15(S)-HETE. The strong pro-angiogenic 
effects of VEGF were used as a control for this study and, as expected, PBS-
stimulated releasates in the presence of VEGF (10 nM) significantly promoted the 
formation of angiogenic sprouts compared to PBS-stimulated releasates alone. 
Incubation of aortic rings with TRAP-6 or collagen-stimulated releasates, similarly to 
VEGF, robustly increased the number of sprouts which was highly reduced by 
aspirin, suggestive of COX-1 products being crucial in supporting angiogenic 
processes. Interestingly, the addition of 15(S)-HETE (1 µM) to aspirin treated-
releasates was able to fully restore the formation of angiogenic sprouts proving 
once more the importance of this metabolite in modulating angiogenesis (Figure 
9.9) (Figure 9.10) (Figure 9.11) (Figure 9.12). 
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a)                                            b) 
 
 
 
 
 
 
 
 
 
c)                                                                            d) 
 
 
 
 
 
 
 
 
 
e)                                                                             f) 
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Figure 9.2 Images of HMEC-1 tube formation in the presence of releasates from 
TRAP-6-stimulated platelets. HMEC-1 in the presence of releasates obtained from 
human PRP stimulated with a-b) PBS, c-d) TRAP-6 (30 µM) or e-f) TRAP-6 and 15(S)-
HETE (1 µM). Images were captured using Olympus IX81 inverted microscope (10X) 
with Hamamatsu Orca-ER digital camera after 16 hour incubation (37°C; 5% CO2) in 
phase or after the addition of a fluorescent complex, calcein (n=3).  Image 
acquisition was performed using Cell M software (Olympus). TRAP-6 stimulated 
platelet releasates caused a robust increase in tube formation compared to PBS-
stimulated controls. 15(S)-HETE did not show any additional effect compared to 
TRAP-6-stimulated releasates alone. 
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a)                                                                            b)                                      
 
 
 
 
 
 
 
 
 
c)                                                                            d) 
 
 
 
Figure 9.3 Images of HMEC-1 in the presence of releasates from TRAP-6-stimulated 
and aspirin-treated platelets. HMEC-1 in the presence of releasates obtained from 
human PRP pre-treated with aspirin (100 µM) and stimulated with TRAP-6 (30 µM) 
and in the presence of a-b) vehicle or c-d) 15(S)-HETE (1 µM). Images were captured 
using Olympus IX81 inverted microscope (10X) with Hamamatsu Orca-ER digital 
camera after 16 hour incubation (37°C; 5% CO2) in phase or after the addition of a 
fluorescent complex, calcein (n=3).  Image acquisition was performed using Cell M 
software (Olympus).  Aspirin-treated platelet releasates showed an impairment of 
the tubule structure compared to untreated platelet releasates. The responses 
were restored in aspirin-treated platelet releasates when 15(S)-HETE (1 µM) was 
added. 
TRAP-6+ 
aspirin 
TRAP-6+ 
aspirin+ 
15(S)-HETE 
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Figure 9.4 HMEC-1 tube formation in the presence of releasates from TRAP-6-
stimulated platelets. HMEC-1 resuspended with releasates obtained from PRP 
stimulated with TRAP-6 (30 µM) or TRAP-6 (30 µM) and 15(S)-HETE (1 µM). Tube 
formation on Matrigel was determined by time-lapse microscopy and the number 
of branch points was measured after a) 4h incubation (4X magnitude), b) 8h 
incubation (4X magnitude) and c) 16h incubation (10X magnitude) at 37°C and 5% 
CO2. One-way ANOVA (*p˂0.05); n=3. TRAP-6 stimulated platelet releasates 
significantly increased tube formation compared to those stimulated with PBS. Pre-
treatment of platelets with aspirin strongly inhibited tubule-like structure formation 
but the addition of 15(S)-HETE fully restored the cell response. ANOVA with 
Bonferroni post-test. Differences were taken to be significant at P values of less than 
0.05 (*p˂0.05); n=3. 
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a)                                                                           b) 
 
 
 
 
 
 
 
 
 
c)                                                                           d) 
     
 
 
 
 
 
 
 
 
Figure 9.5 Images of HMEC-1 tube formation in the presence of releasates from 
collagen-stimulated platelets. HMEC-1 in the presence of releasates obtained from 
human PRP stimulated with a-b) collagen (30µg/ml) or c-d) collagen (30µg/ml) and 
15(S)-HETE (1µM). Images were captured using Olympus IX81 inverted microscope 
(10X) with Hamamatsu Orca-ER digital camera after 16 hour incubation (37°C; 5% 
CO2) in phase or after the addition of a fluorescent complex, calcein (n=3).  Image 
acquisition was performed using Cell M software (Olympus).  
collagen+ 
15(S)-HETE 
collagen 
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a)                                                                           b) 
  
 
 
 
 
 
 
 
 
c)                                                                           d) 
 
 
Figure 9.6 Images of HMEC-1 in the presence of releasates from collagen-stimulated 
and aspirin-treated platelets. HMEC-1 in the presence of platelet releasates 
obtained from human PRP pre-treated with aspirin and stimulated with a-b) 
collagen (30 µg/ml) or c-d) collagen (30 µg/ml) and 15(S)EHETE (1 µM). Images were 
captured using Olympus IX81 inverted microscope (10X) with Hamamatsu Orca-ER 
digital camera after 16 hour incubation (37°C; 5% CO2) in phase or after the addition 
of a fluorescent complex, calcein (n=3).  Image acquisition was performed using Cell 
M software (Olympus).  
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Figure 9.7 HMEC-1 tube formation in the presence of releasates from collagen-
stimulated platelets. HMEC-1 cells were resuspended with releasates obtained from 
PRP stimulated with collagen (30 µg/ml) or collagen (30 µg/ml) and 15(S)-HETE (1 
µM). Tube formation on Matrigel was determined by time-lapse microscopy and the 
number of branch points was measured after a) 4h incubation (4X magnitude), b) 
8h incubation (4X magnitude) and c) 16h incubation (10X magnitude) at 37°C and 
5% CO2. One-way ANOVA (*p˂0.05); n=3. Collagen-stimulated platelet releasates 
significantly increased tube formation compared to PBS-stimulated platelet 
releasates. Pretreatment of platelets with aspirin strongly inhibited tubule-like 
structure formation, but the addition of 15(S)-HETE fully restored the cell response. 
ANOVA with Bonferroni post-test. Differences were taken to be significant at P 
values of less than 0.05 (*p˂0.05); n=3. 
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Figure 9.8 Effect of 15(S)-HETE on HMEC-1 migration. HMEC-1 were used when 
100% confluent on a 6-well plate. A scratch was performed with a 200 pipette tip. 
Platelet releasates were then added and incubated for 20h at 37°C, 5% CO2. Cell 
migration in the presence of releasated obtained from a) TRAP-6- or b) collagen-
stimulated platelets was determined by time-lapse microscopy using Olympus IX81 
inverted microscope (10X) with Hamamatsu Orca-ER digital camera after 20 hour 
incubation (37°C; 5% CO2) in phase.  Image acquisition was performed using Cell M 
software (Olympus) and the percentage (%) of field coverage measured using MCell 
software. ANOVA with Bonferroni post-test. ANOVA with Bonferroni post-test. 
Differences were taken to be significant at P values of less than 0.05 (*p˂0.05); n=4. 
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Figure 9.9 Effect of 15(S)-HETE on formation of angiogenic sprouts from rat aortic 
rings in the presence of releasates from TRAP-6-stimulated platelets. Platelet 
releasates were obtained from human (n=3) PRP treated in vitro with or without 
aspirin (100 µM) and stimulated with PBS or TRAP-6 (30 µM) and finally kept at -
80°C. Releasates were thawed, diluted in OptiMEM+1% FBS (1:3) and supplemented 
with TRAP-6 and/or aspirin in order to have all samples equally treated. Samples 
stimulated with PBS were treated with or without VEGF (10 ng/ml) or 15(S)-HETE (1 
µM), while those stimulated with TRAP-6 with or without 15(S)-HETE (1 µM). Rat 
aortic rings (5 per condition) were fed with platelet releasates+OptiMEM+1% FBS 
and incubated for 5 days at 37°C and 5% CO2. Images were taken in phase (4X) and 
the number of sprouts counted using Mcell software. PBS alone did not stimulate 
formation of sprouts. Conversely, the presence of VEGF significantly increased the 
number of sprouts while 15(S)-HETE produced a moderate increase. Releasates 
from TRAP-6 stimulated platelets significantly promoted the formation of sprouts 
which was strongly inhibited by the presence of aspirin. The addition of 15(S)HETE 
(1 µM) to aspirin-treated releasates was able to restore the formation of angiogenic 
sprouts. ANOVA with Bonferroni post-test. Differences were taken to be significant 
at P values of less than 0.05 (*p˂0.05). 
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Figure 9.10 Images of the effect of 15(S)-HETE on formation of angiogenic sprouts 
from rat aortic rings in the presence of releasates from TRAP-6-stimulated platelets. 
Images were taken using Olympus IX81 inverted microscope (10X) with Hamamatsu 
Orca-ER digital camera after 4 days incubation (37°C; 5% CO2). Image acquisition 
was performed using Cell M software (Olympus). 
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Figure 9.11 Effect of 15(S)-HETE on formation of angiogenic sprouts from rat aortic 
rings in the presence of releasates from collagen-stimulated platelets. Platelet 
releasates were obtained from human (n=3) PRP treated in vitro with or without 
aspirin (100 µM) and stimulated with PBS or collagen (30 µg/mL) and finally kept at 
-80°C. Releasates were thawed, diluted in OptiMEM+1% FBS (1:3) and 
supplemented with collagen and/or aspirin in order to have all samples equally 
treated. Samples stimulated with PBS were treated with or without VEGF (10 ng/ml) 
or 15(S)-HETE (1 µM), while those stimulated with TRAP-6 with or without 15(S)-
HETE (1 µM). Rat aortic rings (5 per condition) were fed with platelet 
releasates+OptiMEM+1% FBS and incubated for 5 days at 37°C and 5% CO2. Images 
were taken in phase (4X) and the number of sprouts counted using Mcell software. 
PBS alone did not stimulate formation of sprouts. Conversely, the presence of VEGF 
significantly increased the number of sprouts while 15(S)-HETE produced a 
moderate increase. Releasates stimulated with collagen significantly promoted the 
formation of sprouts which was strongly inhibited by the presence of aspirin. The 
addition of 15(S)HETE (1 µM) to aspirin-treated releasates was able to restore the 
formation of angogenic sprouts. ANOVA with Bonferroni post-test. Differences were 
taken to be significant at P values of less than 0.05 (*p˂0.05). 
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Figure 9.12 Images of the effect of 15(S)-HETE on formation of angiogenic sprouts 
from rat aortic rings in the presence of collagen-stimulated platelet releasates. 
Images were taken using Olympus IX81 inverted microscope (10X) with Hamamatsu 
Orca-ER digital camera after 4 days incubation (37°C; 5% CO2). Image acquisition 
was performed using Cell M software (Olympus). 
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9.2.4 Conclusions 
The assessment of HMEC-1 angiogenic responses in vitro revealed that 15(S)-HETE 
regulates angiogenesis and, in particular, enhances the formation of tubule-like 
structures which confirms the hypothesis that this metabolite is a pro-angiogenic 
mediator. Indeed, HMEC-1 in the presence of human platelet releasates stimulated 
with high concentrations of either TRAP-6 (30 µM) or collagen (30 µg/ml) formed a 
dense and structured network of tubules compared to releasates from platelets 
stimulated with PBS. Moreover, releasates from platelets treated with aspirin (100 
µM) prior to stimulation displayed a significantly impaired effect on tubule 
architecture, which was fully restored with the addition of 15(S)-HETE (1 µM). 
Addition of 15(S)-HETE to stimulated releasates formed in the absence of aspirin did 
not produce any additional effect. This suggests that the production of 15(S)-HETE 
by activated platelets is already sufficient to drive angiogenesis in these assays. The 
results obtained, thus, suggest that platelets upon activation with TRAP-6 and 
collagen produce high concentrations of the COX-1 product, 15(S)-HETE, which in 
turn may regulate angiogenesis by promoting tube formation. It has been reported 
that the mechanism by which 15(S)-HETE affects angiogenesis in HUVECs is by up-
regulating the expression of VEGF through the activation of PI3 kinase – Act – mTOR 
–S6K1.307 
Cell migration was also assessed as it represents another fundamental step of 
angiogenesis. Migration of HMEC-1 was reduced when cells were incubated with 
TRAP-6 or collagen stimulated releasates from platelet pre-treated with aspirin 
compared to untreated platelet releasates. As for tube formation HMEC-1 viability 
increased in the presence of 15(S)-HETE suggesting that this mediator is involved in 
different steps of angiogenesis, i.e. both cell migration and formation of tubules 
which represent the core of the novel vessel. 
The pro-angiogenic effects of 15(S)-HETE were furthermore confirmed ex vivo by 
assessing the formation of sprouts from rat aortic rings. VEGF, positive control, and 
TRAP-6- or collagen-stimulated platelet releasates strongly promoted the formation 
of sprouts compared to unstimulated releasates. Once again aspirin significantly 
reduced the number of sprouts which increased when 15(S)-HETE was added and 
was comparable to that of VEGF and stimulated releasates.  
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Ultimately, these findings suggest that 15(S)-HETE together with other pro-
angiogenic factors released by activated platelets, (e.g. VEGF, PDGF, ADP) 
contributes in promoting pro-angiogenic responses of human vascular endothelial 
cells.
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The first part of the thesis aimed at qualitatively and quantitatively determining the 
platelet-derived eicosanoids produced in stimulated human blood in vitro in order 
to model that produced acutely during clot formation and to elucidate the 
enzymatic pathways involved in their production. This study aimed at identifying 
potential targets for the development of novel treatments able to ameliorate 
current anti-thrombotic approaches and overcome their side effects.  
To answer these questions I had the opportunity to test blood samples of two 
siblings of Serbian origin affected by a homozygous deletion of the cytosolic 
phospholipase A2 (cPLA2α), which supplies AA to the COX and LOX enzymes, through 
a collaboration with the Department of Clinical Immunology, Barts Health NHS 
Trust, which had these patients under care.316 Initially, the two siblings were found 
to be affected by cryptogenic multifocal ulcerous stenosing enteritis (CMUSE), a 
disease that presented with symptoms such as bowel ulceration and stenosis which 
closely resembled the side effects associated with chronic use of NSAIDs.316 Whole 
exome sequencing studies identified a deletion of the gene encoding for the 
phospholipase A2 which accounted for the patients’ lifelong gastrointestinal 
complications.316 Moreover, function testing of platelets from these patients 
showed a drastic impairment of platelet responses due to their inability to 
synthetize pro-thrombotic AA-derived eicosanoids (e.g. TXA2). These patients, based 
on their genotypic and phenotypic profile, represented a unique human model to 
test how the lack of the constitutive cPLA2α isoform could affect the production of 
AA-derived eicosanoids in stimulated-blood in vitro compared to healthy volunteers. 
In collaboration with Professor Darryl Zeldin (National Institutes of Environmental 
Health, Triangle Park, North Carolina, USA) a lipidomic analysis using LC-MS/MS314 
was performed on blood samples of the patients compared to samples from healthy 
volunteers, both stimulated with specific platelet agonists, collagen and TRAP-6, or 
calcium ionophore (A23187). The latter elicits its stimulatory effect by increasing the 
intracellular calcium levels of blood cells, and is hence not specific to platelets. 
Blood from healthy volunteers stimulated with any of the three agonists produced 
large amounts of prostanoids (notably TXA2, PGE2 and PGD2) and, interestingly, also 
of 11-HETE, 12-HETE and 15-HETE. In particular, the concentrations of 12-HETE 
reached 300-500 ng/ml in PRP stimulated with TRAP-6 or collagen compared to 40-
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80 ng/ml of TXA2. The levels of 5-HETE increased only when blood was stimulated 
with A23187 but not when it was stimulated with platelet agonists. This is 
consistent with 5-HETE being a leukocytel product through the activity of the 5-LOX 
enzyme and, therefore, represented a useful control for the lipidomic analysis.56 The 
interesting finding of stimulated blood generating such large amounts of different 
HETE isoforms in vitro led to the hypothesis that these products could have 
important physiological or pathophysiological purposes. Conversely, stimulated 
blood from the two patients did not produce any increase in the levels of AA-
derived prostanoids or HETEs, confirming the central importance of the constitutive 
cPLA2α enzyme in the production of AA-derived eicosanoids within the blood. 
Ultimately, stimulation of blood with platelet agonists, i.e. TRAP-6 and collagen, 
increased the levels of prostanoids and HETEs, with the only exception of 5-HETE, 
known to be a leukocyte product. This finding led me to hypothesize that both the 
prostanoids and HETEs identified might have been products of platelets. This 
hypothesis was then confirmed by comparing the production of eicosanoids in 
human platelet-rich plasma (PRP), where both leukocytes and erythrocytes are 
absent, and whole blood. Interestingly it was found that all the products were 
platelet-dependent with the exception of 5-HETE, which provided a useful control 
for the selectivity and relevance of the assays.  
Having established the formation of these various mediators through the action of 
cPLA2α in platelets, my next step was to look for functional roles. Firstly, I wanted to 
study whether these elicited autocrine effects on platelet adhesion and/or 
aggregation. To begin, I investigated whether a window of aggregation that was 
COX-independent could be identified by comparing platelet aggregation responses 
of blood samples from the cPLA2α-deficient patients and healthy volunteers treated 
with the selective cPLA2α inhibitor, pyrrophenone,
120 with those of blood from 
healthy volunteers treated with aspirin. By inhibiting the more upstream enzyme, 
cPLA2α, I wanted to establish whether the inhibitory effects on platelet aggregation 
might be greater than those caused by aspirin and, thus, hypothesize the presence 
of a pathway, other than COX-1, contributing to platelet aggregation. The results 
showed that the inhibitory effects on platelet aggregation caused by the lack of 
cPLA2α or COX-1 activity did not differ significantly. However, studies conducted 
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under shear on a collagen coated surface showed a different pattern of aggregation 
in the patients and healthy volunteers treated with pyrrophenone compared to 
those treated with aspirin. Indeed, in blood lacking the cPLA2α, platelets weakly 
adhered to collagen and were unable to form platelet-platelet interactions. Aspirin 
strongly inhibited normal platelet aggregation in these conditions as well, however 
the pattern under shear slightly differed from that of blood lacking cPLA2α activity as 
platelets were still capable to form islands of aggregation although small and 
unstable.  
This set of data determined that the overall inhibition of platelet responses 
following from lack of the cPLA2α or COX-1 activity were quite similar, nevertheless 
the patterns of aggregation under shear differed. Albeit these functional tests 
showed that TXA2 represented the key metabolite that drives platelet aggregation I 
wanted to investigate in more depth whether the pattern differences identified 
might involve other AA-derived eicosanoids. Thus, I next paid particular attention to 
the platelet LOX pathway as there are controversial reports on whether this may 
play a role in regulating platelet function. I initially addressed the effects 12-LOX 
product, 12(S)-HETE, have in modulating the effects of TXA2 on platelet responses as 
there are controversial opinions in the literature as to whether these may play pro- 
or anti-aggregatory effects. For example, both in vitro and in vivo studies on 12-LOX 
KO mice support anti-aggregatory effects of 12-LOX metabolites.266,77,78 Conversely, 
other groups, such as Calzada et al., reported that physiologically relevant 
concentrations of 12-HpETE potentiated platelet function when co-incubated with 
sub-threshold concentrations of AA or collagen, while Sekiya and al. showed that 
12-HETE enhanced thrombin-induced aggregation of bovine platelets.77,79.
80,267 
Moreover, studies in which 12-LOX inhibitors were used, such as 5,8,11-
eicosatrienoic acid and baicalein (10 µM), reported attenuated thrombin- and 
U46619-induced increases of platelet intracellular calcium and aggregation of 
platelets.268 I thereby investigated the effects of the 12-LOX inhibitor, baicalein (10 
µM), and 12(S)-HETE on platelet aggregation, static adhesion and adhesion under 
shear and compared these to the effects produced by COX -1 inhibition with aspirin. 
In my studies, the responses of platelets were not affected by baicalein or 12(S)-
HETE in either aggregation or adhesion studies. In control studies, aspirin inhibited 
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aggregation responses driven by TXA2, and PGI2 as a positive control produced full 
inhibition of platelet aggregation to all agonists.  
In complementary studies I examined the roles PGD2 and PGE2, which are known to 
be platelet COX-1 products, played in regulating platelet function in my studies. My 
results confirmed those already known and, in particular, that PGD2 and PGE2 play 
an inhibitory and modulatory role on platelet aggregation, respectively.45,47,48 In 
particular, PGE2 enhances aggregation at low concentrations acting through EP3 
receptors and at higher concentrations inhibits platelet aggregation via EP4 
receptors.45 The conclusions drawn from these functional tests established that 
12(S)-HETE does not affect platelet aggregation responses to any agonist, conversely 
that COX-1-derived prostanoids clearly play a key role in regulating or modulating 
platelet aggregation responses. The divergent outcomes of previously reported 
studies in this area might be linked to the non-specificity of the inhibitors used, 
which can have actions other than those caused by the inhibition of 12-LOX. There 
are also differences between humans and mice in the platelet 12-LOX signalling 
pathway which could well explain some discrepancies.78 
After thoroughly investigating the potential effects of 12-LOX products, the next 
step was to study whether 11-HETE and 15-HETE, also identified as major platelet 
products, might affect platelet function. However, neither LOX inhibition with a non-
selective LOX inhibitor, NDGA (10 µM), nor the exogenous addition of 11-HETE or 
15-HETE altered any of the agonist-induced platelet aggregation responses 
suggesting once more that these products are not involved in platelet function. 
Before proceeding in the investigation of the functional role of HETEs within the 
vasculature, I was interested in performing an additional lipidomic analysis on 
platelet releasates using LC-MS/MS to study the effects on eicosanoid production of 
TRAP-6 or collagen stimulated PRP and whole blood in the presence of aspirin, 
prasugrel or aspirin and prasugrel in combination, which represents the current 
anti-platelet therapy for secondary prevention of vascular events. For the 
preparation of releasates, platelets were not only stimulated with collagen or TRAP-
6 but also kept under stirring conditions, which more closely mimics in vitro 
conditions in vivo. This set of data would allow more insight on the pathways 
involved in the production of these metabolites and, eventually, provide useful 
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information on how therapies clinically used might affect eicosanoid production 
leading ideally to the identification of novel therapeutical targets. Interestingly, 
aspirin alone or in combination with prasugrel fully inhibited the production of both 
11-HETE and 15-HETE in addition to prostaglandins. Conversely, 12-HETE production 
was not inhibited by aspirin although its levels significantly decreased in the 
presence of aspirin and prasugrel in combination suggesting that this might 
represent a useful marker of platelet activation. These results are consistent with 
studies from Smith’s group in which isolated and semi-purified ovine PGHS-1 in the 
presence of AA was shown to produce TXA2, 15(S)-HETE, 15(R)-HETE and 11(R)-
HETE. By studying the biochemistry of the reaction catalysed by COX-1, Smith’s 
group reported that these products were the results of three different 
arrangements of AA in the catalytical site of the enzyme.26 Indeed, the reaction 
catalysed by COX-1 includes two oxygenations in the conversion of AA to 
prostaglandin endoperoxide product (PGG2) where, within the same oxygenase 
active site, the first oxygenation occurs in the 11R configuration and, following 
cyclization reactions, the second oxygenation is 15S.26 It is likely that these 
alternative COX products can be produced in aggregating platelets because of the 
very high levels of free arachidonic acid.  
This set of data was useful in clarifying the pathways involved in the production of 
HETEs establishing that both 11-HETE and 15-HETE are platelet COX-1, not LOX, 
products generated in large amounts in stimulated blood which also suggests these 
are not side products but actual bioactive mediators. Conversely, COX-1 inhibited 
platelets were still able to synthetize 12-HETE which is suggestive of this being a 12-
LOX product, as already established in the literature.58 However, 12-HETE might 
represent a useful marker of global platelet activation since the presence of aspirin 
and prasugrel in combination significantly reduced the levels produced by 
stimulated platelets.   
Based on the evidence that prostanoids together with 11-HETE and 15-HETE are all 
produced by platelets through the COX-1 activity, I hypothesized that the addition 
of 11-HETE and 15-HETE to TXA2 in combination with PGE2/PGD2 might show an 
effect on aggregation responses, as these are released together following 
endogenous platelet activation. In particular, I assessed the effects of 11(R)-HETE, 
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15(S)-HETE and 15(R)-HETE as these were individually identified in Smith’s 
biochemical studies as the enantiomers produced by COX-1 from AA as a 
substrate.321 In order to assess the effects of these metabolites when exogenously 
added to PRP, their endogenous production was inhibited by combination of aspirin 
and prasugrel. Next the COX-1 products, TXA2, PGE2 and PGD2 together with 11(R)-
HETE, 15(S)-HETE and 15(R)-HETE were added to platelets in the concentrations and 
proportions demonstrated in LC-MS/MS analysis. In these conditions TXA2 was able 
to restore aggregation, which was partially inhibited by the addition of PGE2 and 
PGD2, confirming the strong pro-aggregatory effects of TXA2 and the inhibitory 
effects of PGD2 and of high concentrations of PGE2 on platelet aggregation 
responses. Further addition of 11- and 15-HETE did not alter the platelet 
aggregation responses produced by prostanoids over 7 min. These results once 
more confirmed that the platelet-derived COX-1-dependent HETEs do not influence 
platelet aggregations. On the basis of these data I hypothesized that HETEs might 
produce paracrine effects on neighbouring cells within the vasculature, for instance 
on inflammatory cells or endothelial cells, and, hence, might play roles in 
inflammatory and/or angiogenic processes.   
There have been several reports showing that HETEs interact with neutrophils 
promoting/modulating their trafficking and recruitment at sites of vascular injury.333 
Based on this knowledge I initially studied cell migration to establish whether the 
different HETE isoforms (5-HETE, 11-HETE, 12-HETE and 15-HETE) identified in 
stimulated blood displayed chemoattractant effects on neutrophils isolated from 
human blood. The effects of HETEs were compared to those of LTB4, a potent AA-
derived chemoattractant produced by neutrophils through the 5-LOX pathway. I 
found that 12(S)-HETE, which represents the bioactive enantiomer, produced strong 
chemoattractant effects similar to those of LTB4. Furthermore, 5-HETE, also induced 
neutrophil chemotactic responses, although not as potent as those of 12(S)-HETE. 
These results are in accordance with the existence of a cross-talk between platelets 
and neutrophils through the platelet 12-LOX and the neutrophil 5-LOX supporting 
the production of leukotrienes and lipoxins, both of which are involved in 
inflammatory responses.95,99 This process is referred to as transcellular biosynthesis 
consisting of a donor cell able to transform AA into an intermediate which then 
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becomes a substrate for other cell types to generate an active metabolite.53,99 On 
the basis of these chemotactic results it could be speculated that 12(S)-HETE might 
represent an intermediate substrate for the synthesis of pro-inflammatory 
mediators with the ability of eliciting potent chemoattractant effects on 
neutrophils.    
After recognising the strong neutrophil chemotactic effects of 12(S)-HETE, I wanted 
to further expand this research by studying the effects HETEs might display on 
neutrophil activation.334 In these experiments I studied the effects on neutrophil 
activation of platelet COX-1 dependent 11(R)-HETE, 15(S)-HETE and 15(R)-HETE, and 
of 12(S)-HETE and 5-HETE using both CD11b (MAC-1)  and CD62L (L-selectin) as 
markers of neutrophil activation in human blood. I found that the various HETE 
isoforms generally did not alter the expression of PMNLs markers, particularly in 
comparison to the effects elicited by fMLP or IL-8. Only 12(S)-HETE caused a slight 
increase in the expression of CD11b and decrease in the expression of CD62L. These 
results were found not to be significant due to the variability of the responses 
among individuals and ultimately suggest that HETEs are not involved in promoting 
neutrophil adhesive responses. 
In conclusion these studies demonstrated that 12(S)-HETE and 5-HETE are released 
by platelets and neutrophils, respectively, increasing the cross-talk between these 
two cell types and promoting neutrophil recruitment, thus playing an important 
role in vascular inflammatory processes. However, the roles 11-HETE and 15-HETE 
played within the vasculature still required further investigation. I hypothesized that 
these platelet COX-1 products might be involved in processes other than 
hameostasis/thrombosis and inflammation based on studies which have shown that 
the 15(S)-HETE isoform is involved in neo-vascularization.307 Therefore, I wanted to 
assess whether this mediator could influence/modulate the angiogenic responses of 
human endothelial cells. 
Interestingly, studies have reported that AA-derived 15(S)-HETE stimulates 
angiogenic responses in both HDMVECs and HUVECs by up-regulating VEGF through 
the PI3K-Akt and p38MAPK signalling pathways.307,309 On this premise, I was 
interested in investigating whether the great amounts of 15-HETE that I had found 
to be mainly produced by platelets through the activity of the COX-1 enzyme were 
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able to affect endothelial cell angiogenic responses. The purpose of the study was 
to determine whether this platelet metabolite regulated angiogenesis and ideally 
identify a new target able to possibly ameliorate anti-cancer therapy. Prior to 
investigating these effects, I measured the levels of 15(S)-HETE produced by 
stimulated platelet releasates using enzymatic immune assay (EIA) in order to 
establish this bioactive enantiomer was being produced, and to confirm the data 
obtained from the LC-MS/MS analysis. The results validated the previous data, 
confirming that 15(S)-HETE is produced by activated platelets at the concentrations 
found via LC-MS/MS and is a major COX-1 metabolite as aspirin strongly inhibited its 
production. In order to study the effects of platelet 15(S)-HETE on angiogenic 
responses I prepared releasates from platelets pretreated with aspirin or vehicle 
based on previous studies which demonstrated that aspirin robustly inhibited 
angiogenic responses of HMEC-1.297 The pro-angiogenic effects of platelet 
releasates, determined by HMEC-1 tube formation or cell migration, were 
powerfully inhibited by pre-treatment of platelets with aspirin and returned by the 
addition of 15(S)-HETE. Also HMEC-1 migration was reduced by aspirin and 
recovered by further addition of 15(S)-HETE, although these effects were very 
subtle compared to those produced on tube formation. These results suggest that 
the COX-1 pathway within platelets might play a fundamental role in regulating 
angiogenic responses, particularly the formation of tubule structures that represent 
the core of new vessels, through the production of 15(S)-HETE. Thus, we could 
hypothesize that 15(S)-HETE together with other pro-angiogenic factors released by 
activated platelets (e.g. VEGF, PDGF) interplay in promoting angiogenic processes. 
Further ex vivo studies were performed in order to support the in vitro findings 
through the assessment of the formation of sprouts from rat aortic rings. Once 
again, aspirin significantly reduced the number of sproutings formed which 
increased in the presence of 15(S)-HETE, establishing its pro-angiogenc properties 
by using a more reliable assay. It is already held that TXA2 regulates angiogenic 
processes and, in particular, studies by Italiano et al. have shown that this mediator 
promotes anti-angiogenic effects by stimulating the release of platelet α-granule 
contents including anti-angiogenic factors, such as endostatin.179 Interestingly, my 
results showed that 15(S)-HETE, also a platelet COX-1 product, is involved in 
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angiogenic processes and, in particular, enhances tube formation of HMEC-1. 
Thereby, it could be speculated that the synergy between the effects of 15(S)-HETE 
together with those of other platelet agonists, such as ADP, may account for the 
overall pro-angiogenic responses produced by activated platelets. However, in 
order to fully support this hypothesis the results I have obtained in vitro require to 
be further validated using in vivo models of angiogenesis. In addition, clarification is 
required with regard to the intracellular signal transduction pathways through 
which 15(S)-HETE acts in order to have better insight on the mechanisms by which 
the different platelet agonists interplay in regulating angiogenic responses. In this 
regard there are reports suggesting that the effects of 15(S)-HETE, as for ADP, are 
mediated by the PI3K pathway. Once characterised it could be speculated that the 
15(S)-HETE pathway might represent a useful target for the development of 
therapies able to limit angiogenic processes in pathological conditions, such as 
tumour progression and metastasis. On the basis of this study it may well be that 
some of the anti-cancer effects established for aspirin are explained by inhibition of 
the formation of 15(S)-HETE. 
Throughout my project I identified the cPLA2α enzyme as the isoform responsible for 
the production of eicosanoids in activated platelets via the analysis of blood 
samples from cPLA2α-deficient patients. Alongside, data obtained by LC-MS/MS 
revealed that stimulated platelets generate large amounts of both prostanoids (i.e. 
TXA2, PGE2 and PGD2) and HETEs (i.e. 11-HETE, 12-HETE, 15-HETE), while 5-HETE was 
not produced by platelets, consistent with this being a neutrophil product. I 
furthermore discovered that, along with prostanoids, both 11-HETE and 15-HETE 
are platelet COX-1 products as the presence of aspirin fully inhibited their 
production, whereas the levels of 12(S)-HETE were not altered. This supports the 
evidence of 12(S)-HETE being a platelet 12-LOX metabolite and, thus, the product of 
a different enzymatic pathway. After clarifying the pathways involved in the 
production of these families of eicosanoids, the aim was to elucidate the biological 
role these different products played within the vasculature. Initially their potential 
autocrine effects on platelet responses were investigated studying platelet function 
under static and dynamic conditions which confirmed the pro-thrombotic 
properties of TXA2 and low concentrations of PGE2 and the ant-thrombotic effects 
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of PGD2 and high concentrations of PGE2. Conversely, the different HETE isoforms 
did not produce any significant effect on platelet function. Thus, paracrine effects 
on other blood cells were sought and in particular those on neutrophils. As a 
results, both 12(S)-HETE and 5-HETE significantly induced neutrophil chemotaxis 
and their effects were comparable to those elicited by LTB4, a potent neutrophil 
chemoattractant. Nevertheless, the functional roles of both 11-HETE and 15-HETE 
are still to be fully understood. Ultimately, based on reports that suggested a pro-
angiogenic role of 15(S)-HETE, I was interested in determining whether this 
particular enantiomer modulated and/or regulated this vascular process. After 
identifying by EIA assay that 15(S)-HETE is the actual bioactive metabolite produced 
by activated platelets, I investigated both in vitroand ex vivo the effects of this 
metabolite on angiogenic processes in the presence of platelet releasates 
stimulated with specific platelet agonists and treated with or without aspirin. The 
results showed that inhibition of the COX-1 enzyme by aspirin significantly impaired 
tube formation of HMEC-1 in vitro and sprouting of rat aortic rings ex vivo, which 
were fully restored in the presence of 15(S)-HETE at the concentrations found by 
LC-MS/MS and EIA. These findings suggest that 15(S)-HETE might be an optimal 
target for anti-angiogenic therapies in pathological conditions, such as tumour 
growth, where this process plays a key role. Also, the evidence that aspirin is able to 
inhibit angiogenesis might of relevance in supporting results obtained by recent 
clinical trials and, thus, the use of this anti-platelet drug as an adjuvant for anti-
cancer therapies.298 
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Figure 10.1 Scheme of the enzymatic pathways involved in the production of 
prostanoids and HETEs by activated platelets together with their biological 
function within the vasculature. 
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10.1 Future work and limitations 
 
The interesting findings obtained throughout this study show that upon activation 
platelets produce high levels of COX-1-derived metabolites which are not involved 
in modulating exclusively thrombotic responses, as already established, but also 
angiogenic processes. Aspirin through the inhibition of the COX-1 enzyme impaired 
angiogenic processes in addition to its anti-thrombotic effects. These results 
support recent cinical analyses which have shown that patients treated with anti-
platelet doses of aspirin showed better outcomes in certain types of cancers (e.g. 
colonrectal cancer). However, this beneficial property of aspirin could be 
investigated only in those patients taking the drug for secondary prevention of 
cardiovascular diseases, as the drug is not used for primary prevention because of 
its harmful side effects of increased gastrointestinal and intracranial bleedings. I 
found that 15(S)-HETE is a COX-1 metabolite which plays a key role together with 
other vascular growth factors released by platelets upon activation, in promoting 
angiogenic responses. However, further research is required to establish whether 
this hormone might represent an optimal target for the development of anti-
angiogenic therapies and, thus, enhance anti-angiogenic therapies currently in use. 
On this basis future work should be conducted to test the angiogenic effects of 
15(S)-HETE using in vivo models of angiogenesis in order to support and validate the 
results obtained both in vitro and ex vivo. Alongside, a detailed study of the 
intracellular signal transduction induced by 15(S)-HETE will eventually permit a 
better understanding of the mechanism by which this metabolite acts and the 
interplay among the different growth factors released by activated platelets. 
Indeed, Italiano et al. have already shown that ADP induces pro-angiogenic 
processes through the activation of the PI3K pathway.179 Alongside, reports have 
demonstrated that 15(S)-HETE also induces its pro-angiogenic effects by acting 
through the PI3K/Akt pathway.  It would be useful to investigate whether there are 
any interplays between these pathways. 
Although these preliminary data look very promising, further studies are required 
clearly required to confirm 15(S)-HETE as a potential target for anti-cancer 
treatment. Indeed, most of the data obtained are the results of experiments 
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performed in vitro which certainly require the support of in vivo studies in order to 
take into account the influence of the whole physiology of an organism on the 
responses examined.  
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